

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/076658 A2

(51) International Patent Classification⁷: **C12Q 1/68**,
C12N 15/00, 5/00, G01N 33/50, A61P 25/16

(21) International Application Number: PCT/IB02/04276

(22) International Filing Date: 14 October 2002 (14.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/363,220 8 March 2002 (08.03.2002) US

(71) Applicant (for all designated States except US): **DECODE GENETICS EHF**. [IS/IS]; Sturlugotu 8, IS-101 Reykjavik (IS).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **HICKS, Andrew, A.** [GB/GB]; 104 Bankton Park East, Livingston EH54 9BN (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A SUSCEPTIBILITY GENE FOR LATE-ONSET IDIOPATHIC PARKINSON'S DISEASE

(57) Abstract: Methods of diagnosis of susceptibility to Parkinson's disease; assays for agents that alter the activity of a Parkinson's disease polypeptide, (e.g., PARK8 polypeptide) or which identify PARK8 binding agents, and the agents or binding agents identified by the assays; PARK8 therapeutic agents, including the PARK8 nucleic acids, PARK8 polypeptides, or agents that alter the activity of an PARK8 polypeptides; pharmaceutical compositions comprising the PARK8 therapeutic agents; as well as methods of therapy of Parkinson's disease are disclosed.



WO 03/076658 A2

A SUSCEPTIBILITY GENE FOR LATE-ONSET IDIOPATHIC PARKINSON'S DISEASE

RELATED APPLICATION(S)

This application claims the benefit of U.S. Provisional Application No. 60/363,220, filed March 8, 2002. The entire teachings of the above application are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Parkinson's disease is a neurodegenerative disorder of unclear etiology and pathogenesis that usually occurs in middle-age or later with an onset of symptoms typically after 60 years of age. The signs of the disease include bradykinesia, muscular rigidity, resting tremor, and postural instability. In some rare families characterized by early-onset and a Mendelian pattern of transmission, the role of genetic factors has been clearly established over recent years. In families with autosomal dominant early-onset Parkinson's disease, the first gene to be identified was α -synuclein, (Polymeropoulos, M.H., *et al.*, *Science*. 276: 2045-7 (1997)). Two additional loci have been reported in such families, including *PARK3* on chromosome 2p13 (Gasser, T., *et al.*, *Nat. Genet.* 18:262-5 (1998)), and *PARK4* on chromosome 4p14-16.3, (Farrer, M., *et al.*, *Hum. Mol. Genet.* 8:81-5 (1999)), and a mutation in the ubiquitin carboxy-terminal hydrolase L1 gene in one German family have been reported (Leroy E., *et al.*, *Nature*. 395: 451-2 (1998)). Other families studied report no linkage to these regions (Farrer, M., *et al.*, *Mov. Disord.* 15:1075-83 (2000)). In addition, the Parkin gene on chromosome 6q25.2-27 (*PARK2*) has been shown to be involved in juvenile parkinsonism (Matsumine, H., *et al.*, *Am. J. Hum. Genet.*, 60:588-96 (1997)), and in families demonstrating an autosomal recessive mode of inheritance as well as some sporadic early-onset cases (Kitada T., *et al.*, *Nature*. 392:605-8 (1998), Abbas, N., *et al.*, *Hum. Mol. Genet.* 8:567-74 (1999), Tassin, J., *et al.*, *Am. J. Hum. Genet.*, 63:88-94 (1998) and Lucking, C.B., *et al.*, *N. Engl. J. Med.* 342:1560-7 (2000)). Additionally, two loci on chromosome

1p35-p36, *PARK6* and *PARK7*, have been recently reported to contain another susceptibility gene in families with early-onset recessive Parkinson's disease, (Valente, E.M., *et al.*, *Am. J. Hum. Genet.* 68:895-900 (2001), van Dujin, C.M., *et al.*, *Am. J. Hum. Genet.* 69:629-634 (2001)).

5 The role of genetic factors in both early onset, autosomal dominant and recessive Parkinson's disease have been clearly established, but, these forms represent only a minor part of the total disease spectrum. The common late-onset form of Parkinson's disease does not follow a Mendelian pattern of inheritance and some twin studies have spawned the conclusion that there are no genetic factors
10 involved in its risk, (Tanner, C.M., *et al.*, *JAMA.* 281:341-6 (1999)). The disease is a complex, multifactorial disease resulting from interaction between one or more genes and the environment.

Elucidation of the relative role of genetic and environmental factors is needed. In addition to family information for the study of Parkinson's disease, it is
15 desirable to develop diagnostic methods for the early diagnosis of the disease or to establish predisposition for the development of Parkinson's disease. Understanding the role of genetic and environmental factors can lead to improved therapeutics.

SUMMARY OF THE INVENTION

As described herein, a region on chromosome 1p32 designated as *PARK8*
20 comprising the gene that encodes ring finger protein 11 (hereinafter referred to as "RNF 11") has been correlated through human linkage studies to Parkinson's disease. The present invention relates the use of nucleic acid molecules comprising the *PARK8* gene and encoded proteins for diagnostic and therapeutic methods.

The invention also relates to methods of diagnosing a susceptibility to
25 Parkinson's disease in an individual, comprising detecting a polymorphism in the *PARK8* gene, wherein the presence of the polymorphism in the gene is indicative of a susceptibility to Parkinson's disease. The invention also pertains to methods of detecting an alteration in the expression or composition of a polypeptide encoded by *PARK8* gene in a test sample, in comparison with the expression or composition of a
30 polypeptide encoded by *PARK8* gene in a control sample, wherein the presence of an

alteration in expression or composition of the polypeptide in the test sample is indicative of a susceptibility to Parkinson's disease.

This invention further pertains to methods of identifying an agent which alters activity of a polypeptide encoded by a Parkinson's disease gene, comprising
5 contacting the polypeptide or a derivative or fragment thereof, with an agent to be tested; assessing the level of activity of the polypeptide or derivative or fragment thereof; and comparing the level of activity with a level of activity of the polypeptide or active derivative or fragment thereof in the absence of the agent, wherein if the level of activity of the polypeptide or derivative or fragment thereof in the presence
10 of the agent differs, by an amount that is statistically significant, from the level in the absence of the agent, then the agent is an agent that alters activity of the polypeptide are described. Agents which alter activity of a polypeptide encoded by a Parkinson's disease gene, identified according to this method are also described. The agents which alter activity of a polypeptide encoded by a Parkinson's disease gene, can be:
15 a Parkinson's disease receptor; a Parkinson's disease binding agent; a peptidomimetic; a fusion protein; a prodrug; an antibody; and a ribozyme. These agents can also be utilized in a method of altering activity of a polypeptide encoded by a Parkinson's disease gene.

The invention also relates to a method of identifying an agent which alters
20 interaction of the polypeptide encoded by a Parkinson's disease gene with a Parkinson's disease binding agent, comprising contacting the polypeptide or a derivative or fragment thereof, and the binding agent, with an agent to be tested; assessing the interaction of the polypeptide or derivative or fragment thereof with the binding agent; and comparing the level of interaction with a level of interaction of
25 the polypeptide or derivative or fragment thereof with the binding agent in the absence of the agent, wherein if the level of interaction of the polypeptide or derivative or fragment thereof in the presence of the agent differs, by an amount that is statistically significant, from the level of interaction in the absence of the agent, then the agent is an agent that alters interaction of the polypeptide with the binding
30 agent. Agents which alter interaction of a Parkinson's disease polypeptide with a Parkinson's disease binding agent are also described and can be a Parkinson's

disease receptor; a second Parkinson's disease binding agent; a peptidomimetic; a fusion protein; a prodrug; an antibody; and a ribozyme.

A method of altering interaction of a Parkinson's disease polypeptide with a Parkinson's disease binding agent, comprising contacting the Parkinson's disease
5 polypeptide and/or the Parkinson's disease binding agent with an agent are also described.

The invention additionally relates to a method of identifying an agent which alters expression of a Parkinson's disease gene, comprising contacting a solution containing a nucleic acid of the invention or a derivative or fragment thereof, with an
10 agent to be tested; assessing the level of expression of the nucleic acid, derivative or fragment; and comparing the level of expression with a level of expression of the nucleic acid, derivative or fragment in the absence of the agent, wherein if the level of expression of the nucleotide, derivative or fragment in the presence of the agent differs, by an amount that is statistically significant, from the expression in the
15 absence of the agent, then the agent is an agent that alters expression of a Parkinson's disease gene, as well as agents identified or identifiable by this method.

The invention also relates to a method of identifying an agent which alters expression of a Parkinson's disease gene, comprising contacting a solution containing a nucleic acid comprising the promoter region of a Parkinson's disease
20 gene operably linked to a reporter gene, with an agent to be tested; assessing the level of expression of the reporter gene; and comparing the level of expression with a level of expression of the reporter gene in the absence of the agent, wherein if the level of expression of the reporter gene in the presence of the agent differs, by an amount that is statistically significant, from the level of expression in the absence of
25 the agent, then the agent is an agent that alters expression of a Parkinson's disease gene. The invention also relates to agents identifiable by this method.

The invention further relates to a method of identifying an agent which alters expression of a Parkinson's disease gene, comprising contacting a solution containing a nucleic acid of the invention or a derivative or fragment thereof with an
30 agent to be tested; assessing expression of the nucleic acid, derivative or fragment; and

comparing expression with expression of the nucleic acid, derivative or fragment in the absence of the agent, wherein if expression of the nucleotide, derivative or fragment in the presence of the agent differs, by an amount that is statistically significant, from the expression in the absence of the agent, then the agent is an agent that alters expression of a Parkinson's disease gene. The expression of the nucleotide, derivative or fragment in the presence of the agent comprises expression of one or more variant(s) that differ in kind or in quantity from the expression of variant(s) in the absence of the agent. Agents identified by such a method are also contemplated.

10 In another embodiment of the invention, a method of identifying a polypeptide which interacts with a Parkinson's disease polypeptide, comprising for example, employing a yeast two hybrid system using a first vector which comprises a nucleic acid encoding a DNA binding domain and a Parkinson's disease polypeptide, variant, or fragment or derivative thereof, and a second vector which
15 comprises a nucleic acid encoding a transcription activation domain and a nucleic acid encoding a test polypeptide, wherein if transcriptional activation occurs in the yeast two hybrid system, the test polypeptide is a polypeptide which interacts with a Parkinson's disease polypeptide.

Additionally, the invention pertains to pharmaceutical compositions
20 comprising the nucleic acids of the invention, the polypeptides of the invention, and/or the agents that alter activity of the *PARK8* polypeptides. The invention further pertains to methods of treating Parkinson's disease in an individual, comprising administering a Parkinson's disease therapeutic agent to the individual, in a therapeutically effective amount.

25

BRIEF DESCRIPTION OF THE FIGURES .

The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings.

30 FIG. 1 shows a family pedigree affected by Parkinson's disease.

FIG. 2 depicts multipoint allele lod score of chromosome 1 with versus Z_{lr}

score, with extra microsatellite markers within *PARK8*.

FIGS. 3A-3L depict the nucleic acid sequence of human RNF 11 (SEQ ID NO:1) and the amino acid sequence of the encoded protein RNF 11 (SEQ ID NO: 2).

DETAILED DESCRIPTION OF THE INVENTION

5 Extensive genealogical information for a population with population-based lists of patients have been combined with powerful genome sharing methods to map a major locus in common late-onset Parkinson's disease.

 A genome-wide scan on patients, related within 6 meiotic events (6 meioses separate second cousins), diagnosed within Parkinson's disease and their unaffected
10 relatives has been completed. This linkage investigation revealed a region on chromosome 1p32 designated *PARK8*, to be associated with Parkinson's disease. This locus is distinct from previously published loci contributing to familial Parkinson's disease. *PARK6* and *PARK7* are also located on chromosome 1p but appear to be at least 35 centimorgans away from *PARK8* (Valente, E.M., *et al.*, *Am. J. Hum. Genet.* 68:895-900 (2001); van Duijn, C.M., *et al.*, *Am. J. Hum. Genet.* 69:629-634 (2001)). From the physical map generated herein and public data, there
15 appear to be at least 30 known or possible genes in the region of *PARK8*. This locus does not correspond to known susceptibility loci for Parkinson's disease, and the work described herein represents the first mapping of a gene for common
20 Parkinson's disease. Identification of the susceptibility genes in the region can pave the way for a better understanding of the disease process, which in turn can lead to improved diagnosis and therapeutics.

 Described herein is the first known linkage study of Parkinson's disease showing a connection to chromosome 1p32. Based on the linkage studies
25 conducted, a direct relationship between the *PARK8* locus, specifically the RNF 11 gene, and Parkinson's disease has been discovered.

NUCLEIC ACIDS OF THE INVENTION

 Genomic DNA from patient samples were sequences in the region of the *PARK8* locus and the gene encoding ring finger protein 11 was identified. The

nucleic acid sequence is shown in SEQ ID NO: 1 and FIGS. 3A to 3L. Seven SNP's in the promoter region of the gene and one SNP next to the ATG start codon have been identified. Based upon this discovery, the invention pertains to an isolated nucleic acid molecule comprising *PARK8* fragment or variant thereof and further
5 comprising at least one single nucleotide polymorphism selected from the group consisting of G at nucleotide 1196, C at nucleotide 1393, T at nucleotide 2064, T at nucleotide 2218, C at nucleotide 2435, C at nucleotide 2599, G at nucleotide 2703 and G at nucleotide 3181. The nucleotide numbering is relative to SEQ ID NO: 1.

The isolated nucleic acid molecules of the present invention can be RNA,
10 for example, mRNA, or DNA, such as cDNA and genomic DNA. DNA molecules can be double-stranded or single-stranded; single-stranded RNA or DNA can be either the coding, or sense, strand or the non-coding, or antisense, strand. The nucleic acid molecule can include all or a portion of the coding sequence of the gene and can further comprise additional non-coding sequences such as introns and
15 non-coding 3' and 5' sequences (including regulatory sequences, for example). Additionally, the nucleic acid molecule can be fused to a marker sequence, for example, a sequence that encodes a polypeptide to assist in isolation or purification of the polypeptide. Such sequences include, but are not limited to, those which encode a glutathione-S-transferase (GST)
20 fusion protein and those which encode a hemagglutinin A (HA) polypeptide marker from influenza.

An "isolated" nucleic acid molecule, as used herein, is one that is separated from nucleic acids which normally flank the gene or nucleotide sequence (as in genomic sequences) and/or has been completely or partially purified from other
25 transcribed sequences (*e.g.*, as in an RNA library). For example, an isolated nucleic acid of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. In some instances, the isolated material will form part of a composition
30 (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstances, the material may be purified to essential homogeneity,

for example as determined by PAGE or column chromatography such as HPLC. Preferably, an isolated nucleic acid molecule comprises at least about 50, 80, 90 or 95% (on a molar basis) of all macromolecular species present. With regard to genomic DNA, the term "isolated" also can refer to nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. For example, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotides which flank the nucleic acid molecule in the genomic DNA of the cell from which the nucleic acid molecule is derived.

The nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated. Thus, recombinant DNA contained in a vector is included in the definition of "isolated" as used herein. Also, isolated nucleic acid molecules include recombinant DNA molecules in heterologous host cells, as well as partially or substantially purified DNA molecules in solution.

"Isolated" nucleic acid molecules also encompass *in vivo* and *in vitro* RNA transcripts of the DNA molecules of the present invention. An isolated nucleic acid molecule or nucleotide sequence can include a nucleic acid molecule or nucleotide sequence which is synthesized chemically or by recombinant means. Therefore, recombinant DNA contained in a vector are included in the definition of "isolated" as used herein. Also, isolated nucleotide sequences include recombinant DNA molecules in heterologous organisms, as well as partially or substantially purified DNA molecules in solution. *In vivo* and *in vitro* RNA transcripts of the DNA molecules of the present invention are also encompassed by "isolated" nucleotide sequences. Such isolated nucleotide sequences are useful in the manufacture of the encoded polypeptide, as probes for isolating homologous sequences (*e.g.*, from other mammalian species), for gene mapping (*e.g.*, by *in situ* hybridization with chromosomes), or for detecting expression of the gene in tissue (*e.g.*, human tissue), such as by Northern blot analysis.

The present invention also pertains to variant nucleic acid molecules which are not necessarily found in nature but which encode an RNF 11 polypeptide (*e.g.*, a polypeptide having the amino acid sequence of any one of Parkinson's disease genes

or another variant of a RNF 11 polypeptide). Thus, for example, DNA molecules which comprise a sequence that is different from the naturally-occurring nucleotide sequence but which, due to the degeneracy of the genetic code, encode an RNF 11 polypeptide of the present invention are also the subject of this invention. The
5 invention also encompasses nucleotide sequences encoding portions (fragments), or encoding variant polypeptides such as analogues or derivatives of a RNF 11 polypeptide. Such variants can be naturally-occurring, such as in the case of allelic variation or single nucleotide polymorphisms, or non-naturally-occurring, such as those induced by various mutagens and mutagenic processes. Intended variations
10 include, but are not limited to, addition, deletion and substitution of one or more nucleotides which can result in conservative or non-conservative amino acid changes, including additions and deletions. Preferably the nucleotide (and/or resultant amino acid) changes are silent or conserved; that is, they do not alter the characteristics or activity of the RNF 11 polypeptide. In one preferred embodiment,
15 the nucleotide sequences are fragments that comprise one or more polymorphic microsatellite markers.

Other alterations of nucleic acid molecules of the invention can include, for example, labelling, methylation, internucleotide modifications such as uncharged
linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoamidates,
20 carbamates), charged linkages (*e.g.*, phosphorothioates, phosphorodithioates), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen), chelators, alkylators, and modified linkages (*e.g.*, alpha anomeric nucleic acids). Also included are synthetic molecules that mimic nucleic acid molecules in the ability to bind to a designated sequences via hydrogen bonding and other chemical
25 interactions. Such molecules include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

The invention also pertains to nucleic acid molecules which hybridize under high stringency hybridization conditions, such as for selective hybridization, to a nucleotide sequence described herein (*e.g.*, nucleic acid molecules which specifically
30 hybridize to a nucleotide sequence encoding polypeptides described herein, and, optionally, have an activity of the polypeptide). In one embodiment, the invention

includes variants described herein which hybridize under high stringency hybridization conditions (*e.g.*, for selective hybridization) to a nucleotide sequence comprising a nucleotide sequence selected from SEQ ID NO: 1 or the complement of SEQ ID NO: 1. In another embodiment, the invention includes variants described
5 herein which hybridize under high stringency hybridization conditions (*e.g.*, for selective hybridization) to a nucleotide sequence encoding an amino acid sequence encoded by SEQ ID NO: 1. In a preferred embodiment, the variant which hybridizes under high stringency hybridizations has an activity of RNF 11 (*e.g.*, binding activity).

10 Such nucleic acid molecules can be detected and/or isolated by specific hybridization (*e.g.*, under high stringency conditions). "Specific hybridization," as used herein, refers to the ability of a first nucleic acid to hybridize to a second nucleic acid in a manner such that the first nucleic acid does not hybridize to any nucleic acid other than to the second nucleic acid (*e.g.*, when the first nucleic acid
15 has a higher similarity to the second nucleic acid than to any other nucleic acid in a sample wherein the hybridization is to be performed). "Stringency conditions" for hybridization is a term of art which refers to the incubation and wash conditions, *e.g.*, conditions of temperature and buffer concentration, which permit hybridization of a particular nucleic acid to a second nucleic acid; the first nucleic acid may be
20 perfectly (*i.e.*, 100%) complementary to the second, or the first and second may share some degree of complementarity which is less than perfect (*e.g.*, 70%, 75%, 85%, 95%). For example, certain high stringency conditions can be used which distinguish perfectly complementary nucleic acids from those of less complementarity. "High stringency conditions", "moderate stringency conditions"
25 and "low stringency conditions" for nucleic acid hybridizations are explained on pages 2.10.1-2.10.16 and pages 6.3.1-6.3.6 in "*Current Protocols in Molecular Biology*" (Ausubel, F.M. *et al.*, "*Current Protocols in Molecular Biology*", John Wiley & Sons, (2001), the entire teachings of which are incorporated by reference herein). The exact conditions which determine the stringency of hybridization
30 depend not only on ionic strength (*e.g.*, 0.2XSSC, 0.1XSSC), temperature (*e.g.*, room temperature, 42°C, 68°F) and the concentration of destabilizing agents such as

formamide or denaturing agents such as SDS, but also on factors such as the length of the nucleic acid sequence, base composition, percent mismatch between hybridizing sequences and the frequency of occurrence of subsets of that sequence within other non-identical sequences. Thus, equivalent conditions can be determined
5 by varying one or more of these parameters while maintaining a similar degree of identity or similarity between the two nucleic acid molecules. Typically, conditions are used such that sequences at least about 60%, at least about 70%, at least about 80%, at least about 90% or at least about 95% or more identical to each other remain hybridized to one another. By varying hybridization conditions from a level of
10 stringency at which no hybridization occurs to a level at which hybridization is first observed, conditions which will allow a given sequence to hybridize (*e.g.*, selectively) with the most similar sequences in the sample can be determined.

Exemplary conditions are described in Krause, M.H. and S.A. Aaronson, *Methods in Enzymology*, 200:546-556 (1991). Also, in, Ausubel, *et al.*, *Current*
15 *Protocols in Molecular Biology*, John Wiley & Sons, (2001), which describes the determination of washing conditions for moderate or low stringency conditions. Washing is the step in which conditions are usually set so as to determine a minimum level of complementarity of the hybrids. Generally, starting from the lowest temperature at which only homologous hybridization occurs, each °C by
20 which the final wash temperature is reduced (holding SSC concentration constant) allows an increase by 1% in the maximum extent of mismatching among the sequences that hybridize. Generally, doubling the concentration of SSC results in an increase in T_m of ~17°C. Using these guidelines, the washing temperature can be determined empirically for high, moderate or low stringency, depending on the level
25 of mismatch sought.

For example, a low stringency wash can comprise washing in a solution containing 0.2XSSC/0.1% SDS for 10 min at room temperature; a moderate stringency wash can comprise washing in a prewarmed solution (42°C) solution containing 0.2XSSC/0.1% SDS for 15 min at 42°C; and a high stringency wash can
30 comprise washing in prewarmed (68°C) solution containing 0.1XSSC/0.1%SDS for 15 min at 68°C. Furthermore, washes can be performed repeatedly or sequentially to

obtain a desired result as known in the art. Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleic acid molecule and the primer or probe used.

5 The percent identity of two nucleotide or amino acid sequences can be determined by aligning the sequences for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first sequence). The nucleotides or amino acids at corresponding positions are then compared, and the percent identity between the two sequences is a function of the number of identical positions shared by the
10 sequences (*i.e.*, % identity = # of identical positions/total # of positions x 100). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 60%, and even more preferably at least 70%, 80% or 90% of the length of the reference sequence. The actual comparison of the two sequences can be accomplished by well-known
15 methods, for example, using a mathematical algorithm. A preferred, non-limiting example of such a mathematical algorithm is described in Karlin *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:5873-5877 (1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) as described in Altschul *et al.*, *Nucleic Acids Res.*, 25:389-3402 (1997). When utilizing BLAST and Gapped
20 BLAST programs, the default parameters of the respective programs (*e.g.*, NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. In one embodiment, parameters for sequence comparison can be set at score=100, wordlength=12, or can be varied (*e.g.*, W=5 or W=20).

 Another preferred, non-limiting example of a mathematical algorithm
25 utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.
30 Additional algorithms for sequence analysis are known in the art and include ADVANCE and ADAM as described in Torellis and Robotti, *Comput. Appl. Biosci.*,

10:3-5 (1994); and FASTA described in Pearson and Lipman, *PNAS*, 85:2444-8 (1988).

In another embodiment, the percent identity between two amino acid sequences can be accomplished using the GAP program in the GCG-software package (available at <http://www.accelrys.com/about/gcg.html>) using either a Blossom 63 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4. In yet another embodiment, the percent identity between two nucleic acid sequences can be accomplished using the GAP program in the GCG-software package (available at <http://www.accelrys.com/about/gcg.html>), using a gap weight of 50 and a length weight of 3.

The present invention also provides isolated nucleic acid molecules that contain a fragment or portion that hybridizes under highly stringent conditions to a nucleotide sequence comprising a nucleotide sequence of SEQ ID NO: 1 and the complement of SEQ ID NO: 1, and also provides isolated nucleic acid molecules that contain a fragment or portion that hybridizes under highly stringent conditions to a nucleotide sequence encoding an amino acid sequence of SEQ ID NO: 2. The nucleic acid fragments of the invention are at least about 15, preferably at least about 18, 20, 23 or 25 nucleotides, and can be 30, 40, 50, 100, 200 or more nucleotides in length. Longer fragments, for example, 30 or more nucleotides in length, which encode antigenic polypeptides described herein are particularly useful, such as for the generation of antibodies as described below.

In a related aspect, the nucleic acid fragments of the invention are used as probes or primers in assays such as those described herein. "Probes" or "primers" are oligonucleotides that hybridize in a base-specific manner to a complementary strand of nucleic acid molecules. Such probes and primers include polypeptide nucleic acids, as described in Nielsen *et al.*, *Science*, 254:1497-1500 (1991). As also used herein, the term "primer" in particular refers to a single-stranded oligonucleotide which acts as a point of initiation of template-directed DNA synthesis using well-known methods (*e.g.*, PCR, LCR) including, but not limited to those described herein.

Typically, a probe or primer comprises a region of nucleotide sequence that hybridizes to at least about 15, typically about 20-25, and more typically about 40, 50 or 75, consecutive nucleotides of a nucleic acid molecule comprising a contiguous nucleotide sequence selected from: SEQ ID NO: 1, the complement of SEQ ID NO: 1, or a sequence encoding an amino acid sequence of SEQ ID NO: 2. In preferred embodiments, a probe or primer comprises 100 or fewer nucleotides, preferably from 6 to 50 nucleotides, preferably from 12 to 30 nucleotides. In other embodiments, the probe or primer is at least 70% identical to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence, preferably at least 80% identical, more preferably at least 90% identical, even more preferably at least 95% identical, or even capable of selectively hybridizing to the contiguous nucleotide sequence or to the complement of the contiguous nucleotide sequence. Often, the probe or primer further comprises a label, *e.g.*, radioisotope, fluorescent compound, enzyme or enzyme co-factor.

The nucleic acid molecules of the invention such as those described above can be identified and isolated using standard molecular biology techniques and the sequence information provided in SEQ ID NO: 1, and/or SEQ ID NO: 2. For example, nucleic acid molecules can be amplified and isolated by the polymerase chain reaction using synthetic oligonucleotide primers designed based on one or more of the sequences provided in SEQ ID NO: 1 and/or the complement of SEQ ID NO: 1, or designed based on nucleotides based on sequences encoding one or more of the amino acid sequences provided in SEQ ID NO: 2. See generally *PCR Technology: Principles and Applications for DNA Amplification* (ed. H.A. Erlich, Freeman Press, NY, NY, 1992); *PCR Protocols: A Guide to Methods and Applications* (Eds. Innis, *et al.*, Academic Press, San Diego, CA, 1990); Mattila *et al.*, *Nucleic Acids Res.*, 19:4967 (1991); Eckert *et al.*, *PCR Methods and Applications*, 1:17 (1991); PCR (eds. McPherson *et al.*, IRL Press, Oxford); and U.S. Patent 4,683,202. The nucleic acid molecules can be amplified using cDNA, mRNA or genomic DNA as a template, cloned into an appropriate vector and characterized by DNA sequence analysis.

Other suitable amplification methods include the ligase chain reaction (LCR) (see Wu and Wallace, *Genomics*, 4:560 (1989), Landegren *et al.*, *Science*, 241:1077 (1988), transcription amplification (Kwoh *et al.*, *Proc. Natl. Acad. Sci. USA*, 86:1173 (1989)), and self-sustained sequence replication (Guatelli *et al.*, *Proc. Nat. Acad. Sci. USA*, 87:1874 (1990)) and nucleic acid based sequence amplification (NASBA). The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

10 The amplified DNA can be radiolabelled and used as a probe for screening a cDNA library derived from human cells, mRNA in zap express, ZIPLOX or other suitable vector. Corresponding clones can be isolated, DNA can obtained following *in vivo* excision, and the cloned insert can be sequenced in either or both orientations by art recognized methods to identify the correct reading frame encoding a
15 polypeptide of the appropriate molecular weight. For example, the direct analysis of the nucleotide sequence of nucleic acid molecules of the present invention can be accomplished using well-known methods that are commercially available. See, for example, Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd Ed., CSHP, New York 1989); Zyskind *et al.*, *Recombinant DNA Laboratory Manual*,
20 (Acad. Press, 1988)). Using these or similar methods, the polypeptide and the DNA encoding the polypeptide can be isolated, sequenced and further characterized.

Antisense nucleic acid molecules of the invention can be designed using the nucleotide sequences of SEQ ID NO: 1 and/or the complement of SEQ ID NO: 1, and/or a portion of SEQ ID NO: 1 or the complement of SEQ ID NO: 1, and/or a
25 sequence encoding the amino acid sequence of SEQ ID NO: 2, or encoding a portion of SEQ ID NO: 2, and constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid molecule (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to
30 increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*,

phosphorothioate derivatives and acridine substituted nucleotides can be used.

Alternatively, the antisense nucleic acid molecule can be produced biologically using an expression vector into which a nucleic acid molecule has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid molecule will be of an antisense orientation to a target nucleic acid of interest).

In general, the isolated nucleic acid sequences of the invention can be used as molecular weight markers on Southern gels, and as chromosome markers which are labeled to map related gene positions. The nucleic acid sequences can also be used to compare with endogenous DNA sequences in patients to identify genetic disorders (*e.g.*, a predisposition for or susceptibility to Parkinson's disease), and as probes, such as to hybridize and discover related DNA sequences or to subtract out known sequences from a sample. The nucleic acid sequences can further be used to derive primers for genetic fingerprinting, to raise anti-polypeptide antibodies using DNA immunization techniques, and as an antigen to raise anti-DNA antibodies or elicit immune responses. Portions or fragments of the nucleotide sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Additionally, the nucleotide sequences of the invention can be used to identify and express recombinant polypeptides for analysis, characterization or therapeutic use, or as markers for tissues in which the corresponding polypeptide is expressed, either constitutively, during tissue differentiation, or in diseased states. The nucleic acid sequences can additionally be used as reagents in the screening and/or diagnostic assays described herein, and can also be included as components of kits (*e.g.*, reagent kits) for use in the screening and/or diagnostic assays described herein.

Another aspect of the invention pertains to nucleic acid constructs containing a nucleic acid molecule selected from the group consisting of SEQ ID NO: 1 and the complement of SEQ ID NO: 1 (or a portion thereof). Yet another aspect of the

invention pertains to nucleic acid constructs containing a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO: 2. The constructs comprise a vector (*e.g.*, an expression vector) into which a sequence of the invention has been inserted in a sense or antisense orientation. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses) that serve equivalent functions.

Preferred recombinant expression vectors of the invention comprise a nucleic acid molecule of the invention in a form suitable for expression of the nucleic acid molecule in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term “regulatory sequence” is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in

Goeddel, *Gene Expression Technology: Methods in Enzymology 185*, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*,
5 tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed and the level of expression of polypeptide desired. The expression vectors of the invention can be introduced into host cells to thereby produce polypeptides, including fusion polypeptides, encoded by nucleic acid
10 molecules as described herein .

The recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic or eukaryotic cells, *e.g.*, bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors), yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel,
15 *supra*. Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms
20 "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included
25 within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a nucleic acid molecule of the invention can be expressed in bacterial cells (*e.g.*, *E. coli*), insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

30 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms

“transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing a foreign nucleic acid molecule (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or
5 electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*supra*), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select
10 these integrants, a gene that encodes a selectable marker (*e.g.*, for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid molecules encoding a selectable marker can be introduced into a host cell on the same vector as the nucleic acid
15 molecule of the invention or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid molecule can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in
20 culture, can be used to produce (*i.e.*, express) a polypeptide of the invention. Accordingly, the invention further provides methods for producing a polypeptide using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium
25 such that the polypeptide is produced. In another embodiment, the method further comprises isolating the polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a nucleic acid molecule of
30 the invention (*e.g.*, an exogenous RNF 11 gene, or an exogenous nucleic acid encoding an RNF 11 polypeptide) has been introduced. Such host cells can then be

used to create non-human transgenic animals in which exogenous nucleotide sequences have been introduced into the genome or homologous recombinant animals in which endogenous nucleotide sequences have been altered. Such animals are useful for studying the function and/or activity of the nucleotide sequence and polypeptide encoded by the sequence and for identifying and/or evaluating modulators of their activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens and amphibians. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan, *Manipulating the Mouse Embryo* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, *Current Opinion in Bio/Technology*, 2:823-829 (1991) and in PCT Publication Nos. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169. Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut *et al.*, *Nature*, 385:810-813 (1997) and PCT Publication Nos. WO 97/07668 and WO 97/07669.

POLYPEPTIDES OF THE INVENTION

The present invention also pertains to isolated polypeptides encoded by RNF 11 ("RNF 11 polypeptides"), and fragments and variants thereof, as well as polypeptides encoded by nucleotide sequences described herein (*e.g.*, other variants).

- 5 The term "polypeptide" refers to a polymer of amino acids, and not to a specific length; thus, peptides, oligopeptides and proteins are included within the definition of a polypeptide. As used herein, a polypeptide is said to be "isolated" or "purified" when it is substantially free of cellular material when it is isolated from recombinant and non-recombinant cells, or free of chemical precursors or other chemicals when it
- 10 is chemically synthesized. A polypeptide, however, can be joined to another polypeptide with which it is not normally associated in a cell (*e.g.*, in a "fusion protein") and still be "isolated" or "purified."

- The polypeptides of the invention can be purified to homogeneity. It is understood, however, that preparations in which the polypeptide is not purified to
- 15 homogeneity are useful. The critical feature is that the preparation allows for the desired function of the polypeptide, even in the presence of considerable amounts of other components. Thus, the invention encompasses various degrees of purity. In one embodiment, the language "substantially free of cellular material" includes preparations of the polypeptide having less than about 30% (by dry weight) other
- 20 proteins (*i.e.*, contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins.

- When a polypeptide is recombinantly produced, it can also be substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, less than about 10%, or less than about 5% of the volume of the polypeptide preparation.
- 25 The language "substantially free of chemical precursors or other chemicals" includes preparations of the polypeptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the polypeptide having less than about 30% (by dry weight) chemical precursors
- 30 or other chemicals, less than about 20% chemical precursors or other chemicals, less

than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

In one embodiment, a polypeptide of the invention comprises an amino acid sequence encoded by a nucleic acid molecule comprising a nucleotide sequence
5 selected from the group consisting of SEQ ID NO: 1 and complements and portions thereof.

The polypeptides of the invention also encompass fragments and sequence variants. Variants include a substantially homologous polypeptide encoded by the same genetic locus in an organism, *i.e.*, an allelic variant, as well as other variants.
10 Variants also encompass polypeptides derived from other genetic loci in an organism, but having substantial homology to a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO: 1 and complements and portions thereof, or having substantial homology to a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence of nucleotide sequences
15 encoding by SEQ ID NO: 1 or variant or portion thereof. Variants also include polypeptides substantially homologous or identical to these polypeptides but derived from another organism, *i.e.*, an ortholog. Variants also include polypeptides that are substantially homologous or identical to these polypeptides that are produced by chemical synthesis. Variants also include polypeptides that are substantially
20 homologous or identical to these polypeptides that are produced by recombinant methods.

As used herein, two polypeptides (or a region of the polypeptides) are substantially homologous or identical when the amino acid sequences are at least about 45-55%, typically at least about 70-75%, more typically at least about 80-85%,
25 and most typically greater than about 90 or 95% or more homologous or identical. A substantially homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid molecule hybridizing to SEQ ID NO: 1 or portion thereof, under stringent conditions as more particularly described above, or will be encoded by a nucleic acid molecule hybridizing to a nucleic acid sequence encoding
30 SEQ ID NO: 2, or portion thereof, under stringent conditions as more particularly described thereof.

To determine the percent homology or identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of one polypeptide or nucleic acid molecule for optimal alignment with the other polypeptide or nucleic acid molecule). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence, then the molecules are homologous at that position. As used herein, amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity". The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, percent homology equals the number of identical positions/total number of positions times 100).

The invention also encompasses polypeptides having a lower degree of identity but having sufficient similarity so as to perform one or more of the same functions performed by a polypeptide encoded by a nucleic acid molecule of the invention. Similarity is determined by conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Conservative substitutions are likely to be phenotypically silent. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science*, 247:1306-1310 (1990).

A variant polypeptide can differ in amino acid sequence by one or more substitutions, deletions, insertions, inversions, fusions, and truncations or a combination of any of these. Further, variant polypeptides can be fully functional or can lack function in one or more activities. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical

regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid
5 substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science*, 244: 1081-1085 (1989)). The latter procedure
10 introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity *in vitro*, or *in vitro* proliferative activity. Sites that are critical for polypeptide activity can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.*, 224: 899-904 (1992); de Vos *et al.* *Science*, 255: 306-312 (1992)).
15

The invention also includes polypeptide fragments of the polypeptides of the invention. Fragments can be derived from a polypeptide encoded by a nucleic acid molecule comprising SEQ ID NO: 1 or a portion thereof and the complements thereof. However, the invention also encompasses fragments of the variants of the
20 polypeptides described herein. As used herein, a fragment comprises at least 6 contiguous amino acids. Useful fragments include those that retain one or more of the biological activities of the polypeptide as well as fragments that can be used as an immunogen to generate polypeptide-specific antibodies.

Biologically active fragments (peptides which are, for example, 6, 9, 12, 15,
25 16, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) can comprise a domain, segment, or motif that has been identified by analysis of the polypeptide sequence using well-known methods, *e.g.*, signal peptides, extracellular domains, one or more transmembrane segments or loops, ligand binding regions, zinc finger domains, DNA binding domains, acylation sites, glycosylation sites, or
30 phosphorylation sites.

Fragments can be discrete (not fused to other amino acids or polypeptides) or can be within a larger polypeptide. Further, several fragments can be comprised within a single larger polypeptide. In one embodiment a fragment designed for expression in a host can have heterologous pre- and pro-polypeptide regions fused to the amino terminus of the polypeptide fragment and an additional region fused to the carboxyl terminus of the fragment.

The invention thus provides chimeric or fusion polypeptides. These comprise a polypeptide of the invention operatively linked to a heterologous protein or polypeptide having an amino acid sequence not substantially homologous to the polypeptide. "Operatively linked" indicates that the polypeptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the polypeptide. In one embodiment the fusion polypeptide does not affect function of the polypeptide *per se*. For example, the fusion polypeptide can be a GST-fusion polypeptide in which the polypeptide sequences are fused to the C-terminus of the GST sequences. Other types of fusion polypeptides include, but are not limited to, enzymatic fusion polypeptides, for example β -galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions and Ig fusions. Such fusion polypeptides, particularly poly-His fusions, can facilitate the purification of recombinant polypeptide. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of a polypeptide can be increased by using a heterologous signal sequence. Therefore, in another embodiment, the fusion polypeptide contains a heterologous signal sequence at its N-terminus.

EP-A-0 464 533 discloses fusion proteins comprising various portions of immunoglobulin constant regions. The Fc is useful in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). In drug discovery, for example, human proteins have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists. Bennett *et al.*, *Journal of Molecular Recognition*, 8:52-58 (1995) and Johanson *et al.*, *The Journal of Biological Chemistry*, 270(16): 9459-9471 (1995). Thus, this invention also encompasses soluble fusion polypeptides containing a polypeptide of the

invention and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclass (IgG, IgM, IgA, IgE).

A chimeric or fusion polypeptide can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of nucleic acid fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive nucleic acid fragments which can subsequently be annealed and re-amplified to generate a chimeric nucleic acid sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST protein). A nucleic acid molecule encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide.

The isolated polypeptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. In one embodiment, the polypeptide is produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the polypeptide is cloned into an expression vector, the expression vector introduced into a host cell and the polypeptide expressed in the host cell. The polypeptide can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques.

In general, polypeptides of the present invention can be used as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using art-recognized methods. The polypeptides of the present invention can be used to raise antibodies or to elicit an immune response. The polypeptides can also be used as a reagent, *e.g.*, a labeled reagent, in assays to quantitatively determine levels of the polypeptide or a molecule to which it binds (*e.g.*, a receptor or a ligand) in biological fluids. The polypeptides can also be used as markers for cells or tissues in which the corresponding polypeptide is preferentially expressed, either

constitutively, during tissue differentiation, or in a diseased state. The polypeptides can be used to isolate a corresponding binding agent, *e.g.*, receptor or ligand, such as, for example, in an interaction trap assay, and to screen for peptide or small molecule antagonists or agonists of the binding interaction.

5 ANTIBODIES OF THE INVENTION

Polyclonal and/or monoclonal antibodies that specifically bind one form of the gene product but not to the other form of the gene are also provided. Antibodies are also provided that bind a portion of either variant or the reference gene product that contains the polymorphic site or sites.

- 10 In another aspect, the invention provides antibodies to the polypeptides and polypeptide fragments of the invention, *e.g.*, having an amino acid sequence encoded by SEQ ID NO: 2, or a portion thereof, or having an amino acid sequence encoded by a nucleic acid molecule comprising all or a portion of SEQ ID NO: 1 (*e.g.*, SEQ ID NO: 2, or another variant, or portion thereof). The term “antibody” as used
- 15 herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site that specifically binds an antigen. A molecule that specifically binds to a polypeptide of the invention is a molecule that binds to that polypeptide or a fragment thereof, but does not substantially bind other molecules in a sample, *e.g.*, a biological sample,
- 20 which naturally contains the polypeptide. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind to a polypeptide of the invention. The term “monoclonal antibody” or “monoclonal antibody
- 25 composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of a polypeptide of the invention. A monoclonal antibody composition thus typically displays a single binding affinity for a particular polypeptide of the invention with which it immunoreacts.

Polyclonal antibodies can be prepared as described above by immunizing a suitable subject with a desired immunogen, *e.g.*, polypeptide of the invention or fragment thereof. The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. If desired, the antibody molecules directed against the polypeptide can be isolated from the mammal (*e.g.*, from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, *e.g.*, when the antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein, *Nature*, 256:495-497 (1975), the human B cell hybridoma technique (Kozbor *et al.*, *Immunol. Today*, 4:72 (1983)), the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)) or trioma techniques. The technology for producing hybridomas is well known (see generally Ausubel, *et al.* (Eds.), *Current Protocols in Immunology*, John Wiley & Sons, Inc., New York, NY (2001)). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with an immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds a polypeptide of the invention.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating a monoclonal antibody to a polypeptide of the invention (see, *e.g.*, *Current Protocols in Immunology*, *supra*; Galfre *et al.*, *Nature*, 266:55052 (1977); R.H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); and Lerner, *Yale J. Biol. Med.*, 54:387-402 (1981)). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods that also would be useful.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody to a polypeptide of the invention can be identified and isolated

by screening a recombinant combinatorial immunoglobulin library (*e.g.*, an antibody phage display library) with the polypeptide to thereby isolate immunoglobulin library members that bind the polypeptide. Kits for generating and screening phage display libraries are commercially available (*e.g.*, the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™* Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs *et al.*, *Bio/Technology*, 9:1370-1372 (1991); Hay *et al.*, *Hum. Antibod. Hybridomas*, 3:81-85 (1992); Huse *et al.*, *Science*, 246:1275-1281 (1989); Griffiths *et al.*, *EMBO J.*, 12:725-734 (1993).

Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art.

The invention also is intended to cover human antibodies. Their methods for production, isolation purification and use are known to those skilled in the art using standard methodologies.

In general, antibodies of the invention (*e.g.*, a monoclonal antibody) can be used to isolate a polypeptide of the invention by standard techniques, such as affinity chromatography or immunoprecipitation. A polypeptide-specific antibody can facilitate the purification of natural polypeptide from cells and of recombinantly produced polypeptide expressed in host cells. Moreover, an antibody specific for a polypeptide of the invention can be used to detect the polypeptide (*e.g.*, in a cellular lysate, cell supernatant, or tissue sample) in order to evaluate the abundance and pattern of expression of the polypeptide. Antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for

example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

DIAGNOSTIC AND SCREENING ASSAYS OF THE INVENTION

The present invention also pertains to diagnostic assays for assessing ring finger protein 11 gene expression, or for assessing activity of RNF 11 polypeptides of the invention. In one embodiment, the assays are used in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with Parkinson's disease, or is at risk for (has a predisposition for or a susceptibility to) developing Parkinson's disease. The invention also provides for prognostic (or predictive) assays for determining whether an individual is susceptible to developing Parkinson's disease. For example, mutations in the gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of symptoms associated with Parkinson's disease. Another aspect of the invention pertains to assays for monitoring the influence of agents (*e.g.*, drugs, compounds or other agents) on the gene expression or activity of polypeptides of the invention, as well as to assays for identifying agents which bind to RNF 11 polypeptides. These and other assays and agents are described in further detail in the following sections.

DIAGNOSTIC ASSAYS

Nucleic acids, probes, primers, polypeptides and antibodies to the RNF 11 protein can be used in methods of diagnosis of a susceptibility to Parkinson's disease, as well as in kits useful for diagnosis of a susceptibility to Parkinson's
5 disease.

In one embodiment of the invention, diagnosis of a susceptibility to Parkinson's disease is made by detecting a polymorphism in *PARK8*. The polymorphism can be a mutation in *PARK8*, such as the insertion or deletion of a single nucleotide, or of more than one nucleotide, resulting in a frame shift mutation;
10 the change of at least one nucleotide, resulting in a change in the encoded amino acid; the change of at least one nucleotide, resulting in the generation of a premature stop codon; the deletion of several nucleotides, resulting in a deletion of one or more amino acids encoded by the nucleotides; the insertion of one or several nucleotides, such as by unequal recombination or gene conversion, resulting in an interruption of
15 the coding sequence of the gene; duplication of all or a part of the gene; transposition of all or a part of the gene; or rearrangement of all or a part of the gene. More than one such mutation may be present in a single gene. Such sequence changes cause a mutation in the polypeptide encoded by *PARK8*. For example, if the mutation is a frame shift mutation, the frame shift can result in a change in the
20 encoded amino acids, and/or can result in the generation of a premature stop codon, causing generation of a truncated polypeptide. Alternatively, a polymorphism associated with a susceptibility to Parkinson's disease can be a synonymous mutation in one or more nucleotides (*i.e.*, a mutation that does not result in a change in the polypeptide encoded by *PARK8*). Such a polymorphism may alter binding
25 sites, affect the stability or transport of mRNA, or otherwise affect the transcription or translation of the gene. *PARK8* that has any of the mutations described above is referred to herein as a "mutant or variant gene."

In a first method of diagnosing a susceptibility to Parkinson's disease, hybridization methods, such as Southern analysis, Northern analysis, or *in situ*
30 hybridizations, can be used (see Current Protocols in Molecular Biology, Ausubel, F. *et al.*, eds., John Wiley & Sons, including all supplements through 2001). For

example, a biological sample from a test subject (a “test sample”) of genomic DNA, RNA, or cDNA, is obtained from an individual suspected of having, being susceptible to or predisposed for, or carrying a defect for, Parkinson’s disease (the “test individual”). The individual can be an adult, child, or fetus. The test sample
5 can be from any source which contains genomic DNA, such as a blood sample, sample of amniotic fluid, sample of cerebrospinal fluid, or tissue sample from skin, muscle, buccal or conjunctival mucosa, placenta, gastrointestinal tract or other organs. A test sample of DNA from fetal cells or tissue can be obtained by appropriate methods, such as by amniocentesis or chorionic villus sampling. The
10 DNA, RNA, or cDNA sample is then examined to determine whether a polymorphism in *PARK8* is present, and/or to determine which variant(s) encoded by *PARK8* is present. The presence of the polymorphism or variant(s) can be indicated by hybridization of the gene in the genomic DNA, RNA, or cDNA to a nucleic acid probe. A “nucleic acid probe”, as used herein, can be a DNA probe or
15 an RNA probe; the nucleic acid probe can contain at least one polymorphism in *PARK8* or contains a nucleic acid encoding a particular variant of *PARK8*. The probe can be any of the nucleic acid molecules described above (e.g., the gene, a fragment, a vector comprising the gene, a probe or primer, etc.).

— To diagnose a susceptibility to Parkinson’s disease, a hybridization sample is formed
20 by contacting the test sample containing *PARK8*, with at least one nucleic acid probe. A preferred probe for detecting mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic DNA sequences described herein. The nucleic acid probe can be, for example, a full-length nucleic acid molecule, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100,
25 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to appropriate mRNA or genomic DNA. For example, the nucleic acid probe can be all or a portion of SEQ ID NO: 1, or the complement of SEQ ID NO: 1, or a portion thereof; or can be a nucleic acid encoding all or a portion of SEQ ID NO: 2. Other suitable probes for use in the diagnostic assays of
30 the invention are described above (see. e.g., probes and primers discussed under the heading, “Nucleic Acids of the Invention”). In a preferred embodiment, the probe

can be all or a portion of the promoter region of the *PARK8* gene or complement comprising at least one of the novel SNPs in the promoter region or the SNP proximate to the ATG start codon.

The hybridization sample is maintained under conditions which are
5 sufficient to allow specific hybridization of the nucleic acid probe to *PARK8*.
“Specific hybridization”, as used herein, indicates exact hybridization (*e.g.*, with no mismatches). Specific hybridization can be performed under high stringency conditions or moderate stringency conditions, for example, as described above. In a particularly preferred embodiment, the hybridization conditions for specific
10 hybridization are high stringency.

Specific hybridization, if present, is then detected using standard methods. If specific hybridization occurs between the nucleic acid probe and *PARK8* in the test sample, then *PARK8* has the polymorphism, or is the variant, that is present in the nucleic acid probe. More than one nucleic acid probe can also be used concurrently
15 in this method. Specific hybridization of any one of the nucleic acid probes is indicative of a polymorphism in *PARK8*, or of the presence of a particular variant encoded by *PARK8*, and is therefore diagnostic for a susceptibility to Parkinson’s disease.

In Northern analysis (see Current Protocols in Molecular Biology, Ausubel,
20 F. *et al.*, eds., John Wiley & Sons, *supra*), the hybridization methods described above are used to identify the presence of a polymorphism or of a particular variant, associated with a susceptibility to Parkinson’s disease. For Northern analysis, a test sample of RNA is obtained from the individual by appropriate means. Specific hybridization of a nucleic acid probe, as described above, to RNA from the
25 individual is indicative of a polymorphism in *PARK8*, or of the presence of a particular variant encoded by *PARK8*, and is therefore diagnostic for a susceptibility to Parkinson’s disease.

For representative examples of use of nucleic acid probes, see, for example, U.S. Patents No. 5,288,611 and 4,851,330.

30 Alternatively, a peptide nucleic acid (PNA) probe can be used instead of a nucleic acid probe in the hybridization methods described above. PNA is a DNA

mimic having a peptide-like, inorganic backbone, such as N-(2-aminoethyl)glycine units, with an organic base (A, G, C, T or U) attached to the glycine nitrogen via a methylene carbonyl linker (see, for example, Nielsen, P.E. *et al.*, *Bioconjugate Chemistry*, 1994, 5, American Chemical Society, p. 1 (1994). The PNA probe can
5 be designed to specifically hybridize to a gene having a polymorphism associated with a susceptibility to Parkinson's disease. Hybridization of the PNA probe to *PARK8* is diagnostic for a susceptibility to Parkinson's disease.

In another method of the invention, mutation analysis by restriction digestion can be used to detect a mutant gene, or genes containing a polymorphism(s), if the
10 mutation or polymorphism in the gene results in the creation or elimination of a restriction site. A test sample containing genomic DNA is obtained from the individual. Polymerase chain reaction (PCR) can be used to amplify *PARK8* (and, if necessary, the flanking sequences) in the test sample of genomic DNA from the test individual. RFLP analysis is conducted as described (see Current Protocols in
15 Molecular Biology, *supra*). The digestion pattern of the relevant DNA fragment indicates the presence or absence of the mutation or polymorphism in *PARK8*, and therefore indicates the presence or absence of this susceptibility to Parkinson's disease.

Sequence analysis can also be used to detect specific polymorphisms in
20 *PARK8*. A test sample of DNA or RNA is obtained from the test individual. PCR or other appropriate methods can be used to amplify the gene, and/or its flanking sequences, if desired. The sequence of *PARK8*, or a fragment of the gene, or cDNA, or fragment of the cDNA, or mRNA, or fragment of the mRNA, is determined, using standard methods. The sequence of the gene, gene fragment, cDNA, cDNA
25 fragment, mRNA, or mRNA fragment is compared with the known nucleic acid sequence of the gene, cDNA (*e.g.*, SEQ ID NO: 1, or a nucleic acid sequence encoding the protein of SEQ ID NO: 2, or a fragment thereof) or mRNA, as appropriate. The presence of a polymorphism in *PARK8* indicates that the individual has a susceptibility to Parkinson's disease.

30 Allele-specific oligonucleotides can also be used to detect the presence of a polymorphism in *PARK8*, through the use of dot-blot hybridization of amplified

oligonucleotides with allele-specific oligonucleotide (ASO) probes (see, for example, Saiki, R. *et al.*, *Nature (London)* 324:163-166 (1986)). An “allele-specific oligonucleotide” (also referred to herein as an “allele-specific oligonucleotide probe”) is an oligonucleotide of approximately 10-50 base pairs, preferably
5 approximately 15-30 base pairs, that specifically hybridizes to *PARK8*, and that contains a polymorphism associated with a susceptibility to Parkinson’s disease. An allele-specific oligonucleotide probe that is specific for particular polymorphisms in *PARK8* can be prepared, using standard methods (see Current Protocols in Molecular Biology, *supra*). To identify polymorphisms in the gene that are
10 associated with a susceptibility to Parkinson’s disease, a test sample of DNA is obtained from the individual. PCR can be used to amplify all or a fragment of *PARK8*, and its flanking sequences. The DNA containing the amplified *PARK8* (or fragment of the gene) is dot-blotted, using standard methods (see Current Protocols in Molecular Biology, *supra*), and the blot is contacted with the oligonucleotide
15 probe. The presence of specific hybridization of the probe to the amplified *PARK8* is then detected. Specific hybridization of an allele-specific oligonucleotide probe to DNA from the individual is indicative of a polymorphism in *PARK8*, and is therefore indicative of a susceptibility to Parkinson’s disease.

In another embodiment, arrays of oligonucleotide probes that are
20 complementary to target nucleic acid sequence segments from an individual, can be used to identify polymorphisms in *PARK8*. For example, in one embodiment, an oligonucleotide array can be used. Oligonucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. These oligonucleotide arrays, also described
25 as “Genechips™,” have been generally described in the art, for example, U.S. Pat. No. 5,143,854 and PCT patent publication Nos. WO 90/15070 and 92/10092. These arrays can generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis methods. See Fodor *et al.*,
30 Science, 251:767-777 (1991), Pirrung *et al.*, U.S. Pat. No. 5,143,854 (see also PCT Application No. WO 90/15070) and Fodor *et al.*, PCT Publication No. WO

92/10092 and U.S. Pat. No. 5,424,186, the entire teachings of each of which are incorporated by reference herein. Techniques for the synthesis of these arrays using mechanical synthesis methods are described in, *e.g.*, U.S. Pat. Nos. 5,384,261, the entire teachings of which are incorporated by reference herein.

- 5 Once an oligonucleotide array is prepared, a nucleic acid of interest is hybridized with the array and scanned for polymorphisms. Hybridization and scanning are generally carried out by methods described herein and also in, *e.g.*, Published PCT Application Nos. WO 92/10092 and WO 95/11995, and U.S. Pat. No. 5,424,186, the entire teachings of which are incorporated by reference herein. In
- 10 brief, a target nucleic acid sequence which includes one or more previously identified polymorphic markers is amplified by well known amplification techniques, *e.g.*, PCR. Typically, this involves the use of primer sequences that are complementary to the two strands of the target sequence both upstream and downstream from the polymorphism. Asymmetric PCR techniques may also be
- 15 used. Amplified target, generally incorporating a label, is then hybridized with the array under appropriate conditions. Upon completion of hybridization and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data obtained from the scan is typically in the form of fluorescence intensities as a function of location on the array.
- 20 Although primarily described in terms of a single detection block, *e.g.*, for detection of a single polymorphism, arrays can include multiple detection blocks, and thus be capable of analyzing multiple, specific polymorphisms. In alternate arrangements, it will generally be understood that detection blocks may be grouped within a single array or in multiple, separate arrays so that varying, optimal
- 25 conditions may be used during the hybridization of the target to the array. For example, it may often be desirable to provide for the detection of those polymorphisms that fall within G-C rich stretches of a genomic sequence, separately from those falling in A-T rich segments. This allows for the separate optimization of hybridization conditions for each situation.
- 30 Additional description of use of oligonucleotide arrays for detection of polymorphisms can be found, for example, in U.S. Patents 5,858,659 and 5,837,832,

the entire teachings of which are incorporated by reference herein.

Other methods of nucleic acid analysis can be used to detect polymorphisms in *PARK8* or variants encoded by *PARK8*. Representative methods include direct manual sequencing (Church and Gilbert, *Proc. Natl. Acad. Sci. USA*, 81:1991-1995, (1988); Sanger, F. *et al. Proc. Natl. Acad. Sci.*, 74:5463-5467 (1977); Beavis *et al.*, U.S. Pat. No. 5,288,644); automated fluorescent sequencing; single-stranded conformation polymorphism assays (SSCP); clamped denaturing gel electrophoresis (CDGE); denaturing gradient gel electrophoresis (DGGE) (Sheffield, V.C. *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 232-236 (1991)), mobility shift analysis (Orita, M. *et al.*, *Proc. Natl. Acad. Sci. USA*, 86: 2766-2770 (1989)), restriction enzyme analysis (Flavell *et al. Cell* 15: 25 (1978); Geever, *et al.*, *Proc. Natl. Acad. Sci. USA* 78:5081); heteroduplex analysis; chemical mismatch cleavage (CMC) (Cotton *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 4397-4401 (1985)); RNase protection assays (Myers, R.M. *et al. Science* 230: 1242 (1985)); use of polypeptides which recognize nucleotide mismatches, such as *E. coli* mutS protein; allele-specific PCR, for example.

In another embodiment of the invention, diagnosis of a susceptibility to Parkinson's disease can also be made by examining expression and/or composition of an *PARK8* polypeptide, by a variety of methods, including enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. A test sample from an individual is assessed for the presence of an alteration in the expression and/or an alteration in composition of the polypeptide encoded by *PARK8*, or for the presence of a particular variant encoded by *PARK8*. An alteration in expression of a polypeptide encoded by *PARK8* can be, for example, an alteration in the quantitative polypeptide expression (*i.e.*, the amount of polypeptide produced); an alteration in the composition of a polypeptide encoded by *PARK8* is an alteration in the qualitative polypeptide expression (*e.g.*, expression of a mutant *PARK8* polypeptide or of a different variant). In a preferred embodiment, diagnosis of a susceptibility to Parkinson's disease is made by detecting a particular variant encoded by *PARK8*, or a particular pattern of variants.

Both quantitative and qualitative alterations can also be present. An “alteration” in the polypeptide expression or composition, as used herein, refers to an alteration in expression or composition in a test sample, as compared with the expression or composition of polypeptide by *PARK8* in a control sample. A control sample is a sample that corresponds to the test sample (*e.g.*, is from the same type of cells), and is from an individual who is not affected by Parkinson’s disease. An alteration in the expression or composition of the polypeptide in the test sample, as compared with the control sample, is indicative of a susceptibility to Parkinson’s disease. Similarly, the presence of one or more different variants in the test sample, or the presence of significantly different amounts of different variants in the test sample, as compared with the control sample, is indicative of a susceptibility to Parkinson’s disease. Various means of examining expression or composition of the polypeptide encoded by *PARK8* can be used, including spectroscopy, colorimetry, electrophoresis, isoelectric focusing, and immunoassays (*e.g.*, David *et al.*, U.S. Pat. No. 4,376,110) such as immunoblotting (see also *Current Protocols in Molecular Biology, supra.*, particularly Chapter 10). For example, in one embodiment, an antibody capable of binding to the polypeptide (*e.g.*, as described above), preferably an antibody with a detectable label, can be used. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')₂) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

Western blotting analysis, using an antibody as described above that specifically binds to a polypeptide encoded by a mutant *PARK8*, or an antibody that specifically binds to a polypeptide encoded by a non-mutant gene, or an antibody that specifically binds to a particular variant encoded by *PARK8*, can be used to

identify the presence in a test sample of a particular variant or of a polypeptide encoded by a polymorphic or mutant *PARK8*, or the absence in a test sample of a particular variant or of a polypeptide encoded by a non-polymorphic or non-mutant gene. The presence of a polypeptide encoded by a polymorphic or mutant gene, or
5 the absence of a polypeptide encoded by a non-polymorphic or non-mutant gene, is diagnostic for a susceptibility to Parkinson's disease, as is the presence (or absence) of particular variants encoded by the *PARK8* gene.

In one embodiment of this method, the level or amount of polypeptide encoded by *PARK8* in a test sample is compared with the level or amount of the
10 polypeptide encoded by *PARK8* in a control sample. A level or amount of the polypeptide in the test sample that is higher or lower than the level or amount of the polypeptide in the control sample, such that the difference is statistically significant, is indicative of an alteration in the expression of the polypeptide encoded by *PARK8*, and is diagnostic for a susceptibility to Parkinson's disease. Alternatively, the
15 composition of the polypeptide encoded by *PARK8* in a test sample is compared with the composition of the polypeptide encoded by *PARK8* in a control sample. A difference in the composition of the polypeptide in the test sample, as compared with the composition of the polypeptide in the control sample (*e.g.*, the presence of different variants), is diagnostic for a susceptibility to Parkinson's disease. In
20 another embodiment, both the level or amount and the composition of the polypeptide can be assessed in the test sample and in the control sample. A difference in the amount or level of the polypeptide in the test sample, compared to the control sample; a difference in composition in the test sample, compared to the control sample; or both a difference in the amount or level, and a difference in the
25 composition, is indicative of a susceptibility to Parkinson's disease.

Kits (*e.g.*, reagent kits) useful in the methods of diagnosis comprise components useful in any of the methods described herein, including for example, hybridization probes or primers as described herein (*e.g.*, labeled probes or primers), reagents for detection of labeled molecules, restriction enzymes (*e.g.*, for RFLP
30 analysis), allele-specific oligonucleotides, antibodies which bind to mutant or to non-mutant (native) *PARK8* polypeptide, means for amplification of nucleic acids

comprising *PARK8*, or means for analyzing the nucleic acid sequence of *PARK8* or for analyzing the amino acid sequence of an *PARK8* polypeptide, etc.

SCREENING ASSAYS AND AGENTS IDENTIFIED THEREBY

The invention provides methods (also referred to herein as “screening
5 assays”) for identifying the presence of a nucleotide that hybridizes to a nucleic acid of the invention, as well as for identifying the presence of a polypeptide encoded by a nucleic acid of the invention. In one embodiment, the presence (or absence) of a nucleic acid molecule of interest (*e.g.*, a nucleic acid that has significant homology with a nucleic acid of *PARK8*) in a sample can be assessed by contacting the sample
10 with a nucleic acid comprising a nucleic acid of the invention (*e.g.*, a nucleic acid having the sequence of SEQ ID NO: 1 which may optionally comprise at least one polymorphism, or the complement thereof, or a nucleic acid encoding an amino acid having the sequence of SEQ ID NO: 2 or a fragment or variant of such nucleic acids), under stringent conditions as described above, and then assessing the sample
15 for the presence (or absence) of hybridization. In a preferred embodiment, high stringency conditions are conditions appropriate for selective hybridization. In another embodiment, a sample containing the nucleic acid molecule of interest is contacted with a nucleic acid containing a contiguous nucleotide sequence (*e.g.*, a primer or a probe as described above) that is at least partially complementary to a
20 part of the nucleic acid molecule of interest (*e.g.*, a *PARK8* nucleic acid), and the contacted sample is assessed for the presence or absence of hybridization. In a preferred embodiment, the nucleic acid containing a contiguous nucleotide sequence is completely complementary to a part of the nucleic acid molecule of *PARK8*.

In any of these embodiments, all or a portion of the nucleic acid of interest
25 can be subjected to amplification prior to performing the hybridization.

In another embodiment, the presence (or absence) of a polypeptide of *PARK8*, such as a polypeptide of the invention or a fragment or variant thereof, in a sample can be assessed by contacting the sample with an antibody that specifically hybridizes to the polypeptide of *PARK8* (*e.g.*, an antibody such as those described

above), and then assessing the sample for the presence (or absence) of binding of the antibody to the polypeptide of *PARK8*.

In another embodiment, the invention provides methods for identifying agents (*e.g.*, fusion proteins, polypeptides, peptidomimetics, prodrugs, receptors, binding agents, antibodies, small molecules or other drugs, or ribozymes which alter (*e.g.*, increase or decrease) the activity of the polypeptides described herein, or which otherwise interact with the polypeptides herein. For example, such agents can be agents which bind to polypeptides described herein (*e.g.*, *PARK8* binding agents); which have a stimulatory or inhibitory effect on, for example, activity of polypeptides of the invention; or which change (*e.g.*, enhance or inhibit) the ability of the polypeptides of the invention to interact with *PARK8* binding agents (*e.g.*, receptors or other binding agents); or which alter posttranslational processing of the *PARK8* polypeptide (*e.g.*, agents that alter proteolytic processing to direct the polypeptide from where it is normally synthesized to another location in the cell, such as the cell surface; agents that alter proteolytic processing such that more polypeptide is released from the cell, etc.

In one embodiment, the invention provides assays for screening candidate or test agents that bind to or modulate the activity of polypeptides described herein (or biologically active portion(s) thereof), as well as agents identifiable by the assays. Test agents can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S., *Anticancer Drug Des.*, 12:145 (1997)).

In one embodiment, to identify agents which alter the activity of a *PARK8* polypeptide, a cell, cell lysate, or solution containing or expressing a *PARK8* polypeptide (*e.g.*, SEQ ID NO: 2 or another variant encoded by *PARK8*), or a fragment or derivative thereof (as described above), can be contacted with an agent

to be tested; alternatively, the polypeptide can be contacted directly with the agent to be tested. The level (amount) of *PARK8* activity is assessed (*e.g.*, the level (amount) of *PARK8* activity is measured, either directly or indirectly), and is compared with the level of activity in a control (*i.e.*, the level of activity of the *PARK8* polypeptide or active fragment or derivative thereof in the absence of the agent to be tested). If the level of the activity in the presence of the agent differs, by an amount that is statistically significant, from the level of the activity in the absence of the agent, then the agent is an agent that alters the activity of *PARK8* polypeptide. An increase in the level of *PARK8* activity relative to a control, indicates that the agent is an agent that enhances (is an agonist of) *PARK8* activity. Similarly, a decrease in the level of *PARK8* activity relative to a control, indicates that the agent is an agent that inhibits (is an antagonist of) *PARK8* activity. In another embodiment, the level of activity of a *PARK8* polypeptide or derivative or fragment thereof in the presence of the agent to be tested, is compared with a control level that has previously been established. A level of the activity in the presence of the agent that differs from the control level by an amount that is statistically significant indicates that the agent alters *PARK8* activity.

The present invention also relates to an assay for identifying agents which alter the expression of the *PARK8* gene (*e.g.*, antisense nucleic acids, fusion proteins, polypeptides, peptidomimetics, prodrugs, receptors, binding agents, antibodies, small molecules or other drugs, or ribozymes) which alter (*e.g.*, increase or decrease) expression (*e.g.*, transcription or translation) of the gene or which otherwise interact with the nucleic acids described herein, as well as agents identifiable by the assays. For example, a solution containing a nucleic acid encoding *PARK8* polypeptide (*e.g.*, *PARK8* gene) can be contacted with an agent to be tested. The solution can comprise, for example, cells containing the nucleic acid or cell lysate containing the nucleic acid; alternatively, the solution can be another solution which comprises elements necessary for transcription/translation of the nucleic acid. Cells not suspended in solution can also be employed, if desired. The level and/or pattern of *PARK8* expression (*e.g.*, the level and/or pattern of mRNA or of protein expressed, such as the level and/or pattern of different variants) is

assessed, and is compared with the level and/or pattern of expression in a control (*i.e.*, the level and/or pattern of the *PARK8* expression in the absence of the agent to be tested). If the level and/or pattern in the presence of the agent differs, by an amount or in a manner that is statistically significant, from the level and/or pattern in the absence of the agent, then the agent is an agent that alters the expression of *PARK8*. Enhancement of *PARK8* expression indicates that the agent is an agonist of *PARK8* activity. Similarly, inhibition of *PARK8* expression indicates that the agent is an antagonist of *PARK8* activity. In another embodiment, the level and/or pattern of *PARK8* polypeptide(s) (*e.g.*, different variants) in the presence of the agent to be tested, is compared with a control level and/or pattern that has previously been established. A level and/or pattern in the presence of the agent that differs from the control level and/or pattern by an amount or in a manner that is statistically significant indicates that the agent alters *PARK8* expression.

In another embodiment of the invention, agents which alter the expression of the *PARK8* gene or which otherwise interact with the nucleic acids described herein, can be identified using a cell, cell lysate, or solution containing a nucleic acid encoding the promoter region of the *PARK8* gene operably linked to a reporter gene. After contact with an agent to be tested, the level of expression of the reporter gene (*e.g.*, the level of mRNA or of protein expressed) is assessed, and is compared with the level of expression in a control (*i.e.*, the level of the expression of the reporter gene in the absence of the agent to be tested). If the level in the presence of the agent differs, by an amount or in a manner that is statistically significant, from the level in the absence of the agent, then the agent is an agent that alters the expression of *PARK8*, as indicated by its ability to alter expression of a gene that is operably linked to the *PARK8* gene promoter. Enhancement of the expression of the reporter indicates that the agent is an agonist of *PARK8* activity. Similarly, inhibition of the expression of the reporter indicates that the agent is an antagonist of *PARK8* activity. In another embodiment, the level of expression of the reporter in the presence of the agent to be tested, is compared with a control level that has previously been established. A level in the presence of the agent that differs from the control level

by an amount or in a manner that is statistically significant indicates that the agent alters *PARK8* expression.

Agents which alter the amounts of different variants encoded by *PARK8* (e.g., an agent which enhances activity of a first variant, and which inhibits activity of a second variant), as well as agents which are agonists of activity of a first variant and antagonists of activity of a second variant, can easily be identified using these methods described above.

In other embodiments of the invention, assays can be used to assess the impact of a test agent on the activity of a polypeptide in relation to a *PARK8* binding agent. For example, a cell that expresses a compound that interacts with *PARK8* (herein referred to as a "*PARK8* binding agent", which can be a polypeptide or other molecule that interacts with *PARK8*, such as a receptor) is contacted with *PARK8* in the presence of a test agent, and the ability of the test agent to alter the interaction between *PARK8* and the *PARK8* binding agent is determined. Alternatively, a cell lysate or a solution containing the *PARK8* binding agent, can be used. An agent which binds to *PARK8* or the *PARK8* binding agent can alter the interaction by interfering with, or enhancing the ability of *PARK8* to bind to, associate with, or otherwise interact with the *PARK8* binding agent. Determining the ability of the test agent to bind to *PARK8* or an *PARK8* binding agent can be accomplished, for example, by coupling the test agent with a radioisotope or enzymatic label such that binding of the test agent to the polypeptide can be determined by detecting the labeled with ^{125}I , ^{35}S , ^{14}C or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, test agents can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. It is also within the scope of this invention to determine the ability of a test agent to interact with the polypeptide without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a test agent with *PARK8* or a *PARK8* binding agent without the labeling of either the test agent, *PARK8*, or the *PARK8* binding agent. McConnell, H.M. *et al.*, *Science*, 257:

1906-1912 (1992). As used herein, a “microphysiometer” (*e.g.*, Cytosensor™) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between ligand and polypeptide. See the Examples Section for a discussion of known *PARK8* binding partners. Thus, these receptors can be used to screen for compounds that are *PARK8* receptor agonists for use in treating Parkinson’s disease or *PARK8* receptor antagonists for studying Parkinson’s disease. The linkage data provided herein, for the first time, provides such correction to Parkinson’s disease. Drugs could be designed to regulate *PARK8* receptor activation which in turn can be used to regulate signaling pathways and transcription events of genes downstream.

In another embodiment of the invention, assays can be used to identify polypeptides that interact with one or more *PARK8* polypeptides, as described herein. For example, a yeast two-hybrid system such as that described by Fields and Song (Fields, S. and O. Song, *Nature* 340: 245-246 (1989)) can be used to identify polypeptides that interact with one or more *PARK8* polypeptides. In such a yeast two-hybrid system, vectors are constructed based on the flexibility of a transcription factor which has two functional domains (a DNA binding domain and a transcription activation domain). If the two domains are separated but fused to two different proteins that interact with one another, transcriptional activation can be achieved, and transcription of specific markers (*e.g.*, nutritional markers such as His and Ade, or color markers such as lacZ) can be used to identify the presence of interaction and transcriptional activation. For example, in the methods of the invention, a first vector is used which includes a nucleic acid encoding a DNA binding domain and also an *PARK8* polypeptide, variant, or fragment or derivative thereof, and a second vector is used which includes a nucleic acid encoding a transcription activation domain and also a nucleic acid encoding a polypeptide which potentially may interact with the *PARK8* polypeptide, variant, or fragment or derivative thereof (*e.g.*, a *PARK8* polypeptide binding agent or receptor). Incubation of yeast containing the first vector and the second vector under appropriate conditions (*e.g.*, mating conditions such as used in the Matchmaker™ system from Clontech) allows

identification of colonies which express the markers of *PARK8*. These colonies can be examined to identify the polypeptide(s) which interact with the *PARK8* polypeptide or fragment or derivative thereof. Such polypeptides may be useful as agents which alter the activity of expression of an *PARK8* polypeptide, as described
5 above.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either *PARK8*, the *PARK8* binding agent, or other components of the assay on a solid support, in order to facilitate separation of complexed from uncomplexed forms of one or both of the
10 polypeptides, as well as to accommodate automation of the assay. Binding of a test agent to the polypeptide, or interaction of the polypeptide with a binding agent in the presence and absence of a test agent, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein (*e.g.*, a
15 glutathione-S-transferase fusion protein) can be provided which adds a domain that allows *PARK8* or a *PARK8* binding agent to be bound to a matrix or other solid support.

In another embodiment, modulators of expression of nucleic acid molecules of the invention are identified in a method wherein a cell, cell lysate, or solution
20 containing a nucleic acid encoding *PARK8* is contacted with a test agent and the expression of appropriate mRNA or polypeptide (*e.g.*, variant(s)) in the cell, cell lysate, or solution, is determined. The level of expression of appropriate mRNA or polypeptide(s) in the presence of the test agent is compared to the level of expression of mRNA or polypeptide(s) in the absence of the test agent. The test agent can then
25 be identified as a modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater (statistically significantly greater) in the presence of the test agent than in its absence, the test agent is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less (statistically
30 significantly less) in the presence of the test agent than in its absence, the test agent is identified as an inhibitor of the mRNA or polypeptide expression. The level of

mRNA or polypeptide expression in the cells can be determined by methods described herein for detecting mRNA or polypeptide.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (*e.g.*, a test agent that is a modulating agent, an antisense nucleic acid molecule, a specific antibody, or a polypeptide-binding agent) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein. In addition, an agent identified as described herein can be used to alter activity of a polypeptide encoded by *PARK8*, or to alter expression of *PARK8*, by contacting the polypeptide or the gene (or contacting a cell comprising the polypeptide or the gene) with the agent identified as described herein.

PHARMACEUTICAL COMPOSITIONS

The present invention also pertains to pharmaceutical compositions comprising nucleic acids described herein, particularly nucleotides encoding the polypeptides described herein; comprising polypeptides described herein (*e.g.*, SEQ ID NO: 2, and/or other variants encoded by *PARK8*); and/or comprising an agent that alters (*e.g.*, enhances or inhibits) *PARK8* expression or *PARK8* polypeptide activity as described herein. For instance, a polypeptide, protein (*e.g.*, an *PARK8* receptor), fragment, fusion protein or prodrug thereof, or a nucleotide or nucleic acid construct (vector) comprising a nucleotide of the present invention, an agent that alters *PARK8* polypeptide activity, an agent that alters Parkinson's disease gene expression, or an *PARK8* binding agent or binding partner, can be formulated with a physiologically acceptable carrier or excipient to prepare a pharmaceutical

composition. The carrier and composition can be sterile. The formulation should suit the mode of administration.

Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions (*e.g.*, NaCl), saline, buffered saline, alcohols, glycerol, ethanol,
5 gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, dextrose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidone, etc., as well as combinations thereof. The pharmaceutical preparations can, if desired, be mixed with auxiliary agents, *e.g.*, lubricants,
10 preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active agents.

The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition can be a liquid
15 solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl pyrrolidone, sodium saccharine, cellulose, magnesium carbonate,
20 etc.

Methods of introduction of these compositions include, but are not limited to, intradermal, intramuscular, intraperitoneal, intraocular, intravenous, subcutaneous, topical, oral and intranasal. Other suitable methods of introduction can also include gene therapy (as described below), rechargeable or biodegradable
25 devices, particle acceleration devices ("gene guns") and slow release polymeric devices. The pharmaceutical compositions of this invention can also be administered as part of a combinatorial therapy with other agents.

The composition can be formulated in accordance with the routine procedures as a pharmaceutical composition adapted for administration to human
30 beings. For example, compositions for intravenous administration typically are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may

also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water, saline or dextrose/water. Where the composition is administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

For topical application, nonsprayable forms, viscous to semi-solid or solid forms comprising a carrier compatible with topical application and having a dynamic viscosity preferably greater than water, can be employed. Suitable formulations include but are not limited to solutions, suspensions, emulsions, creams, ointments, powders, enemas, lotions, sols, liniments, salves, aerosols, etc., which are, if desired, sterilized or mixed with auxiliary agents, *e.g.*, preservatives, stabilizers, wetting agents, buffers or salts for influencing osmotic pressure, etc. The agent may be incorporated into a cosmetic formulation. For topical application, also suitable are sprayable aerosol preparations wherein the active ingredient, preferably in combination with a solid or liquid inert carrier material, is packaged in a squeeze bottle or in admixture with a pressurized volatile, normally gaseous propellant, *e.g.*, pressurized air.

Agents described herein can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The agents are administered in a therapeutically effective amount. The amount of agents which will be therapeutically effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in*

vitro or *in vivo* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the symptoms of Parkinson's disease, and should be decided according to the judgment of a practitioner and each patient's
5 circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a
10 notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use of sale for human administration. The pack or kit can be labeled with information regarding mode of administration, sequence of drug administration (*e.g.*, separately, sequentially or concurrently), or the like. The pack
15 or kit may also include means for reminding the patient to take the therapy. The pack or kit can be a single unit dosage of the combination therapy or it can be a plurality of unit dosages. In particular, the agents can be separated, mixed together in any combination, present in a single vial or tablet. Agents assembled in a blister pack or other dispensing means is preferred. For the purpose of this invention, unit
20 dosage is intended to mean a dosage that is dependent on the individual pharmacodynamics of each agent and administered in FDA approved dosages in standard time courses.

METHODS OF THERAPY

The present invention also pertains to methods of treatment (prophylactic
25 and/or therapeutic) for Parkinson's disease, using a *PARK8* therapeutic agent. A "*PARK8* therapeutic agent" is an agent that alters (*e.g.*, enhances or inhibits) *PARK8* polypeptide activity and/or *PARK8* gene expression, as described herein (*e.g.*, a *PARK8* agonist or antagonist). *PARK8* therapeutic agents can alter *PARK8* polypeptide activity or gene expression by a variety of means, such as, for example,
30 by providing additional *PARK8* polypeptide or by upregulating the transcription or

translation of the *PARK8* gene; by altering posttranslational processing of the *PARK8* polypeptide; by altering transcription of *PARK8* variants; or by interfering with *PARK8* polypeptide activity (*e.g.*, by binding to a *PARK8* polypeptide), or by downregulating the transcription or translation of the *PARK8* gene. Representative

5 *PARK8* therapeutic agents include the following: nucleic acids or fragments or derivatives thereof described herein, particularly nucleotides encoding the polypeptides described herein and vectors comprising such nucleic acids (*e.g.*, a gene, cDNA, and/or mRNA, such as a nucleic acid encoding a *PARK8* polypeptide or active fragment or derivative thereof, or an oligonucleotide); polypeptides

10 described herein and/or other variants encoded by *PARK8*, or fragments or derivatives thereof; other polypeptides (*e.g.*, *PARK8* receptors); *PARK8* binding agents; peptidomimetics; fusion proteins or prodrugs thereof; antibodies (*e.g.*, an antibody to a mutant *PARK8* polypeptide, or an antibody to a non-mutant *PARK8* polypeptide, or an antibody to a particular variant encoded by *PARK8*, as described

15 above); ribozymes; other small molecules; and other agents that alter (*e.g.*, enhance or inhibit) *PARK8* gene expression or polypeptide activity, or that regulate transcription of *PARK8* variants (*e.g.*, agents that affect which variants are expressed, or that affect the amount of each variant that is expressed). More than one *PARK8* therapeutic agent can be used concurrently, if desired.

20 The *PARK8* therapeutic agent that is a nucleic acid is used in the treatment of Parkinson's disease. The term "treatment", as used herein, refers not only to ameliorating symptoms associated with the disease, but also preventing or delaying the onset of the disease, and also lessening the severity or frequency of symptoms of the disease. The therapy is designed to alter (*e.g.*, inhibit or enhance), replace or

25 supplement activity of a *PARK8* polypeptide in an individual. For example, a *PARK8* therapeutic agent can be administered in order to upregulate or increase the expression or availability of the *PARK8* gene or of specific variants of *PARK8*, or, conversely, to downregulate or decrease the expression or availability of the *PARK8* gene or specific variants of *PARK8*. Upregulation or increasing expression or

30 availability of a native *PARK8* gene or of a particular variant could interfere with or compensate for the expression or activity of a defective gene or another variant;

downregulation or decreasing expression or availability of a native *PARK8* gene or of a particular variant could minimize the expression or activity of a defective gene or the particular variant and thereby minimize the impact of the defective gene or the particular variant.

5 The *PARK8* therapeutic agent(s) are administered in a therapeutically effective amount (*i.e.*, an amount that is sufficient to treat the disease, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and/or also lessening the severity or frequency of symptoms of the disease). The amount which will be therapeutically effective in the treatment of a
10 particular individual's disorder or condition will depend on the symptoms and severity of the disease, and can be determined by standard clinical techniques. In addition, *in vitro* or *in vivo* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder,
15 and should be decided according to the judgment of a practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

 In one embodiment, a nucleic acid of the invention can be used, either alone or in a pharmaceutical composition as described above. For example, *PARK8* or a
20 cDNA encoding the *PARK8* polypeptide, either by itself or included within a vector, can be introduced into cells (either *in vitro* or *in vivo*) such that the cells produce native *PARK8* polypeptide. If necessary, cells that have been transformed with the gene or cDNA or a vector comprising the gene or cDNA can be introduced (or re-introduced) into an individual affected with the disease. Thus, cells which, in
25 nature, lack native *PARK8* expression and activity, or have mutant *PARK8* expression and activity, or have expression of a disease-associated *PARK8* variant, can be engineered to express *PARK8* polypeptide or an active fragment of the *PARK8* polypeptide (or a different variant of *PARK8* polypeptide). In a preferred embodiment, nucleic acid encoding the *PARK8* polypeptide, or an active fragment or
30 derivative thereof, can be introduced into an expression vector, such as a viral vector, and the vector can be introduced into appropriate cells in an animal. Other

gene transfer systems, including viral and nonviral transfer systems, can be used. Alternatively, nonviral gene transfer methods, such as calcium phosphate coprecipitation, mechanical techniques (*e.g.*, microinjection); membrane fusion-mediated transfer via liposomes; or direct DNA uptake, can also be used.

5 Alternatively, in another embodiment of the invention, a nucleic acid of the invention; a nucleic acid complementary to a nucleic acid of the invention; or a portion of such a nucleic acid (*e.g.*, an oligonucleotide as described below), can be used in “antisense” therapy, in which a nucleic acid (*e.g.*, an oligonucleotide) which specifically hybridizes to the mRNA and/or genomic DNA of *PARK8* is
10 administered or generated *in situ*. The antisense nucleic acid that specifically hybridizes to the mRNA and/or DNA inhibits expression of the *PARK8* polypeptide, *e.g.*, by inhibiting translation and/or transcription. Binding of the antisense nucleic acid can be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interaction in the major groove of the
15 double helix.

 An antisense construct of the present invention can be delivered, for example, as an expression plasmid as described above. When the plasmid is transcribed in the cell, it produces RNA which is complementary to a portion of the mRNA and/or DNA which encodes *PARK8* polypeptide. Alternatively, the
20 antisense construct can be an oligonucleotide probe which is generated *ex vivo* and introduced into cells; it then inhibits expression by hybridizing with the mRNA and/or genomic DNA of *PARK8*. In one embodiment, the oligonucleotide probes are modified oligonucleotides which are resistant to endogenous nucleases, *e.g.* exonucleases and/or endonucleases, thereby rendering them stable *in vivo*.
25 Exemplary nucleic acid molecules for use as antisense oligonucleotides are phosphoramidate, phosphothioate and methylphosphonate analogs of DNA (see also U.S. Pat. Nos. 5,176,996; 5,264,564; and 5,256,775). Additionally, general approaches to constructing oligomers useful in antisense therapy are also described, for example, by Van der Krol *et al.*, *Biotechniques*, 6:958-976 (1988); and Stein *et al.*, *Cancer Res.*, 48:2659-2668 (1988). With respect to antisense DNA,
30

oligodeoxyribonucleotides derived from the translation initiation site, *e.g.* between the -10 and +10 regions of *PARK8* sequence, are preferred.

To perform antisense therapy, oligonucleotides (mRNA, cDNA or DNA) are designed that are complementary to mRNA encoding *PARK8*. The antisense
5 oligonucleotides bind to *PARK8* mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, indicates that a sequence has sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex
10 DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid, as described in detail above. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can
15 ascertain a tolerable degree of mismatch by use of standard procedures.

The oligonucleotides used in antisense therapy can be DNA, RNA, or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotides can be modified at the base moiety, sugar
20 moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotides can include other appended groups such as peptides (*e.g.* for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al. Proc. Natl. Acad. Sci. USA*, 86:6553-6556 (1989); Lemaitre *et al., Proc. Natl. Acad. Sci. USA*, 84:648-652
25 (1987); PCT International Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT International Publication No. W089/10134), or hybridization-triggered cleavage agents (see, *e.g.*, Krol *et al. BioTechniques*, 6:958-976 (1988)) or intercalating agents. See, *e.g.*, Zon., *Pharm. Res.*, 5:539-549 (1988). To this end, the oligonucleotide may be conjugated to another molecule
30 (*e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent).

The antisense molecules are delivered to cells which express *PARK8* *in vivo*. A number of methods can be used for delivering antisense DNA or RNA to cells; *e.g.*, antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (*e.g.*, antisense linked to
5 peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systematically. Alternatively, in a preferred embodiment, a recombinant DNA construct is utilized in which the antisense oligonucleotide is placed under the control of a strong promoter (*e.g.*, pol III or pol II). The use of such a construct to transfect target cells in the patient results in the
10 transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous *PARK8* transcripts and thereby prevent translation of the *PARK8* mRNA. For example, a vector can be introduced *in vivo* such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as
15 long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art and described above. For example, a plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the
20 desired tissue, in which case administration may be accomplished by another route (*e.g.*, systematically).

Endogenous *PARK8* expression can also be reduced by inactivating or “knocking out” *PARK8* or its promoter using targeted homologous recombination (*e.g.*, see Smithies *et al.*, *Nature*, 317: 230-234 (1985); Thomas and Capecchi, *Cell*,
25 51:503-512 (1987); Thompson *et al.*, *Cell*, 5:313-321 (1989)). For example, a mutant, non-functional *PARK8* (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous *PARK8* (either the coding regions or regulatory regions of *PARK8*) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express *PARK8* *in vivo*.
30 Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of *PARK8*. The recombinant DNA constructs can be directly

administered or targeted to the required site *in vivo* using appropriate vectors, as described above. Alternatively, expression of non-mutant *PARK8* can be increased using a similar method: targeted homologous recombination can be used to insert a DNA construct comprising a non-mutant, functional *PARK8*, or a portion thereof, in place of a mutant *PARK8* in the cell, as described above. In another embodiment, targeted homologous recombination can be used to insert a DNA construct comprising a nucleic acid that encodes a *PARK8* polypeptide variant that differs from that present in the cell.

Alternatively, endogenous *PARK8* expression can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of *PARK8* (*i.e.*, the *PARK8* promoter and/or enhancers) to form triple helical structures that prevent transcription of *PARK8* in target cells in the body. See generally, Helene, C., *Anticancer Drug Des.*, 6(6):569-84 (1991); Helene, C., *et al. Ann. N.Y. Acad. Sci.*, 660:27-36 (1992); and Maher, L. J., *Bioassays*, 14(12):807-15 (1992). Likewise, the antisense constructs described herein, by antagonizing the normal biological activity of one of the *PARK8* proteins, can be used in the manipulation of tissue, *e.g.* tissue differentiation, both *in vivo* and *for ex vivo* tissue cultures. Furthermore, the anti-sense techniques (*e.g.* microinjection of antisense molecules, or transfection with plasmids whose transcripts are anti-sense with regard to a *PARK8* mRNA or gene sequence) can be used to investigate the role of *PARK8* in developmental events, as well as the normal cellular function of *PARK8* in adult tissue. Such techniques can be utilized in cell culture, but can also be used in the creation of transgenic animals.

In yet another embodiment of the invention, other *PARK8* therapeutic agents as described herein can also be used in the treatment or prevention of Parkinson's disease. The therapeutic agents can be delivered in a composition, as described above, or by themselves. They can be administered systemically, or can be targeted to a particular tissue. The therapeutic agents can be produced by a variety of means, including chemical synthesis; recombinant production; *in vivo* production (*e.g.*, a transgenic animal, such as U.S. Pat. No. 4,873,316 to Meade *et al.*), for example, and can be isolated using standard means such as those described herein.

A combination of any of the above methods of treatment (*e.g.*, administration of non-mutant *PARK8* polypeptide in conjunction with antisense therapy targeting mutant *PARK8* mRNA; administration of a first variant encoded by *PARK8* in conjunction with antisense therapy targeting a second encoded by *PARK8*), can also be used.

The invention will be further described by the following non-limiting examples. The teachings of all publications cited herein are incorporated herein by reference in their entirety.

EXEMPLIFICATION

10 *Identification of the PARK8 locus with linkage to Parkinson's disease*

A genome wide scan was performed on 117 patients and 168 relatives within 51 families using 781 microsatellite markers. Sixty-three percent (63%) of the patients were men, and eighty-one (81%) of the 117 had age-at-onset symptoms over 50 years, with a mean age-at-onset of 65.8 years. The comprehensive genome wide database has been established at deCODE genetics, Inc.

Encrypted patient identifiers, approved by the National Bioethics Committee of Iceland and the Data Protection Commission of Iceland (DPC), were used. Patients were identified as described in "Familial Aggregation of Parkinson's disease in Iceland", by S. Sveinbjornsdottir, A.A. Hicks, T. Jonsson, *et al.*, *N. Engl. J. Med.*, 343:1765-70 (2000). Briefly, patients identified through a total population survey carried out in Iceland in 1953-1963 were combined with an ongoing population-based study which identifies patients from a variety of sources including the Parkinson's Disease Society, neurologists, general practitioners and records of levodopa and other Parkinson's disease drug prescriptions, (Gudmundsson, K.R., *Acta. Neurol. Scand.*, 43, Supplement; 33:1-61 (1967)). All nursing homes and homes for the elderly in Reykjavik and those in approximately 70% of the rest of Iceland were visited to examine patients. Living patients were reevaluated and all relevant medical records were reviewed by two independent neurologists. Patients were considered to have Parkinson's disease if they have at least two of the following cardinal signs: tremor; rigidity, bradykinesia or postural instability while

other causes of parkinsonism were excluded (Hoen, M.M.and M.D. Yahr, *Neurology*, 17:427-442 (1967)). 951 cases of Parkinson's disease were identified which represents over 90% of the total number of patients diagnosed in Iceland during the last 50 years. Only patients who were related to other patients within 6 meiotic events (6 meioses separate second-cousins) as determined using deCODE's genealogy database were included. 117 patients and 168 of their first degree unaffected relatives were included. Informed consent was obtained from all patients and their relatives whose blood and DNA samples were used in the linkage scan. All personal identifiers associated with medical information and blood samples were encrypted by the DPC as described in "Protection of Privacy by Third-party Encryption in Genetic Research in Iceland," by J.R. Gulcher, K. Krisjansson, H. Gudbjartsson and K. Stefansson, *Eur. J. Hum. Genet.*, 8:739-742 (2000). The genealogy database was encrypted by the DPC in the same manner.

Genome-wide linkage scan

A genome-wide scan was performed using a framework map of 781 microsatellite markers. The marker order and positions for the framework mapping set were obtained from the Marshfield genetic map (<http://research.marshfieldclinic.org/genetics>), except for a three-marker putative inversion on chromosome 8 (Gulcher, J.R., *et al.*, *Eur. J. Hum. Genet.*, 8:739-42 (2000), and Jonsdottir, G.M., *et al.*, *Am. J. Hum. Genet.*, 67 (Suppl. 2), 332, (2000)).

Statistical significance was determined by applying affecteds-only allele-sharing methods (which does not specify any particular inheritance model) implemented in the ALLEGRO (deCODE genetics, Inc.) program. ALLEGRO is a linkage program developed at deCODE genetics which calculates lod scores based on multipoint calculations and is available for non-commercial use. Baseline linkage analysis uses (1) the S_{pairs} scoring function, (Kruglyak, L., *et al.*, *Am J. Hum. Genet.* 58: 1347-63 (1996)), (2) the exponentially allele-sharing model, (Kong, A., and N.J. Cox, *Am. J. Hum. Genet.* 61: 1179-88 (1997)), and (3) a family weighting scheme which is halfway, on the log scale, between weighting each affected pair equally and weighting each family pair equally (Yu, A., *et al.*, *Am. J. Hum. Genet.*,

67 (Suppl. 2) 10 (2000), Kruglyak, L., *et al.*, *Am. J. Hum. Genet.*, 58:1347-63 (1996), Gudbjartsson, D.F., *et al.*, *Nat. Genet.*, 25:12 (2000)). In the analysis all genotyped individuals who are not affected were treated as “unknown”. P values were computed two different ways and the larger (less significant) one was reported.

5 The first P value, which is computed based on the large sample theory; $Z_{lr} = (\text{square root of}) (2 \log_e (10) \text{ lod})$, is approximately distributed as a standard normal distribution under the null hypothesis of no linkage (Kong, A. and N.J. Cox, *ibid.*). Apart from the P value completed using normal approximation, because of the concern with a small sample behavior using ALLEGRO, a second P value was

10 computed by comparing the observed lod score to its complete data sampling distribution under the null hypothesis (Kruglyak, L., *et al.*, *ibid.*). When a data set consists of more than a handful of families, these two P values tend to be similar. Conservatively, the larger of the two was reported. The P values can be adjusted for multiple comparisons. An adjusted P value of 2×10^{-5} corresponds approximately to

15 a P value of 0.05 after adjusting for a genome-wide scan.

Genotypes of polymorphic markers provide uncomplete information about DNA sharing among patients. The degree of completeness can be increased by typing additional markers. This measure is closely related to a classical measure (Dempster, N.M., *et al.*, *J. R. Statist. Soc. B.*, 39:1 (1977)). Information equals zero

20 if the marker genotypes are completely uninformative and equals one if the genotypes determine the exact amount of allele sharing by descent among the affected relatives.

Genetic and Physical mapping

High resolution genetic mapping and basepair resolution physical mapping

25 were used to locate microsatellite markers and genes. Additional microsatellite markers were designed using genomic sequences from the January 9, 2000 data freeze assembly of the University of California at Santa Cruz (<http://genome.ucsc.edu>). Genotype data from 112 Icelandic nuclear families containing 812 individuals (sibships with their parents, containing two to seven

siblings were used to create a genetic map over the interval of *PARK8*. Misassembly or misordering of the contigs revealed were corrected and confirmed with selective coincident hybridization experiments of the BAC library. The combined genetic-physical map determined a most likely order of markers and the inter-marker
5 distances have a resolution of about 0.5 centimorgans.

Parametric modeling

After obtaining a significant allele-sharing lod score, parametric models are fitted to the data to explore the contribution of the susceptibility gene to the disease population. When fitting parametric models, affected-only analysis was performed.
10 As a result, only the ratio of penetrances are relevant. A range of single locus dominant, additive and multiplicative models was fit. With a dominant model, the penetrance of homozygous carrier of the at-risk allele is assumed the same as for a heterozygous carrier. The penetrance of carriers can be smaller than one and non-carriers are allowed to have non-zero penetrance. It is only the ratio of the
15 penetrances that affect the lod score. An additive model assumes that the difference between the penetrances of a heterozygous carrier of the at-risk allele versus a non-carrier is the same as the difference between a homozygous carrier and a heterozygous carrier. With a multiplicative model, the ratio of the penetrance of a heterozygous carrier versus a non-carrier is assumed to be the same as the ratio of
20 the penetrances of homozygous and heterozygous carriers. Compared to a dominant model, a multiplicative model tends to fit better with a higher assumed at-risk allele frequency and a lower penetrance ratio between the heterozygous carrier and a non-carrier. The additive model tends to be in-between the dominant and multiplicative models. With affected-only analysis, while one model may fit slightly better than
25 another, it is usually not enough to be confident whether the true model of inheritance is dominant, multiplicative or recessive. With complex disease, none of these simple models are likely to be exactly true. The effect of a gene and its variants, it is believed, can only be reliably determined after the at-risk variant, or variants, are identified. However, apart from the statistical significance, the fitted
30 parametric models provide an idea as to how much the gene is contributing to the

disease. For example, the corresponding contribution to the sibling recurrence risk ratio and the population attributed risk can be calculated. The sibling recurrence risk ratio is a measure of the magnitude of inheritance and is related to the power of detecting linkage. Population attributed risk is defined as the fraction of cases
5 reduced if the population were to consist entirely of non-carriers of the at-risk allele. The best fitting dominant, additive and multiplicative models tend to give similar sibling recurrence risk ratios, but the corresponding population attributed risks are more variable.

Results of linkage and localization

10 The linkage scan was conducted on a total of 117 Parkinson's disease patients within 51 families. FIG. 1 is an example of the extended families used in the study, which include multiple Parkinson's disease patients. The patients and 168 of their relatives not diagnosed with Parkinson's disease were genotyped using 781 microsatellite makers. The data was analyzed and significance determined by
15 applying affected-only, allele sharing methods. The methods do not formally specify a particular inheritance model, but instead search for genomic regions shared by affected relative by descent more often than expected under the baseline of no linkage. Lod scores based on multipoint calculations, which used the information from all the markers simultaneously were computed using the ALLEGRO program
20 (deCODE genetics, Inc.).

Sex indicators have been shuffled for some individuals in the top two generations, and unaffected siblings, offspring and mates of the patients are not shown, to protect privacy. The solid squares and circles represent affected men and women, respectively. The patients in this family had ages at onset of symptoms
25 between 66 and 78 years old. The slashed symbols represent deceased individuals for whom we have no DNA. Haplotypes shown are for 10 markers from a shared region spanning 37 markers, plus one marker just outside the region on either side. The shared region is represented by a solid box.

The allele sharing lod scores and the corresponding Z_{lr} scores for the entire
30 genome using the markers in the framework map were determined. The most

prominent linkage was found to chromosome 1p32. Two lod score peaks of 3.9, separated by about 13 centimorgans, were observed near D1S2652 and D1S2846, respectively. Additional lod scores of 1.6 on chromosome 5 near D5S666, 1.2 on chromosome 7 near D7S661 and 1.1 on chromosome X near DXS8080 were also
5 observed. While the lod score of 3.9 ($Z_{lr}=4.2$, $P=1.1 \times 10^{-5}$ unadjusted on chromosome 1) was already genome-wide significant according to the Lander-Kruglyak criterion (single test P value of less than 2×10^{-5} which corresponds to a genome-wide adjusted P value of 0.05; Lander E., *et al.*, *Nat. Genet.*, 11:241-247 (1995)), the information content was below 60%, indicating that the marker data was
10 still far from capturing all the allele-sharing information inherent in the material. It is more meaningful to have a lod score associated with high information content. Apart from ensuring that the results are a true reflection of the information contained in the material, it reduces the potential problem of multiple comparisons, as multipoint lod scores can increase or decrease substantially as markers are added.
15 The information content for linkage at the 1p32 region was increased by genotyping an additional 44 markers over an approximately 44 cM segment which spans the region between markers D1S2884 and D1S198.

Correct marker order and good estimates of inter-marker distances are extremely important for multipoint linkage analysis (Halpern, J. and A.S. Whittemore, *Hum. Hered.*, 49:194-196 (1999) and Daw, E.W., *et al.*, *Genet. Epidemiol.*, 19: 366-380 (2000)). However, the microsatellite marker maps in the public domain have limited accuracy at inter-marker distances less than 2 to 3 centimorgans. High-resolution genetic and physical mapping were used to increase the accuracy of the order of additional markers and to provide reliable inter-marker
25 distances. With the additional markers and the map described herein, the lod score peak near marker D1S2846 dropped, while the lod score peak near marker D1S2652 increased to 4.9 with a corresponding Z_{lr} score of 4.8 (as shown in FIG. 2). This corresponds to a P value of 1.0×10^{-6} before adjusting for multiple comparisons, and a P value smaller than 0.005 after adjusting for a genome-wide search. The
30 information content over the 20cM interval centered on the peak exceeds 0.85 and averages 0.95. The locus was designated *PARK8*. The peak centered near marker

D1S231, with markers D1S2874 to D1S475, telomeric and centromeric, respectively, defining a drop of one in lod score from the peak. The segment is estimated to be approximately 7.6 centimorgans in genetic length and approximately 9.5 million bases.

5 To understand the contribution of this locus to the population, a variety of parametric modes were fitted to the data. By specifying allele frequencies and penetrances that maximize the lod score, a lod score between 5.3 and 5.6 can be obtained for dominant, additive or multiplicative models. While this indicated that the current data does not allow for elucidation of a direct mode of inheritance, an
10 estimate of how much this susceptibility gene contributes to familial risk can be obtained. With an additive model that assumes that the carriers of one and two at-risk alleles have respectively 30 times and 59 times the risk of getting the disease compared to the non-carriers, log scores between 5.5 and 5.6 are obtained for the at-risk allele frequency ranging from 0.4% to 2.8%. These models correspond to a
15 sibling recurrence risk ratio ranging from 3.2 to 4.6. The best fitting dominant and multiplicative models give similar numbers, which is not surprising as the power to detect linkage with affected-only analysis is more directly tied to the recurrence risk ratio instead of the exact mode of inheritance (Risch, N., *Pairs Genet. Epidemiol.*, 1: 109-22J and *Hum. Genet.*, 46: 229-241 (1990)). Compared to the observed sibling
20 risk ratio of 6.7 earlier reported (Sveinbjornsdottir, S., *et al.*, *N. Engl. J. Med.*, 343: 1765-1770 (2000)), the gene at this locus alone can account for a substantial fraction of the familial aggregation of late-onset Parkinson's disease. The difference can be attributed to other contributing genes and the shared environment of the siblings.

25 *Identification of the RNF gene*

 The identified gene is RNF 11 (Seki, N., *et al.*, *Biochem. and Biophys. Acta.*, 1489:421-427 (1999) and encodes, in three exons, ring finger protein 11. This protein contains a modified RING-H2 domain (also called C3H2C3) similar to the RING domain (C3H2C4) found in Parkin, and which is characteristic of a protein
30 with a role in the ubiquitination pathway. This pathway, important for the breakdown of protein in the cell, comprises a number of enzyme activities

commonly referred to as E1, E2 and E3 activity. E1 and E2 are ubiquitin conjugating enzymes while E3 is ubiquitin ligase activity, important for substrate recognition. Parkin, the mutated protein in juvenile and early onset Parkinson's disease, has been shown to function as an E3 ligase. By homology, RNF 11 may
5 function in the important process of protein turnover. In a disease whose pathology is characterized by protein aggregates, the possible significance of RNF 11 and disturbances in its function should not be underestimated.

Upon sequencing of DNA samples from individuals in Iceland, 7 new SNPs were found in the RNF 11 promoter region. These were found at nucleotides 1196,
10 1393, 2064, 2218, 2435, 2599 and 2703 of SEQ ID NO: 1. One additional SNP (at nucleotide 3181) was found in the sequence data of Exon 1, five bases upstream of the start ATG codon and may affect the KOZAK sequence. Three exons were found which encode RNF 11. Exon 1 is located at positions 3059 to 3308, Exon 2 is located at positions 36385 to 36554, and Exon 3 is located at positions 37580 to
15 39685. All numbering is relative to SEQ ID NO: 1. The amino acids coding RNF 11 are represented by SEQ ID NO: 2. These SNP's have not been documented prior to this disclosure.

Transcription binding sites were identified by sequence homology to known transcriptional binding sites, such as those for BRN-2 (a neuronal-specific
20 transcriptional regulator (nucleotides 1182-1197); MEF-2 nucleotides (2416 to 2437); GC or SP1 (nucleotides 2665-2677); ATF or CREB (nucleotides 2589-2600 and 2694-2705); NGFIC or EGR1, 2, or 3 (nucleotides 2779-2789) and HEN1 (nucleotides 2803-2824). SNP's were identified within the BRN-2 site, MEF-2 site, ATF/CREB (2589-2600) site, and ATF/CREB (2694-2705).

25

Western Blots

Western blots of patients' brain material who presented Parkinson's Disease (PD), Alzheimer's (ALZ), mixed (PD/ALZ) or control brain material with no disease, were run on a western using RNF-11 peptide-generated antibodies. The
30 peptide sequence used to generate antibodies was KGVYDPGRDGSEKKIRE (SEQ ID NO: 3). It was observed that some patients contained significantly larger amounts

of RNF-11 and oligomeric forms of RNF-11 (higher molecular weights) than the control patients who did present the diseases. Further, patients with pathological features of both Parkinson's and Alzheimer's demonstrated RNF immunoreactivity with senile plaques as well as Lewy bodies and neurophil threads reminiscent of

5 Lewy neurites.

Additionally, experiments were done with yeast two hybrid experiments were performed to identify specific interacting protein(s). Multiple libraries were screened and individual clones were isolated from different brain libraries. Specific interactions were shown with U33821.1, human TAX-1 binding protein (TXBP151);
10 AF095745.1, human ubiquitin protein ligase (ITCH); AF110265.1, human EGF receptor substrate (EPS15R); AF241230.1, human TAK-1 binding protein 2 (TBP2); AF293385.1 human PLIC-2; AF301463.1, SMURF2 (ubiquitin ligase); AF062085.1 human epsin 2b; and U22897.1 nuclear domain 10 protein (ndp52).

While this invention has been particularly shown and described with
15 reference to preferred embodiment thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

CLAIMS

What is claimed is:

1. An isolated nucleic acid molecule comprising a *PARK8* gene, wherein the nucleic acid molecule comprises at least one single nucleotide polymorphism selected from the group consisting of: G at nucleotide 1196, C at nucleotide 1393, T at nucleotide 2064, T at nucleotide 2218, C at nucleotide 2435, C at nucleotide 2599, G at nucleotide 2703 and G at nucleotide 3181, and combinations thereof, the nucleotide positions being relative to SEQ ID NO: 1.
2. The isolated nucleic acid molecule of Claim 1, wherein the Parkinson's disease gene has the nucleotide sequence of SEQ ID NO:1.
3. An isolated nucleic acid molecule comprising a nucleotide sequence having all or a portion of the promoter region for the gene encoding ring finger 11 protein and, comprising at least one single nucleotide polymorphism selected from the group consisting of: G at nucleotide 1196, C at nucleotide 1393, T at nucleotide 2064, T at nucleotide 2218, C at nucleotide 2435, C at nucleotide 2599, G at nucleotide 2703 and G at nucleotide 3181, and combinations thereof, the nucleotide positions being relative to SEQ ID NO: 1.
4. A method for assaying the presence of a first nucleic acid molecule in a sample, comprising contacting said sample with a second nucleic acid molecule comprising the nucleic acid molecule of Claim 1.
5. A vector comprising an isolated nucleic acid molecule corresponding to exon 1, exon 2, exon 3 or combinations thereof of the *PARK8* gene,

- operatively linked to a promoter for the *PARK8* gene having at least one single nucleotide polymorphism selected from the group consisting of: G at nucleotide 1196, C at nucleotide 1393, T at nucleotide 2064, T at nucleotide 2218, C at nucleotide 2435, C at nucleotide 2599, G at nucleotide 2703 and G at nucleotide 3181, and combinations thereof, the nucleotide positions being relative to SEQ ID NO: 1.
- 5
6. A recombinant host cell comprising the vector of Claim 5.
7. A method of diagnosing a susceptibility to Parkinson's disease in an individual, comprising detecting a polymorphism in a Parkinson's disease gene, wherein the presence of the polymorphism in the gene is indicative of a susceptibility to Parkinson's disease.
- 10
8. The method of Claim 7, wherein the polymorphism of the gene is selected from the group consisting of nucleotide position 1196, 1393, 2064, 2218, 2435, 2599, 2709, 3181 and combinations thereof; wherein the nucleotide position is relative to SEQ ID NO: 1.
- 15
9. A method of diagnosing a susceptibility to Parkinson's disease, comprising detecting an alteration in the expression or composition of a polypeptide encoded by *PARK8* gene in a test sample, in comparison with the expression or composition of a polypeptide encoded by *PARK8* gene in a control sample, wherein the presence of an alteration in expression or composition of the polypeptide in the test sample is indicative of a susceptibility to Parkinson's disease.
- 20
10. The method of Claim 9 wherein the alteration in the expression or composition of a polypeptide encoded by *PARK8* gene comprises expression of a polypeptide in a test sample that differs from a variant polypeptide expressed in a control sample.
- 25

11. The method of Claim 9 wherein the alteration in expression results in either a higher amount or lower amount of polypeptide compared to the amount of polypeptide expression in the control sample.
12. A method of identifying an agent which alters activity of a polypeptide encoded by a *PARK8* gene, comprising:
- 5 a) contacting the polypeptide or a derivative or fragment thereof, with an agent to be tested;
- b) assessing the level of activity of the polypeptide or derivative or fragment thereof; and
- 10 c) comparing the level of activity with a level of activity of the polypeptide or active derivative or fragment thereof in the absence of the agent,
- wherein if the level of activity of the polypeptide or derivative or fragment thereof in the presence of the agent differs, by an amount that is statistically
- 15 significant, from the level in the absence of the agent, then the agent is an agent that alters activity of the polypeptide.
-
13. An agent which alters activity of a polypeptide encoded by *PARK8* gene, identifiable according to the method of Claim 12.
- 20 14. An agent which alters activity of a polypeptide encoded by *PARK8* gene, wherein the agent is selected from the group consisting of: a Parkinson's disease receptor; a Parkinson's disease binding agent; a peptidomimetic; a fusion protein; a prodrug; an antibody; and a ribozyme.
- 25 15. A method of altering activity of a polypeptide encoded by *PARK8* gene, comprising contacting the polypeptide with an agent of Claim 14.

16. A method of identifying an agent which alters interaction of the polypeptide encoded by *PARK8* gene with a Parkinson's disease binding agent, comprising:
- a) contacting the polypeptide or a derivative or fragment thereof, and the binding agent, with an agent to be tested;
 - b) assessing the interaction of the polypeptide or derivative or fragment thereof with the binding agent; and
 - c) comparing the level of interaction with a level of interaction of the polypeptide or derivative or fragment thereof with the binding agent in the absence of the agent,
- wherein if the level of interaction of the polypeptide or derivative or fragment thereof in the presence of the agent differs, by an amount that is statistically significant, from the level of interaction in the absence of the agent, then the agent is an agent that alters interaction of the polypeptide with the binding agent.
17. A method of identifying an agent which alters expression of a *PARK8* gene, comprising:
- a) contacting a solution containing a nucleic acid of Claim 1 or a derivative or fragment thereof, with an agent to be tested;
 - b) assessing the level of expression of the nucleic acid, derivative or fragment; and
 - c) comparing the level of expression with a level of expression of the nucleic acid, derivative or fragment in the absence of the agent,
- wherein if the level of expression of the nucleotide, derivative or fragment in the presence of the agent differs, by an amount that is statistically significant, from the expression in the absence of the agent, then the agent is an agent that alters expression of *PARK8* gene.
18. A method of identifying an agent which alters expression of *PARK8* gene, comprising:

- a) contacting a solution containing a nucleic acid comprising the promoter region of a *PARK8* gene operably linked to a reporter gene, with an agent to be tested;
- b) assessing the level of expression of the reporter gene; and
- 5 c) comparing the level of expression with a level of expression of the reporter gene in the absence of the agent,
- wherein if the level of expression of the reporter gene in the presence of the agent differs, by an amount that is statistically significant, from the level of expression in the absence of the agent, then the agent is an agent that alters
- 10 expression of a *PARK8* gene.
19. A method of identifying an agent which alters expression of a *PARK8* gene, comprising:
- a) contacting a solution containing a nucleic acid of Claim 1 or a derivative or fragment thereof with an agent to be tested;
- 15 b) assessing expression of the nucleic acid, derivative or fragment; and
- c) comparing expression with expression of the nucleic acid, derivative or fragment in the absence of the agent, wherein if expression of the nucleotide, derivative or fragment in the presence of the agent differs, by an amount that is statistically significant, from the expression in
- 20 the absence of the agent, then the agent is an agent that alters expression of *PARK8* gene.
20. The method of Claim 19, wherein the expression of the nucleotide, derivative or fragment in the presence of the agent comprises expression of one or more variant(s) that differ in kind or in quantity from the expression
- 25 of one or more variant(s) in the absence of the agent.
21. A method of altering expression of *PARK8* gene, comprising contacting a cell containing *PARK8* gene with an agent of Claim 20 identifiable according to the method of Claim 19.

22. A method of identifying a polypeptide which interacts with a *PARK8* polypeptide, comprising employing a yeast two hybrid system using a first vector which comprises a nucleic acid encoding a DNA binding domain and a *PARK8* polypeptide, variant, or fragment or derivative thereof, and a
5 second vector which comprises a nucleic acid encoding a transcription activation domain and a nucleic acid encoding a test polypeptide, wherein if transcriptional activation occurs in the yeast two hybrid system, the test polypeptide is a polypeptide which interacts with a Parkinson's disease polypeptide.
- 10 23. A Parkinson's disease therapeutic agent selected from the group consisting of: a Parkinson's disease gene or fragment or derivative thereof; a polypeptide encoded by a Parkinson's disease gene; a Parkinson's disease receptor; a Parkinson's disease binding agent; a peptidomimetic; a fusion protein; a prodrug; an antibody; an agent that alters Parkinson's disease gene
15 expression; an agent that alters activity of a polypeptide encoded by Parkinson's disease gene; an agent that alters posttranscriptional processing of a polypeptide encoded by a Parkinson's disease gene; an agent that alters interaction of a Parkinson's disease polypeptide with a Parkinson's disease binding agent; an agent that alters transcription of variants encoded by a
20 Parkinson's disease gene; and a ribozyme.
24. A pharmaceutical composition comprising a Parkinson's disease therapeutic agent of Claim 23.
25. The pharmaceutical composition of Claim 24, wherein the Parkinson's disease therapeutic agent is an isolated nucleic acid molecule comprising a
25 Parkinson's disease gene or fragment or derivative thereof.

26. The pharmaceutical composition of Claim 24, wherein the Parkinson's disease therapeutic agent is a polypeptide selected from the group consisting of SEQ ID NO: 2.
27. A method of treating Parkinson's disease in an individual, comprising
5 administering a Parkinson's disease therapeutic agent to the individual, in a therapeutically effective amount.
28. Use of a Parkinson's disease therapeutic agent for the manufacture of a medicament for the treatment of Parkinson's disease.
29. A Parkinson's disease therapeutic agent for treatment of Parkinson's disease.

1/14




FIG. 1

2/14




FIG. 2

3/14
FIG. 3A

Nucleic Acid Sequence of RNF-11 gene

```

cccagctatt caggaggctg aggcaggaga attgcttgaa ccggggaagt agaggttgcg 60
gtaagccaag atcgcaccat tgcactctag cctgggcaac acaagcaaaa ctctgtctca 120
aaaaataaaa attaaaaaaa attaaaaacta actaaataaaa tctatgtctg gccaggcata 180
cagtggctca cacctgtaat tccagcactt tgggaggctg aggcgggagg atcgcttgcg 240
cccaggagtt tgagaccagc ctgggcaaca tggcaagact tctgtctctac caaaaacaaa 300
aacaatgca aggcattggtg gtgtgcatct gtagttctag ttactggaga ggccctgaagc 360
aggaggatca cctgagccca ggaggttgaa gctgcagtga gcctcgatca agccagcctg 420
ggtgacagag tgagaccctg tctccaaaaa aaacaaacaa tgtctacaaa ttctagcact 480
gtgtaaatat tatgtcaaat aattgtataa attattatta ataaaaattt ctttaggttt 540
gacaataaatt tgtggggtaa attttctcac tttgtaaaaa ttccagggtta cctctgattt 600
ctggtaaat tagccaatca taaattaaat gagttcttgg aagctcaaca attccaaaac 660
caaaattgtg agtcagtttg ttctttcttt ccttcttttc tttctttttc tttttctttc 720
tttctttctt tttctttctt tttctttctt tctcttttct tctcttttct ctttctcttt 780
ctctcccttc ctctcttctt tctctctctg ctcccttctc tctctctctc tttctctctc 840
cttttttttt tgagactgag tcttactcac tccctcgccc acgctagagt gcagtggcac 900
aatctgggct cactgcgctg caacttcac ctcccagggt caagcgggtt tccctgcctca 960
ccctcccgag tagctgggac tacaggcggt caccagcaca cctggctagt ttttgtattt 1020
ttagtagaga tgggggtttca ccatgttggc caggctactc tcgaatccct gacctcaagt 1080
gatccaccgc ccttgacctc ccaaattgct gggattacag acgtaagcca ccacgcctgg 1140
cccaaaatta tgagtctttt caaaaatttt atatcaaaaa ggtgatattt aatgtggaat 1200
ttgagtgcatt taaataaga tagtgacttc gtagaatagg gactgcagag taagagtgtt 1260
cagaccatt cgagtttaat atagccctac ctctaagaat cctttctgtt cctcactcaa 1320
atgaactaat tgctgtcttt cagttctctt aaaaaccttg gggtcctgtg cagggtgtgg 1380
gcttaggact cacctgatta cttgtcttcc cagggtgtct ctgggctcta tcaggaacaa 1440
gocaggtatg atcatccttt tcccagttcc ttagcgtggg gtctggtata cacacgcaca 1500
cacaacttca gtaaattggt aatgaaacga aaggcagtc agatccacct gttgaatgaa 1560
cgtctatcag gagcactgtc atccttcttg ctctctctt ttgcatatgt tgtttgagct 1620
gctcattcaa ccaaggagag agcatactct accttgggca gtgtgccagc cttgcacaga 1680
gggacagatg attcagcttg atcaggctgt gacagagaaa agctcagggt ctgagagcac 1740
acaggatgag actaaccag actggagggt caggagagtc tcccaggggg aaatgaagt 1800
gcattcagaa ggattcctga gaataatgat tagcctgatg agaagcagaa aggttgggag 1860
tggagggaag tgggtttctg tgagagaaac aatatggaca aaggcccccag gcagaggcaa 1920
tagtattcca gataacgaaa agcatttttag agagtctagt ttagaatttg tgaaggaggt 1980
gacaatgctg ctaatgagat tgaaagggag tcagatttgt aaaccattta aggattgtct 2040
taaggacagc cttgaggaga cactgaagggt tttaacagga gaatgacatg atccgattta 2100
aattttaaaa agataactct gtcaactgtg ccaacagtga attggatgtg ggcaatgatg 2160
aactcaggaa cagctgagag tctattgcag aagccaaggt gagagatgat ggtgcttgg 2220
actttgggtg tgaggactgga aagaaatgaa caatctgata tacaactgga agaataatct 2280
ctctggctgt gatgtggaag gataaggacg tgattggaca ggcagggatg gttcagtaac 2340
gagctaggac tttattgtga agggataaag ggggaagctt taacatttta atcatgggac 2400
tgatccattc cgatatgggt ttatataaat agaccgcttg gcggagggtg gtgagaagac 2460
tgtcaggcag tgcacaggtg agaactgagc cctagacggg gcaggagcaa tgaatgtggg 2520
gaggcgggg agacgggaga ttgggttcgg agccaggtac ggagccaagc agtcagagag 2580
aagcaaaaat tgacgcagca ccgagaacag ctgctagtgg agagggggat gggcgccgcc 2640
ggagccgcc tcgcctctg gcgcggggg cgggaccaga gcacgcacgg cgcgatgacg 2700
cagtgcgccg gccggcctcg ttctggctgc cgcgtctcg ctgaggcgga gtaggatgag 2760
gcccgcgggc gtggctccgg cgtcggcggg ggcagcagca gctgaggcag cagctgaggc 2820
agccgcgagc gccgcgcccc ccccgcctga cctggattag gccagcagc tccgtggccg 2880
ccgcgcgggc gcgggggggc ggggtgggga agtgcttctg cttcccggcc ccccccccc 2940
atcgctgcct cgcaggaggc gaacgcgcgc accccagcgg agcccgcggc ccagccttga 3000
tcccccaacc ccgggggctg gcatgagcgg cccctcggcg gcaccgtggg gcggtggagt 3060
cgctccggcc tgatccccgg cctgtcgccc gacccacct cgccaaccga ggcggaccgc 3120
ggagtgtgag aacgacccca ccgctgcttt ctcctcccc agatcacgca cccagctcc 3180
ggaagatggg gaactgcctc aaatccccc cctcgatga catctcctg cttcagcagt 3240
ctcagtcgga ccgggcgagg tttggcgagg ggcggagag ggatcaggag ccgcgcgcg 3300
catatcaggt aggggagggt gtgtgttggg gggagcagat agaggcagct ctggcggaga 3360

```

4/14
FIG. 3B

ttgagggggc	ttcgggggccc	tctctgcccc	tggcttcggc	aaggcctggc	ctgggcccga	3420
ttgacccctt	agggctggat	ctgagggcat	ttgctctctg	atctcagagt	aagggtgatt	3480
cttcgcctgc	cctcgggcac	cgtgtgggga	tgataccctc	tgcccttgag	ttctgggagc	3540
agagtatgtg	atcacatccc	cttggccagt	gtctggtggg	tcgcttggtg	agtttgaggag	3600
tgacattttc	ctgtctttat	gtctgaatcg	tatgattttc	tcacgcgacc	gccaaactgga	3660
ttatgggttc	tggataggtg	gttgccaagc	accaccccc	cgccccatct	atgttttcat	3720
gtgtggtcgt	cctcttacct	acctccctcg	tctttttgtt	aattggatct	ggcagggtttt	3780
ccctctgctt	gggagacgga	tctccaagtg	gtgattttta	ccctagcgac	atcgagttac	3840
ttgtgtgtgt	gtgtatatat	atatatatgt	gtatatatat	atatatatat	atgtatataa	3900
attttaatcc	ctcctctttt	tgtccacccc	atatgacaca	ccttttaaac	gtgctgactt	3960
aagaaaaact	gattagcttg	aaactttggaa	acctttaaac	ctggcttggg	aaattccttc	4020
gggtactcgt	gttctccctt	tgtatcaaag	actctcctaa	atacgttgta	ctgctttttg	4080
tacaataatc	agtagtccca	gatgtgttgc	agaattcgag	tgaagacctc	ttaaactcaa	4140
aatagggtatg	tggatgttat	aatccacaat	agatgtgtga	aaaccttttc	tgtacttttt	4200
ccatttttaga	tgatattgaa	tacacccttt	tccagagggc	ttcaatagta	gtagtgttta	4260
atttcttctt	gaagagttta	gttttctgac	tgggtaggct	cctttgttgt	ttcatgtgat	4320
gacatcatta	tctagtgttt	tcttttctca	ttcctgtgta	aaccaatgtc	tcatacacacc	4380
agaaaaacct	gatcatatat	atgctcgttt	tctgaataaa	attcttcttg	gggcattttca	4440
tatataccag	taagggtccag	tcttgattgt	ggtattacag	aagcctccat	gacttctccc	4500
tcttacgttc	tatatccag	gcoctacaaa	tacaccaggc	tgttcacagc	tttgttttgc	4560
tccagttcct	ctctgcttgg	agoccttcgc	ccgggtcagc	caggtggaca	tctaactctc	4620
tttgagaact	cagctttcat	gtctgaagtc	ccagcattcc	cttccttccc	agcccgaatc	4680
ccttgtgtcc	ccactgaaac	ctctacactt	ccataagcaa	tatctataac	acttttagtgt	4740
tgtatctttg	ttagatgtgt	gtctcatcct	tgtaatcgcc	tccttcagtg	caagctgogt	4800
gaaggtagag	aatctgtgtt	tccgggttgc	tgttgtatcc	ctcgcatctg	cctcagtagg	4860
gactcagtaa	ctgggagata	aattacgagt	aaaagccctt	gagaacaggg	actctccctt	4920
cgctcagttt	ctggcacata	agcacctaaa	tgtgaatta	attaatgaag	ttgaatttag	4980
tattttctgt	atttacacaa	atattttttc	caaagtaagt	tgtcacaggg	tagtctctta	5040
aaaatcaaag	ctgaatctgg	gtgtctttac	aagtaccttt	gagtgaagca	agcaagctat	5100
gtttatcctt	cactgtcttt	ccctcctatg	tttactatac	aacaaaagtg	cttattttaac	5160
tttttttttt	taatgagatg	gagtcctcgt	ctgtcacccc	ggctggagtg	cagtgggaca	5220
atctcactgc	ttactgcaac	ctccacctcc	cgggttctag	cgattctcct	gcctcagcct	5280
cctgagtagc	tgggattaca	ggcgcggtgc	accacacctc	gctaattttt	gtatttttag	5340
taaagacggg	gtttccacct	gttggtcagg	ctggtcttga	actcctgacc	tcaagcagtc	5400
caccacacct	agtctcccaa	agtgtcaggga	ttacaggcat	gagccaccgc	atctggcatg	5460
aagttttttt	tttaaaatct	cttatgtctc	ctaccctcac	ccccttctat	ttttaaaaaa	5520
atagagacag	ggactccctat	gttgcoctagg	ctggtcttga	actcctggcc	tcaagcaaat	5580
tctcctgcct	cctatccctt	ttcttaattg	aatatctttg	acttgttctc	tttctcctat	5640
ccttatgata	attgtactat	taaagggtact	agaattttatg	gaaactgtgt	ttgccttttc	5700
cagaagaact	aggtgatgac	gagggatgag	gggttttttg	tgtcatgaag	gaactttttt	5760
tggaaatggt	atatttttga	cagtgggagt	tttttatggt	tgcagtttcc	tgaagtgaat	5820
gacgcagact	aatatacaaa	ttcagtatca	atcagaagaa	aattacttta	aaacatggga	5880
gcataaaaaa	aaactttttg	agaaaaagta	ttgtccccc	cccccaaga	aataagatct	5940
gtcttaggaa	tggttatttt	agatgatctg	agaaacagca	atccaaggtt	atttattcat	6000
ttattttgagt	tgagaatctc	cctctgtcat	ccagggttaga	ctggattgct	cacttggcag	6060
cctcaaactc	ctggcttcag	gtgatcctcc	tccctcagcc	tcccaaagac	tgggattaca	6120
ggcgttagct	acctcacaca	gcagatttat	agtattctca	gttgataaaa	gtaacttttt	6180
caacaaatta	tatgtaatta	acagtgaata	gctgattgta	aagggaacatg	ttctcttgag	6240
gtgagtagtt	aaaagatgtc	attgttttgct	gcttttatatg	tacaatgtac	atataatgac	6300
aagagccagt	tacagttatt	tcctatttaac	atctgacaaa	tttgttttta	tttatttttg	6360
ccttaaagta	aatccctgca	ccattatgat	ccaagtttgt	aggaagtgtg	tatttctttc	6420
catggtttct	tttgtagcct	cctaacagtt	atccctgctt	tcacccttgt	cctcgctaag	6480
gcctgtcctc	aatacaacag	ccacagttat	tttggtaaaa	ctgagcatga	cagtctcccc	6540
aaccctctgt	gtggatcctt	gtttcattca	aagtaaaaaa	cagattcctt	atagtgtcgc	6600
ataaacctta	cataatctgt	accccttggt	tccacgcatg	tcccttgaca	cctacagcta	6660
acccctttgt	tggcttccct	ccagcttccc	tgtcctcatt	gctattctag	gacctttgtc	6720
ctccttatct	tgggaatact	ttcccagat	ttcatggctg	actgactccc	ttacctcctt	6780
caagtctttt	ctcactgccc	ccttaaacct	tctctgacca	ccctgtttga	aagtgcaacc	6840

5/14
FIG. 3C

tgccctaata	acctggaagt	ccctctcacc	ctgttggttt	ccccccaat	accattttatt	6900
acattccaac	atgtgttaga	aagttgcgtt	gtctattacc	tgtcttctcc	cactaggttag	6960
aaaggaggaa	aggggatttt	tttttttaat	tggtgtttcc	taagtactta	taacagtgcc	7020
tggcacatgt	taggcattca	gtaatttggt	tgaacgaatg	aatagatttc	ttttaaatga	7080
actaatgtat	ttgaggcagg	tatagttgca	ctgcttacaa	gaactctgca	tattcctagt	7140
gccatttttg	cttctatatt	gtagatcagg	tttttttttg	tttgtttttt	tgttttgtga	7200
ctgggcctcc	ctgtgttacc	caggctggtc	tctctctgta	tatatatggt	tgggtttttt	7260
tgttttctct	tttttgagac	caagtctcac	cttggtgccc	agctagagtg	cagtgggtgc	7320
atcttggtc	tgccctctgg	gttcaagcga	ttctcctgcc	tcagcctctg	gagtagttgg	7380
tactacaggc	atgcgccacc	aaggccaact	gatttttgta	cttttggttag	agatggagtt	7440
ttgccatgtt	gaccaggctg	gtctcaaact	cctgacttca	ggtgatctgc	ccaccttggc	7500
cttcagaggt	gctgggatta	caggcgtaag	cccctgagcc	tgccctttat	attttttaaa	7560
tttaaaaaat	agagacaggg	tctcattatg	ttgctagtct	caaactcctg	ggctcaaggg	7620
atactcctgc	ctcagcctct	tgagtagcta	gggttacagg	tgcacttcta	ctctgccttg	7680
ctcaggtttt	aaaaaaaaatt	tatttccttt	agagatgagg	tcttgctgtg	ttgcccaggc	7740
tggaggggcag	tagctattca	cagggtgcaat	tatagtgcac	tgcagcctcc	acttctctgt	7800
ctcaaaggat	cttgtggctt	cagcctcctg	agtagctggg	actacagggt	tacaccaccg	7860
tgtctagctg	ttgtagatca	gttttaagga	atcctaaaaa	gtcaaattcc	agtaatatata	7920
aatacagcaa	ttggtttaca	ctaagtgtta	agtgatttag	gggtttttac	cgtgtatata	7980
tatcacccga	agatatttat	gtaatgggaa	agtacttggg	ggagaaaaag	aaagtacttg	8040
aatccctatt	cttgaagtat	tggatgcaaa	gagatttagg	gtgtttgtca	aattagaaaag	8100
tagaaacaaa	tttgtcgcac	cctctaccca	actcccttat	tcctaaatgt	ttaaaaataa	8160
tacagaggaa	atctgcccag	cgaaggcaat	cttgggaagg	cagtgagtgg	gaggataagc	8220
caggaaaggc	tgaagaaggg	aggctccatga	gagggggagg	ccaggtaggc	agcccagccc	8280
tgaaggcat	atgtaaaaca	gcttgaggta	cccctgtgtc	actgtcaaga	gctttgttat	8340
gtgctaaatt	gaggggaggca	ctttgttaaa	agagtgtaat	attcattgaa	caacaaacca	8400
tgttacattt	tctaattctga	atatataaaa	ataaggatag	gtgtctctca	attttgcagt	8460
agttatatag	tttgagattc	gccagtcctc	ttccccgacc	tatacttttt	gattgataca	8520
tttgaaattt	taaaatcctg	agaaaataag	tttgtatagc	attgaatgca	agtatagctc	8580
tgctttttaga	gtcagattgt	cctgtgttca	aattctggct	ctgccgctta	catgtaaaaat	8640
atgaaaaagg	aaagaattta	tcagatttgt	ttggggagct	tttttgacaa	ataagaaaaat	8700
gtaacatttt	ggatatttca	aatttgtgtc	gcataaaagt	ttcttcaaga	tacctttttt	8760
tttttttttt	tttggtggg	cacagtggct	cacacctgtc	atcccagcac	ttaggtggca	8820
gaggcaggag	gatcacttga	cccagggaat	tcgagaccag	cctgggcaac	aaagtgagac	8880
ccccatctct	attaaaatac	caaacaaaaa	caaaaaacaa	acaaaaccaa	aaaccctctt	8940
ttgttggttaa	aaggatttgt	ttatcctgta	gaatgcacta	aaaataaccc	ccttccttat	9000
aaaaaatcta	gaatgtactg	cttattttta	agcatgcaat	gctataatgt	tttgtggggg	9060
atgggcttgt	tttttttaga	gatggagtct	cactttgcc	aggctagtgt	cgaactcctg	9120
ggctcaagtg	atcctcccac	catgtctccc	agtggtggga	ttacggatgt	gagtcactgt	9180
gccctgcttg	taatggtata	ttaatgcctc	attttcttga	taacttacga	agttaaattt	9240
agataattaa	agggtttgtg	ttttttatta	gcatttttgt	taacattttg	gtggaaaata	9300
tctocaaaat	tatttcacgt	atctaggcct	tattatacaa	ttattcagct	tttaacaatt	9360
tacctttttg	aagttttatc	cctccccttc	tttatgtctc	agaagttcag	ccttcttatt	9420
gaggggcaga	tcaactaac	ccacctttgt	taataaagcc	ttcactgacc	atttttttcc	9480
tgtctctgct	gatttgtcat	gtacagtttt	tttgtgtttg	taacattttat	ctggaaatca	9540
tatatgtcct	tattagcttt	tgttgcttta	acagttgttt	ctccacatca	gtttcctcaa	9600
gaatgagaat	gatacattaa	acttgtaaga	tatcttagtg	gagtagaatg	ttaccttcca	9660
tattgtagac	accagtgaa	tatttgatga	tagactaaat	tagaactgtg	acttcttacc	9720
ttgtaaggtc	accatcataa	ttgtcctcat	cagttcttac	agcaacataa	ttgatgtctc	9780
ctcctcattc	atttttatacc	atggttgccag	ataaatttca	tcccggatca	gatcacttgc	9840
ctcataatcc	ttaatgattg	ttattattat	tattattatt	ttttgaaaaca	gagtcttcac	9900
tctgttgccc	aggctggagt	gcagtggtgc	cacctcagct	cactgcagcc	tccgcctccc	9960
gggtccgagc	aattctcctg	cctcagcctc	cagagtagct	gggattacag	gcatgcgcca	10020
ccacaccag	ctaatttttg	tatttttaat	agaaatgggg	tttcaccata	ttgctcaggc	10080
tgggtgtgcaa	ctcctaacct	caggtaatcc	actcaccttg	gcctccgtaa	gagctgggat	10140
tacaggcgtg	agccaccacg	cccgccctt	aatgattctt	tattaggact	aacctgaa	10200
gatctctgac	ttagcattca	aagtcattgat	ttggctctac	atatactttt	tcagctcttc	10260
atagccttgt	gctttctttt	atacaacctg	tatactccag	tcatactgag	cagtttgctg	10320

6/14
FIG. 3D

tattccatgt	atgtcttctg	ctttcctgtc	tttgccatt	ctgtatccat	tgcccagaat	10380
gtttcttctt	aatccttccc	agtctcattt	ctaatatcca	gggcccagtt	caaatgccaa	10440
gaatccacga	attctgattt	ctcctacata	cacttttctt	aatctgaact	cctttattca	10500
tgcaccattc	ttaagacact	ttaccctttt	aatttttaatt	atttgtgaca	gtgtcacatc	10560
tgctctttta	gaattcaagt	ctggttcatt	ttcacattgc	tagaactaca	attttcacaa	10620
agcacgcact	tatactttag	tgaatgtaat	gatcagcatt	ttgctgtaag	agtgtgcaat	10680
tgtatgggtg	ttagtgtcta	ttaagcattc	ccagaatcct	gtgcttttagt	gtttggccta	10740
tcactttctaa	tttataaagt	acgttgagct	ttgggaaagt	taattttcatt	atataattttt	10800
tgaattttgt	tttttttttg	tttgttttgt	tgagacgaag	tctcgctgtg	tcaccaggc	10860
tggagtgcag	tggcgcgatc	tcagctcact	gcaagctcog	cctcccgggt	tcacgccatt	10920
ctcctgcctc	agcctgtccc	gagtagctgg	gactacaggt	gcccgcacc	acacctggct	10980
aattttttgt	attttttagta	gggacggggg	ttcacogtgg	tcttgatctc	ctgaccttgt	11040
gatcctcctg	cctcggcctc	ccaaagtgtc	gggattacaa	gcgtgagcca	ccgcgcccag	11100
cctgaatttg	gtttttgtgt	ccatgaagtt	cagcttgctc	aggtgacttt	tataaataag	11160
taaccagtta	tttgttattt	gtgtgacccc	attgttgtag	gatttttctt	tgtttctgcc	11220
tgacctctca	ttctgaatgt	gctttaataa	aggctgattt	tttggcatta	agatttgtatg	11280
catcactaag	agtaagatag	tctgttcaga	gttttaattct	agagctaatt	atagggtaac	11340
ttgagaagat	ggagatggga	tggtgagtta	cttggtacat	aagatctgag	cacttgattt	11400
tcttaaaaata	tttttttaggt	aatagtagaa	acctttgttg	cagaattttg	atcttttaaaa	11460
gtttttaatag	aaatacttat	gtagattggg	attctttttc	tttcttttag	acataatctt	11520
actctgttgc	ctaggctgaa	tgtagtggca	tggtcacggc	tcactgaagc	ctcaacctca	11580
cgggcccacg	ccatcctccc	acctcagcct	cctgagtagc	tgggactata	ggcgtgcacc	11640
actttgcctg	gctaattttt	atttttttgt	gagacgggtc	aagcagtcct	cccatctcag	11700
tctcctgaat	agctgggacc	acaggtgcat	accaccacac	ccagctattt	tttgtatttt	11760
tagtagagac	ggggctctcac	tatattgccc	aggctgggtc	caaactcctg	aactcaagca	11820
gtccacccac	ctcggcctcc	caaagtgtct	agattacaag	tgtgagccac	catgcccacc	11880
caacagcctt	tttttttggg	gatggagtct	tactccatcg	cccaggctgg	agtcagtggt	11940
tgagttctca	gcccactgca	acttctgcca	cctgggttca	agcgattctc	atgcctcagc	12000
ctcctgagta	gctgggatta	gaggcaagca	ccaccacacc	tggctaattt	tttgtatttt	12060
tagtagagat	gggggtttcac	catgttggcc	agactgggtc	taactcctga	cctcgtgac	12120
cacccaccta	ggcctaccaa	agtgtctgaga	ttacaggcgt	gagctactgg	gctggacacc	12180
aacagcctat	ttttaataaac	ccatatgagt	acaggacaga	aatacatccc	taactctgtg	12240
cctgaagtaa	ggaaggtaat	acataaaaaga	catatttgca	aacgacttga	ggcaagaaaa	12300
gaaatacaaac	acatctctaa	ttctgattgt	atctgcaatc	aacctcttat	cacttccctc	12360
ttcatgtgca	gaattttacct	tggctgagac	acagtcaaga	aagaagacag	gtggccaggc	12420
acagtggctc	acacctgtaa	tctcagta	ttgggagggt	gagggtgggcg	ggtcacctga	12480
ggttaggagt	ttgagaccag	cctgaccaac	atagagaaac	cccgtctcta	ctaaaaatgc	12540
aaaaaatagcc	gggtgtgggtg	gcacatgcct	gtaatccag	ctacttggga	ggctgaggca	12600
ggagaatctc	ttgaacccag	gaggtggagg	ttgtgttgca	gctagggtg	gctgttgac	12660
tctagcctgg	gcaacaagag	tgaaactcca	tctcaacaac	aacaacaaaa	aagaagacga	12720
caggctgtgt	gcagtggctc	atacctgtac	accagcactt	tgggaaggcca	agtgggaagg	12780
attgcttgag	cccaggagtt	cgaaaccagc	ctgggcaaaa	tagcgagatc	togtctctac	12840
aaaaaaataa	aaaattagtc	aggtgtgttg	gcacatgcct	gtagtccag	ctataggctg	12900
aggcagaagg	aatgcttgag	ctcaggagtt	ggaagggtata	atgagctgtg	atggcaccat	12960
tgcactccag	cctgggcaac	agagtgaatg	ggggcatggg	gaaggccagg	tgtggtggct	13020
cacacctgta	atctcagcgc	tttggtaggc	tgaggcggga	ggattgcttg	catccaggag	13080
tttgagacca	gtctaggcaa	cacagtgaga	ctcccatttc	tacaagaaaa	tatttaggct	13140
gtaagtggag	agttatttgt	tagtgggtag	agttttctgt	tttataagat	gaaaagttat	13200
ggagatggat	agtttaattg	ctacataact	ttatgtaata	ccactgaact	atacactgaa	13260
aaattggagc	tgggcttgtg	cctgtggctc	cagttaatca	ggaagctgag	gcaggagggt	13320
tacctgagcc	caggagttcg	aggctgcagt	gagttataat	tgagccactg	oattccagcc	13380
taggcagcag	agtgcagcct	tatctcttaa	aaaaaaaaaa	aaaaaggaaa	aaataatagg	13440
ctgtaaacag	ttgatctcct	accagtaact	tttaatatgt	aattaacaaa	tatttatggg	13500
atttttaaca	tgctcagagt	tcaggctttt	ttcagctgtg	atctaaatga	aagtgcagag	13560
gaggtgggtg	gagaagtgcg	tggaatgtgt	agtgaaagat	tgaggaagag	ctggcttaga	13620
tagccacagt	gtgtagttat	tttttttttt	agagacgggg	tttcaccttg	ttgcctaggc	13680
tggagtgcag	tggctattca	caggtatgat	catagcacac	tacagccgca	aactcctgag	13740
ctcaagccaa	cctcctgggt	cagcctccca	agtagctggg	accacaggct	catgccacca	13800

7/14

FIG. 3E

catccagtca	aagtgtcttg	gttttttgg	tttcaattag	gttcctcagg	ttaaattggaa	13860
gtatgtgggt	ttttgttttt	ttgttttttt	tttttgtaaa	gacagtgtct	cattatgttg	13920
gccaggctgg	tcttgaactc	ctggccccc	gccatcctcc	tgccctaccc	tcctaaagt	13980
aagtgtcgg	ataacaggca	tgagctgcta	ggcctggcca	aagttgaaaa	gtaaagtgat	14040
aagggagaag	taaaatgtatt	ttatcctctt	ggagaatttg	cttgacctat	tgatttttat	14100
attcaaattg	gcctttttg	ctcttagatg	agttccttat	tttgacaatg	aatgctgttg	14160
tccctatctt	ttaattaaat	tgccagccta	gagtgtactc	ccaggggcca	aatgagtaat	14220
tatcttggtt	cttaatctag	aaagcatact	gtaaggtaac	taaaggatct	gaaagtgtgg	14280
gaatgaagaa	agcaaccctc	caaatatatt	tgcttctaaa	actcttaaaa	ttttctgaac	14340
actcataaag	ttgaatggct	ttaagaagag	tgagacttta	taattgacct	agttagttaa	14400
agttacatgt	aaatttgtat	aacagtttaa	accttatttt	tgtggaagaa	aaagaagcag	14460
tttaccataa	ttgagtagcg	aggccttaag	ggtaagaaat	accatgcttg	atacctagtt	14520
tcttcttttt	tttttttttt	tttttttgag	atggagcttc	gctcttggtg	ctcaggttgg	14580
agtgacgtgt	cacgagaaaa	tacattttaca	gtgctatact	gtattttctt	tttctttttt	14640
tttttttttg	ctttgagatg	gagtccttgc	ctgtcaccct	ggctggagtg	cagtggcacg	14700
atcttggtct	attgcaacct	ctgcctcctg	gggtgaagcg	attctcctgc	ctcagcctcc	14760
cgggtagctg	ggattatagg	cggcgccaac	atgcctggct	aattttgtat	ttttagtaga	14820
ggcagggttt	ctccatgtca	ggctgggtgc	gaactcccga	cctcaggtga	tcgctcgcc	14880
tcggcctcac	aaagtgtctg	gattactggc	gtcagccacg	gcgcccggcc	tctagtttct	14940
tctatcagtt	agcaagtatg	ttttaagctc	aacggggaaa	ggagaaatga	tgagtctctt	15000
acccctagga	gcctacagtt	aagggataag	acatgaagca	attatgaggt	cagcatgaaa	15060
tagtacataa	tcaattatta	aatggttttg	tatatagttt	tgaagttgtg	tgatcagttt	15120
gtgatagggc	agtgaatcac	aaatgtactt	tttagcttct	gtatcctttg	gataatctta	15180
cttggaactt	gagtataaaa	aatgaataaa	aacaacagag	ctgccctgat	taaattgagt	15240
ggtaggagct	ggagtcaaaa	agatagcctt	ctgtattcac	aggttccaca	tcctctgatc	15300
catccaatca	cagaaaaat	ttgggaaaga	aaacaataaa	aaataatata	agagctaata	15360
caaattaaaa	aaatatatag	tgtaactatt	acataacatt	gtattaggt	ttataagtaa	15420
tctagcgatg	attttaaagta	tatgggaggg	gttacagggt	atgtgcaaat	atgccatttt	15480
atataagggg	cttgggcatc	tgaggatttt	gggtgtcaag	gattttggag	tcagtcgggt	15540
cggactaatt	gttagatgg	ggacatgaat	ttagagggtc	ttgagttgtg	taattttgt	15600
cagtaaaagt	atgtgtgtgt	aaattttaat	taaaatgtat	tatacagaaa	ctagtgtatc	15660
tttaacagaa	tatcttgagt	ttcttttgat	tgactgtatt	attggtcgat	tgattgagat	15720
agggctctcg	ctgtgttacc	caggatagca	ttgggtctaa	gtgatcttcc	tgccctcagc	15780
tcccaaagct	ctgggattac	agggtgtgag	cactgcaccc	agcaggtttc	ttaattacgt	15840
aggctagctg	acttgcaaaa	tatagccaca	actataatat	agtctgtttc	caagccccc	15900
aaaggctccc	tcctgcccc	tccaacagtt	agtacctttt	ttccaaaggt	aactgttggt	15960
ccttatgacc	tcctatcacc	catatttggt	ttgtgtgggc	atgaatttca	aactgaataa	16020
cattctagca	ttctttgtga	aatttgtgtt	cttacgtaat	ggcagtagtt	cacattcttt	16080
ttcattgcta	tgacgtattc	aaaattgtgt	aaataacca	cattttactt	attctacca	16140
ttatgtgtat	ttgggtagta	tcaatttttg	ctgtataaaa	taaagatgct	gtgaacatta	16200
tacctgagca	cctattttga	gtatatatcc	agggatagag	ttactggata	atggagccac	16260
atgtatatatt	agtttttcct	gcagcatttt	actacagaaa	ttttcaaaaa	tacaacagag	16320
ttgacagaat	tgtttgaata	cccatattca	ttcctaccac	ctagattctg	cagtaaacgt	16380
tttgctgtat	ttgctttcac	acatacctat	tcgtcgttct	tctgtcaatc	tatcctgttg	16440
atgtgtttca	aaaataagtt	gccaaatagt	tttccaagtg	gttgccactaa	ttttctgctt	16500
gtactgacaa	tatgagagtt	tcattttgtg	cacgtcttca	ccagtatctg	gtattgtcaa	16560
tctttatttt	tgaacttttt	tttagctttg	aagtataatt	gatataatta	tataacttta	16620
tgatgtacac	catgggtgtt	taatatatgt	atacatcatg	aaatgattac	cacagacaag	16680
ctaatttaca	gatccttcac	ctcacagtta	tgatttgcta	ttgtgagaat	atttaagatg	16740
tattttcata	gcagttttca	agtatacaca	atacattatg	ctaagctgta	gtcactatgt	16800
tatacaacag	atctctggaa	ttgtagatct	gttttatttt	agacatttta	ataggtgtgt	16860
agaagtatag	aaatgcagtt	gacctttgaa	caacatagag	ttgaaatagcg	tgggtccact	16920
tacagtgtcta	atttgtttac	acaagtatgt	tggaaattttt	gtttgagatt	tgtgacaatt	16980
tttttttttt	acgcttaatt	cgcttttatt	tccttgtcta	aaaaccctat	gttgtagcca	17040
cagctggagc	ctgggtccgc	tgccagggaga	ctctggcggtg	ggccttgatg	aggtggctcag	17100
tgaattcctg	atcgggagac	ttggtaaaata	cagtctcctt	ccagaggtcg	gggttcaggt	17160
agctgtaggt	cttagaaatg	gcaccaaagg	tggccttggc	gaagttgccc	aggttgccag	17220
tgacgcccc	ggctgaggtg	cagcagtcac	cgataccagc	catcatgagc	agcttcttgg	17280

8/14
FIG. 3F

gcacaggtgc	ggagacaatg	ccagtgcgcc	tgggtacagg	gatgaggtgc	accagtgcag	17340
agccgcagcg	gcctgtcacc	ttgcaaggga	cggtgtgggg	cttgccaatc	ttgttcccc	17400
agtagcctct	gcgcacgggg	acaatggaga	gcttggccag	gatgatggcc	ccatggatgg	17460
cggtggccac	ctccttggag	cacttaacac	ccagaccgac	gtggccattg	tagtccccga	17520
tagcaacaaa	cgccctgaac	ctgggtgcgt	ggccagcacg	ggtctgcgtc	tgcactggca	17580
taatcttcaa	aacctcatcc	ttgagagagg	ccccaggaa	aaagtcaatg	atctctgatt	17640
ccttaatggg	cagggagaa	agatagatct	cctccaggga	cttgatcttc	atgtccttca	17700
ccaagcagcc	cagcttgggtg	acgggcatcc	actccttata	ctcggccttg	cctccgcgag	17760
ctccgcggcg	tcgcccccg	ccccgtctac	ggctgcgacc	ccggccccgg	atgccactgc	17820
cgaaacctcc	gcggaagcca	ccgcagttcc	ccatcccagg	gcctccgggc	ccccccccgc	17880
tgcactgggtg	tcatccacca	tttgggtgtt	tctcggagaa	gaaaggattt	gtgacaattt	17940
gaataaaactt	aggtgattct	catttttttga	aatatcaaaa	aattaaggta	tgtcatgatg	18000
gatgcataaaa	atatgtaaat	actagtccat	tttatcattt	actaccgtaa	agcattcaca	18060
tctattataaa	aaaattaaaa	tttgggcttg	gcatggtggc	taatacctgt	catcccacac	18120
cttttgggagg	cagaggcagg	aggatcactt	gaactcagga	ttttgagaca	gcctgggcag	18180
gagagcaaga	cctcatcttt	acaaaaaatc	aaaagaatta	gctggagccg	ggcggggtgg	18240
ctcacgcctg	taatctcagc	actttgggag	gccaagggtg	gtggatcact	tgaggtcagg	18300
agttttgcgac	gagcctggcc	aacatggtga	aaccctgttt	ctactaaaaa	tataaaaaatt	18360
agctgggtgt	ggtagtgcat	gcctgtaatc	tcagctactc	aggaggctga	ggcaagagaa	18420
ttgcttgaat	ccgggagaca	ggctgcagtg	agccaagatc	atgccactgc	actccagcca	18480
gggtgacaga	gcaagactcc	atctcaaaag	aaaaaaaaaa	aaaaaaaaaa	agaaaacagaa	18540
aaagaaaata	cagtataaca	ctgtaaaatg	attttctctt	ccttatgatt	ttcctaataat	18600
tcttttctct	ggcttatttc	gtaagaatgc	aatatgttat	acatgtaaca	tacaaaatat	18660
gggttaataca	agtttgtgtt	atccataagg	tttcttttgt	caacagtagc	ttattagtag	18720
tttaagttttt	gggaagtcaa	agtttaggcc	atgcatgggg	catatacccc	taatcctagg	18780
tatatgtctt	gggaagccaa	gacagaagcc	aagacagcag	atcatttgag	ctcaggaatt	18840
cgagaccagc	ctgggcaaca	cagcaaaaact	ctgtttctat	aaaaaataca	aaaatttagct	18900
ggatgtgggtg	gcggggcacct	atagtccag	ctacctgaga	ggctgaagca	ggaaaattgc	18960
ttgagcctgg	gaggcggagg	ttgcagtatg	ccaagattgc	gtcattgcac	tccagcctgg	19020
gtaacgggag	tgaaccctg	tctcaaaaaa	aagaaaaatt	atatgaagg	ttgcgactgc	19080
actgggggtt	gagaccccta	acccccatgt	tcaagggtca	actgtatttc	attgtgggtt	19140
taatttgcac	tttcccagtg	agtagtagag	ttaacctttt	caagtgcctt	ttggcctttc	19200
gggtattgtc	ttttgtgaag	tcttttgtcc	agtttgtgtg	tgtgtgtgtg	tgtgtgtgtg	19260
tgtgttttgg	ggggacagag	agtcttgctc	tgttgcccag	gctggagtg	agtggcgcga	19320
tcttggctca	ctgcaacctc	cacctcccag	gttcaagcga	ttctcctgcc	tcagcctccc	19380
aagtagctgg	gattataggc	gcccaccacg	cgcggtcaat	ttttttgtag	tttttagtaga	19440
gatgggggtt	caccatgtca	gccaggcttg	tctcaaaaact	cctgacctcg	tgatccgccc	19500
gcctctgcct	cccaacgtgc	tgggtttaca	gatgcgatcc	accacgccc	acgttgtcca	19560
gttttttaact	gggttgtctg	tctgttaaaa	acttgatttg	taggagttta	aagtataattt	19620
tactaataaaa	aaagaatgg	aattgttctc	tgcataatat	ttagaaaaata	aggccgggca	19680
caggggttca	agcctgtgat	ttcagtgcct	tgggatgcca	aggtgagagg	atcccttaag	19740
ggaaggagg	tgagaccagc	ctgggcagaa	tactgacacc	ccatctctac	aaataatata	19800
aaaaagttag	gtgtgggtgg	atgcacctgt	agtcccagct	acttgggaaga	ttgaggcagg	19860
aggatcactt	gagcccagga	gctcgaggta	acagtgagat	atgatcacac	cactacactc	19920
cagcctgggc	aacctcaaga	tctgtctctc	taaaaaaaaa	aaaaaaaaagg	aggtggggga	19980
aacgaaataa	agaatagaag	gaaagtagag	attgtgttag	atcctagaat	gtgaagataa	20040
gtaaaatgat	ctccatgttc	tctgtaccgg	cgttctagag	agggatgtag	gtaaaatggat	20100
ataaaataca	ctgccataaa	ttttatgaag	aagaatgttt	aggggtgctat	aatttgcctca	20160
acacttcatt	atttttgctt	tcttgatatt	ttaaaataata	ctatgaatgt	ttaatcgata	20220
aaacacttct	tgttttagaa	tattttattt	gtataaaattt	tttttaggaat	tgttggatct	20280
tgccaggcac	aatgactcat	gcctgtaatc	ctagcacttt	gggatgtgga	ggcgggagga	20340
ttgcttgagc	ctagaaattg	gagactagcc	tggacaacat	agtgagggtcc	catctctaaa	20400
aaaaaaaaaag	ggaagggaatt	gctaaatcaa	aggatgtgag	gatttttaag	ctctacacga	20460
tcaatcggat	catcctaaat	aatttatcga	aacagtggaa	aaatatgttc	cacaataaag	20520
catacctctt	tggtgaccaa	aatgtggcat	tgatgaatat	tgggggggttc	cccctaaaaac	20580
tttaaccccc	tttgtgttgg	cacattctct	agataattct	gttgatttagg	ttatagtttt	20640
ttttttaaat	caaagaataa	aacatggctc	ccttgattag	agttagatat	tccttgcttc	20700
cttgaatgaa	ttcctttttc	tttttctgtt	tttgagatgg	agtcttgctg	tgttgcccag	20760

9/14
FIG. 3G

gcctgtagta	cattggcagc	atctccactt	actgcaacct	ctgcctccca	ggttcaagca	20820
gttgtgcctc	agcctcccga	gtagctggga	ctacaggtgt	atgccaccat	gcttgggctaa	20880
tttttttgta	tttttaattt	ttttttgaga	tggagtctcg	ctctgtcacc	caggttggag	20940
tgcagtggca	ggatctcggc	tcactgcaag	ctccatcccc	tgggttcaaa	cgattctcct	21000
gtctcagccg	cctcccaagt	agctaggatt	acaggcgtgt	gccaccactc	cctgctaatt	21060
tttgtatttt	tagtagagag	gggatttcac	tatgttggcc	aggcaggtct	cgaactccca	21120
gactcaagtg	atctgcccac	ctcgtcctcc	caaaatgctg	ggattacagg	tataagccac	21180
tgcacccggc	catttttttg	tatttttgta	aaggcagagt	ttcgccacat	tggccaggct	21240
ggtctggact	tcaggttgcc	ctggccccct	aaagtgtctg	gattacaggc	atgagcacc	21300
agcctagttc	ctttttcaaa	tgaatagcac	ataagtatat	gctggctctt	actaacttta	21360
ctctggggaga	aaaaaacata	gctccaattt	tcttttcatt	ataggctctt	tcttgaatag	21420
aatacttgca	tagaaaagca	atagcttata	cattgggtgag	gggagtgttt	acattgcccc	21480
caacatactg	tttaatgcat	aacatacatt	attttatttta	attatcacat	agtatctgta	21540
aagaggaact	atattatttt	taatactatt	aatatgctat	ataatatgta	tatatatgtt	21600
tctactactt	atatatcatg	caatgtgtac	attatagctg	acatagagac	tcagcagttt	21660
gtactctgga	taagtttgtt	acattttaatt	ttttattttt	cttttttagtg	acagggtctc	21720
acactgttga	ccatgcttga	gtgcagtggc	acaatcatag	ctcattgcag	cctcaaaactc	21780
tgggctcaag	cgatccacct	gcctcagcct	cctgagtagc	tgggactaga	ggtgcagtgc	21840
accacacctg	gctaattttt	gtcttttttg	cagagacaag	gtctcactct	ttttcccagg	21900
ctggctttga	attcctgggc	ttaagcaatt	ctaccttggc	ttcccaaagt	gttgggatta	21960
caggcgtggg	cgactgcacc	cagctgtggt	tcacttttct	gctgggtgtt	ttggaagcac	22020
aaaagtgatt	aatcctgata	aaaaccagtt	tgtctatttt	tttctttggg	gagcttttgg	22080
tatgttcaag	gagggggtca	aacttgattc	ttctgcatgt	gaotagcctg	atgttccagc	22140
accatttggt	gaaaatagtt	ttcttttctc	attgaattat	cttgggtattc	ttgccaagaa	22200
tcagttgtct	ataaatatga	gagtacatct	ctggactctt	ctgttccatt	ggtctatatg	22260
tctgtcctta	ggctagtact	gtactgtagc	tttataagta	aggtttgaaa	tcagaaaagt	22320
tgagtctttt	ttgttgttgt	tgttctccct	tttcaggatt	gttatggcta	ttcttagtcc	22380
cttgtatttc	catgtgaatt	ttaggatcaa	ctgtcaattt	ctgcaaatga	gccagctaga	22440
atttttgatag	agctacattt	aatttttttt	aatgaacca	cattgaaata	ttcaacgatt	22500
gccaaaacat	tatcacccca	aaccactgt	ttatcttaga	gttcattctt	ggtgttgtac	22560
atggatttgc	catgtataat	gacatgcac	caccattata	gtatcatacg	tgtagtttta	22620
ctgctctaaa	aattttccgt	gttccatctg	ttcatccctc	cccccaacac	ctgacaacca	22680
ctgatggctc	tattgtctcc	atagttttgc	catttgcaga	atgttgcata	tttggaatca	22740
tacagtatgt	agccttttca	gattggcttc	tttcatgtag	taatatgtat	ttaaagtctc	22800
tccatgtttt	tcatggcttg	atagctcatt	tatttttttag	tgctgaataa	cattccattt	22860
gcattgatata	actgtagttt	atctatttac	ctatcgaagg	acaccatagt	tacttccaca	22920
tttcgatagt	catgaataaa	gctcctgtaa	acatttgttt	ctgggttttg	gttggatgta	22980
tttttcaact	cctttgggta	aataccaaag	ggtgcaattg	ctggatcaaa	tggtataaat	23040
atgttttagtt	gtgtgagaat	tatcaaaact	tcaccctaag	cataccattt	ttgttgttgt	23100
tgttgttgtt	attgtttttt	gagatggagt	ctcgtgtca	cccaggctgg	agtacagtat	23160
ggcgtgatct	cagctcacca	caacctccac	ctccctggct	caagcgattc	tcgtgcctta	23220
gcctcccgag	tagcttggat	tacaggcacg	tgccaccatg	cccagcta	ttttgcattt	23280
ttagtagaga	cggggtttca	ccatgttggc	caggctgggt	tcaaactcct	gacctcaggt	23340
gatcctcccg	ccttggcttt	ccaaagtgt	gggattactg	gcgtgagcca	ccgtgcctgg	23400
tcgcaaagca	taccattttg	cattcccacc	agcagtaaat	gagagtctct	gttaccacac	23460
atccttgcca	ggactttaatg	tcagtgtttt	ggattttcac	cattctgata	ggtgtgtgtg	23520
gtattttttg	ttttaatttg	cagttctcag	tgcttctcag	tacctccac	ccaccttate	23580
tgggacagga	tggctggagg	ggctggagtt	gggtagtctt	ctttccccag	gtagggttaag	23640
ctctggtaaa	agtttctccc	agaactttat	attaaattaa	aagtttcgca	tgaggataag	23700
acttaattag	agcagaatgc	tctggcatat	ttaaaatggt	ttattttcct	ctccgcctcc	23760
tggaagcact	cagtgagga	cctggtagag	gtttttggagg	taaaattcac	aaaagtgtgg	23820
tggccccaat	tgggtccact	tggagttttt	attttatttt	tctttatttt	ttattttacat	23880
tttttgtttg	tttttttggt	ttggagatag	tcttgctctg	cggaccagaa	tgggaatacaa	23940
tggcacaaac	tcagctcact	gcaacctctg	ccccctccga	ttcaagctat	tcttgtgcct	24000
cagcctctct	cgagcagctg	ggattacaga	tgtacaccac	catgcccgac	taatttttgt	24060
attttttgta	gagatgggg	ttcgccacat	tgcccaggct	ggtctcaaga	tcctagcctc	24120
aagtgatccg	cctgcctcag	cctcccaaag	tgttgggatt	acaggcgtga	gctactgtgc	24180
ccagccttga	ctttttaata	atagccattc	tgactgatga	gatgggtatct	cattgtgggtt	24240

10/14
FIG. 3H

tttgatttgc	atttctcttc	ttatttcttt	tcttttcttt	tcttttcttt	tttttttttt	24300
gagacaaagt	ctgttgctga	tgctcaggct	ggagtacagt	ggtgcaatct	tggctcactg	24360
aaacctccgc	ctcccagggt	caagcagttc	tcttgcttca	gcctcccagag	tagctgggat	24420
tataggcacc	caccaccatg	cccaactaat	ttttgcattt	gtagtagaga	tggagtttca	24480
ccatgttgcc	caggctggcc	tcgaactcct	gacctcaggt	gatccgcctg	ccttggcctc	24540
ctaaagtgtc	gggattacgg	gtgtgagcca	ctgcaccag	ccaatttgca	tttctctagt	24600
gatcagtgat	aatcggaatg	gcacgcaatt	tacaacatta	gttgttttatt	tctggaattt	24660
tccatatagt	atttttcagac	catggttgac	cacagttaac	tgaaaccttg	caataagtgg	24720
ggactgctgg	agatcctctt	catttttaaag	atgcagaaat	aggttgggca	gtagagcagg	24780
gcaactagga	gaaatgcatt	taaacaatag	ggataactgc	acagtgaggc	agaaaaatgtt	24840
atataataca	ctagatttgg	ctcaaaggca	gtcacaggag	cctctaggag	ttcatattcca	24900
gtagagtcca	ggagaggaat	gagatactgg	aattaagtag	gttatacagt	gatacttgaa	24960
gtaatgagac	ttcttttaaaa	tgaaatgggt	cttctaaaaa	tgtttcataa	atcctaaagg	25020
taggcacaac	atatggcaca	taaaattatca	gaaataccca	tatgtataac	atctcttttt	25080
tcatttggaa	gtaaacagcc	ctgcctcagc	aaaatttctcg	agttaataaa	atgttttttag	25140
tgtccccgtg	tcttcttttt	tattctcagt	tggtgatttc	ctttcttttg	ccaatctccc	25200
tgataggcaa	tctgtgtctt	ctgtctaacg	tttctctctt	gaatttatag	tgtagttatt	25260
actaaggcac	caattcctat	caattaaggc	tcatttcagt	gtaatgtgga	tgtgttttat	25320
ttagtattat	gtccactggg	cctttgtata	tttagcgttt	gcaccactcc	ccacccatt	25380
ttcatgtgac	aactggaggc	cttgttcaaa	aaactaccag	aaaaaggaca	tgtatcccat	25440
cctttatggc	tttcttgtaa	caccagaaac	tatccagcct	tgttttgtcc	tgtttactgt	25500
aagatcctaa	gccagtgggt	ctcaaccagg	atgaatttgc	tctccaggaa	acgttttagca	25560
aagtctagag	acattttttg	gttgtcacaa	tgtggcaggg	aagagggtgc	cactggcatc	25620
tagtggatgg	agagaactgc	caaacaccct	gtgatgtaca	ggacagcccc	tacaacaaag	25680
aattgtctta	ctaaaatgtc	agtattgccc	aggttgagaa	gcccttcact	aagcaagccc	25740
cttttctctt	ctaaccctcag	ttaggtcctt	aattaagttt	gtttcttcaa	ctgaaaagtg	25800
gaggttattg	caactttttt	aaatggttgc	aaagataaat	gaatttaagg	cgtggaaata	25860
tttagcacag	tatctgacac	acagtggcac	tctgctgaaa	gaataaatta	gggttttttaa	25920
aaaatgttgt	ataatgcagc	ttctcatcca	tcttgatttt	cctgcaaaaa	ttctcatgtt	25980
aaatgttttg	atccattatc	actgtaaatc	tcttacatgt	tatagaaatt	cctgtattta	26040
agcttctaaa	atttccctaga	ctacctctta	aatatgtttt	gatttttggg	catgaaagca	26100
atgattatac	caacactgga	acaaatcttt	ttaagtaaca	gaaacctttt	cctgttcttt	26160
tctaaagcac	ttcagtgaat	taaagattgg	tgaggagtgt	agggtcaaagt	ttaagtcatt	26220
cagtaattga	atattttctg	ttgtcaaaaga	gttaataagt	tcattgatcaa	atagctgatg	26280
taggagaaga	cgttagaaaag	atttcagaaa	cactaaactt	atcgcattct	ccttgtgctt	26340
ttaattttat	gtagcaattc	aaggccatca	atagttgtag	tcttaaaagc	ccctaaaagc	26400
agaaatgata	ttacttttgtg	gattgttttag	attttttatga	tgtacccctg	tttgcaagggt	26460
ggtgttaggt	cctatgaatt	aggagtgtgt	aagtttagtt	aattggctga	ggcccatgtt	26520
tgetctgtta	atttttttgt	gaattagttt	ttaacatacg	gatcctgcac	aagataaatt	26580
tataccttta	aacatttccag	tttttttggt	tcgttaaagg	tgttcaaaact	ttttattttg	26640
gcttccagtt	cattgtctgg	atttacaaat	acaattaatt	tatgtgtgtt	cttttaacct	26700
gcaaccttgc	tgaattcatt	ttaggagggt	ttggttagag	tccttgggat	tttctaaata	26760
ggctcatgtc	tgtttgtctc	tctttaatta	aaatttttta	gggtgtgttt	ttgtaaagcg	26820
ttaatatcca	gttttgggtg	ttttcattct	cagactgatt	ctcaacctgg	ccctctttca	26880
aactttcaca	ccttctccct	tttcaactct	actcccttcc	ccagaaatca	ctgaaatgac	26940
ttctgagcac	attgtcattt	tatcttactg	attcaaaatt	attattagat	acgttattat	27000
accttgagg	taacagaata	gtgcatccag	agtctttaat	tatgtaggac	aattgtgtta	27060
gtgggtgaaa	gctgttaggc	ttttggattc	ttgcacctac	tttttattga	tttttttttc	27120
ctcattgtca	gttcttcatc	tgctgttagt	gtgtctgccc	ttaaactacc	tcttctact	27180
tctaataatt	tggcatgttg	gaaaaccaga	tactcaagct	catcacagta	ttttctagca	27240
actcccaata	gagagatccc	agaggcagtg	gcagttaagt	tgcattttca	cctgtgaata	27300
aactattctg	gggttttagat	acataggtag	tttatatttt	tttaagttaa	aaatttttta	27360
aagtttggaa	caaatttgc	taataaagtc	agtttttagcg	ggaaattcac	atgcacatga	27420
gaatcgaaag	aaagaacctt	taatgttgat	gtaagcttat	cattcccttt	tcacatatac	27480
ctcaccacct	cctctgtgtt	taattatctg	gacttttttc	tcatccctag	attttgtttc	27540
tcaaaaatgt	ttctccctta	aaacatgttt	taatgaactc	tgtaagatct	aagttcttaa	27600
tctcaaagta	atcttttagat	tgaggagtac	taaaatttag	atccacagac	ccttttaagg	27660
cagggataga	actgctttca	gtgtgattga	tttctttagt	aatcttatgt	gttttattca	27720

11/14
FIG. 3I

aaaacgttat	ctgaaatagc	tttcattgga	ctgcataagg	tttccatggc	aaaaaaaaa	27780
agtgttaaga	atccgtgaga	ggcaatccca	gagtgagctc	ctgtcattgc	tgccagaaac	27840
cacaaagcct	tttgagagtt	ctgaaactctg	agtcacagag	ttctgatagg	tatgtgggtat	27900
tgtaattcag	ttgaattttg	ctggttggaa	atcttaggtaa	attgtcagac	gtaattaaga	27960
tttgcagcat	gaaatgggccc	caaataatata	tggagtcttg	ctctgttgcc	caggatggag	28020
tgcagtggca	cgatctcagc	tcaactgcaac	ctccacctcc	cagggttcaag	tgattctcct	28080
gcctcagcct	cccaccacgc	cctgtctgtg	ataagatttt	tttttttttt	tcttgagacg	28140
gagtcttgct	ctgttgccca	ggctggagtg	cagtggcacg	atctcagctt	actgcaagct	28200
cgctctcccg	ggttcacacc	attctcctgc	ctcagcctcc	ggagtagctg	ggactacagg	28260
cacctgccac	cacgctcagc	ctgtgataag	atcttttaaat	aaaaatttca	gggctcgttg	28320
ctatggctca	tgctgtaat	cccagcagtc	tgggtcact	gcaacctccg	tctctccggt	28380
tcaagcgatt	ctcctgcctc	agactcccg	gcagctggga	ttacaggcac	ataccaccac	28440
ccccagctaa	ttttttctgt	tttagtagag	atggagtttc	actatgttgg	ccaggctggt	28500
ctcgaaactcc	tggtctcagg	tgatccaccc	gccttggcct	ccctagtagc	ctgaggctac	28560
aggcatgtac	caccactcct	ggctaatttt	tgtagggatg	gggtttcgcc	atgttgccca	28620
ggctgggatt	gcggtgtga	gccactgcac	ttggcccaa	aacaattttt	aacggatgat	28680
gctgggacac	ctacatataa	ccacatagtt	aagtgaagtt	gggccccttt	cttactatat	28740
gcaaaaatta	actcagaatg	gttcatacac	ctaaatgtaa	gagctaaaac	tttataaacc	28800
tcttagaaga	tataggagca	aatgctcatg	acottgggtt	tgacaaactt	cttaggatac	28860
tgaaagtaaa	agtaacaaaa	gttgaatttt	attaaaaatt	aaaatttggt	cttcaaataa	28920
cgtaaagaaa	gtgaaaagat	aacctatagg	atgcaagaaa	atatttgggc	ttttttttgt	28980
ttgtttgttt	gtttgagaca	gagtcctcct	ctgtcatcta	gactggagtg	cagcagcaca	29040
atcttggtct	attgcaatgc	cacctccag	gttcaagcag	ttcttggtcg	tcagcctccc	29100
aagtagttgg	gattacaggt	gtgcactacc	accgcctgct	aatctttttt	tttttttttt	29160
ttttttttgt	attttttagta	gagacaagg	ttgaccatgt	tggccaggct	ggtcttgaac	29220
tcctgacctc	aggtgatctg	cctgcctcag	cctctcgaag	aaaatacttg	taaatcattg	29280
gtctgctaag	ggacttgtgt	ccaggagata	acaaaaagat	aatttgctat	cagagagggc	29340
aaatcaaaa	cacaatgaga	tatcacatct	tatccacttg	aatgggtata	ataaaaaagat	29400
taagtttaag	caatgctgta	gagaaactgg	aacattctat	ttcccttttt	aaaatgcaca	29460
cttcattgat	ttccagtggtg	ttcagagtta	cacaaccatc	acttaaccaat	acagctctcg	29520
atgggattgt	aagatgggtgc	aggtgctttg	gaaaaagttg	gcagttctac	aaaagggttt	29580
gcagagttcc	attcattgggt	ttatatacc	aataaaaatga	aaacatgtac	aaaaacttat	29640
acatgtatct	tcataaacact	gttattcaca	gtagctaac	agtagaaaca	acccatgtcc	29700
atcagtgact	aaacaaaatg	gtggtggact	attcagtgat	aaaaaggaat	gcaattctga	29760
taaatgctgc	atcatgggtg	aactttgaaa	acatgctaag	tgaaagtcga	gccacaaaag	29820
accacatatt	agtatgattc	catacacagg	cataccttgt	tttattgcac	ttcacagggg	29880
tgtgtgtgtg	tgtgtgttta	cacaacttga	agggtttgtg	cagctctgca	tgaaacaatt	29940
cttttggc	cattttccca	gcagctcatt	tcatttctct	gctacatttg	gtaattctcg	30000
tgctttcaga	ctctttcatt	atatctttta	cagtgatctg	tgatcagttt	tattagggtg	30060
gtctggaacg	aaacccacac	atctgaataa	tgcttatcta	tgaaatgccc	agaataggca	30120
aatctataga	gacaaaaagc	aaattagtta	gtagtagcct	agggccgggg	agtttggggg	30180
agtgactgtt	aatgagtaca	ctttcttttg	ggggtaatga	aaatgttcta	aaattgataa	30240
gtgatgggtg	catagctctg	aacacactgg	aaaccattga	agtgtgtatt	ttaaataggg	30300
aaatagaatg	tgaattatat	ctctaagggt	ttacagttaa	tggaagcctt	tcaccttacc	30360
gtgatactgt	atcttctcag	tgctgagatg	tgctttttta	ggctaggcct	ggctgctcac	30420
tcctgggac	ccagcacttt	ggaaggccaa	ggcaggagga	ttgcttgagc	ccagggaattc	30480
tagaccagcc	tgggcaacat	agtgaaaacc	tgtctctaca	aaatgtatat	ttttaattag	30540
cggggcatag	tagcatgggc	ctgtagctcc	agctactcag	gagactgaag	tgggaggatc	30600
acttgagccc	ggggggctcg	caaggctgca	gtgagccaag	attgtgccac	tgcaactctag	30660
cctaggtaac	agaatgagac	cctatctcaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaat	30720
atatatatat	atatatacac	acacacacac	acacacacac	acacacacac	ttatcaggaa	30780
gatagatgtg	atgctagctt	ttacatctct	ctgtgtaatt	gttcagggaac	tgcatcagtg	30840
ctaactctggg	ggttttttgt	ttgggtcaaga	tttcatggaa	catcagaagt	agaacataca	30900
ttgagaccaa	ctattctaaa	tcctccattt	tatggcttta	aatgtcagtc	tggcaaaatt	30960
cagagaaaaac	atcttcccagt	aggagactgc	agctgggaag	aagggtgggtg	cagcagcagc	31020
ttgtaaggat	ataaagagaa	ggatcagaag	agctggctct	tatttcctac	tggaggaaaa	31080
gataccgctt	ttgggtgacaa	gctgcagctc	ttagcagtga	ctttattttt	ccttcaccac	31140

12/14
FIG. 3J

aaaccagact	tgtgctat	ccagcctcag	cacattat	aggcacttcc	ccactgcatt	31200
gttttcg	ctgaaattgt	atcacattcc	ctaaattgaa	tccaactttt	aatgtagtgc	31260
ccttcagaca	gacacgtttt	acattcacct	gttttgtgtc	tttcttggct	taaaccacct	31320
aagattaggg	cccatacat	tcttgacaac	atccatcatt	ttatagggtgc	ttcatttata	31380
tattaacaaa	caaccggaat	gcttcagaga	tttttgcgcat	cagatcagac	cttgcgtgtt	31440
ttgatgtttg	accctatctt	ctggccgggt	gcagtggtgc	acacctgtat	cacacctgta	31500
atcccaacac	tttgggaggg	caaggcaggt	ggatcacttg	aggccaggat	tcgagaccag	31560
cctggccaac	atgggtgaaac	cctgtctcta	ctaaaaataa	aaaaattagc	tgggctgtgt	31620
ggcgcggtgc	tgtactccca	gctactcgag	gttgaggtgg	gagaattgct	tgaacctggg	31680
aggtggaggt	tgtagtggagc	caagatcgcg	ccactgcatt	ccagcctggg	tgacagagt	31740
agaccctgtc	tccaaaaaaa	aaaaaaaaaa	gactgtatct	tctgtcctgc	ttcagcatat	31800
tttataaacc	tgtcttccat	ttctattcta	cccccttcca	tgctgctgca	tttttccaca	31860
atgcataat	taatttttaa	ttattccttt	tctccttttc	ttaaaggcag	atgatttcc	31920
ttggattctc	gctctttctc	tcttttgc	gcagacatat	ggagaactaa	agaaagtatt	31980
aaggaaaaga	ttgttttaaa	ttatttgaaa	tttgcttttc	tgtgaattcc	atcttgaaat	32040
ttaaactcac	agggcaagcc	catgtgtctc	ctaataca	acgaggaaat	ggtagttagg	32100
taagactgta	taagacattt	aagtagatga	tagtggaaaa	gggaagagag	gaagtcagag	32160
gaatcaggaa	ggatgagatg	tctatctcca	gtgactagt	gtgtcattag	agaagagccc	32220
atatattaag	taagccctta	tcttggtaa	tgtttactt	atctgtttat	tccttacaat	32280
actttttttt	ttttttttt	aacagagtct	agctctgtgtg	gccaggctgg	agtgcagtgg	32340
cgtgatctca	gctcactgca	acctccgcct	cccaggttca	agcaattctc	atgtcgcagc	32400
ctccagagta	gctgggataa	cagagctaaa	tgactgcac	tggcctccaa	ccctttatta	32460
agataggat	tttgtctgtt	atgctgatga	ggaaccttaa	tgctcagaga	tattaagaag	32520
cttgcgtaag	gccacataca	taattaaata	ccagagcaga	aattccaggg	aatgcctgta	32580
ctctttccat	tatgtat	tgttcattaa	cctaggtagg	gggcatagaa	attctgagtt	32640
tgagaggcat	gtggaaggaa	gtatatgttg	tttgggtttg	gacctattga	agttcctgtg	32700
ggatgggtag	gtggagt	gaaagagaca	acaaccag	tattttcact	tgggagaatg	32760
ttgggtgtaa	tttatatcaa	gttttccttt	ttgggtttat	tgttatttaa	tccaaatcat	32820
tagcagtttt	tctttttttt	ttctttttga	gacagcagtt	tttctttttc	ttattgttat	32880
ttaatccaaa	tcatttagcag	tttttctttt	ttctttttct	ttcactttgt	caccocagtct	32940
ggagtgtagt	ggtgtgatct	cgtctcactg	tagctcaacc	tcctgggctc	aagcgatcct	33000
gctgcctcag	tccccaggt	agctgggact	acaggtgtac	atcaccactt	ctggctaatt	33060
tttgtatctt	ttatagagac	gggggtttcac	catgttgccc	aggctggctc	caaactcctg	33120
agctcaagct	atccgcctgt	cttggccttc	caaactgcaa	ggattacagg	cgtgagccac	33180
tgtgccaggc	gcattagcaa	tttttcatag	catatctaca	aagttcta	atgtatataa	33240
tgtatattac	aagaacataa	gtgctttgat	ttaggttatt	cagttatata	attatgttga	33300
gtcccaactg	tgtgccagat	accgtgctga	gtaggtagta	aacatttggt	agcaaaacag	33360
acatagcccc	tgcccttatc	agactaccca	catagccrgg	acacagtggc	tctcacctgt	33420
aatctcagca	cttgggagg	ccaaggctag	aggatcgctt	gaggccagga	gtttgggtcag	33480
cctgggtcagc	gagacactgt	ttctaccaa	acaaaaaat	tgctgggcat	ggtgttgtgt	33540
acctgtaatc	ccagctactg	gggaggctgc	agtgggagga	ttacttgagc	ctagaagttg	33600
gagggttgag	tgagatgtgt	ttgtatacct	tttgtcatta	ggtccatatt	taggcccctga	33660
aataggctaa	tcaaaatatt	tatttat	tcatttgttt	tcagctgggg	acgaaacaca	33720
gtagctttgc	aaatataaag	tgggagcaca	acctagcact	ggcgttggag	gtcctcaaaa	33780
cagtcctccag	gttttggat	tcaataggag	ggctcttagg	acttagtata	taatcttact	33840
cacatctatg	atttgttaca	gcaaagaatc	aaagcaaat	cagctaaggg	gaaaggtgct	33900
ttggtctaaa	gggaactaag	cacaagcttc	caagagttat	ctcctagtgg	agtcacacag	33960
gacatgctta	attccttcaa	catatatgaa	aggttttctg	ccagagaagc	tcatttggag	34020
actcagtgcc	ccaggtagctg	attaggcacc	cactgcctag	catatgacaa	aattcctgat	34080
tctcagaggg	gaagcaggtg	ttgaacataa	accatatagt	gttcgcagat	agggaatggg	34140
gggaaccacc	cccaaatcca	tatctttttt	tgttgttaag	atggagtctc	tctctgttgc	34200
ccaggctaga	gtacagtggc	aagatcttgg	ctcactgcaa	cctctgcctc	ccgggttaaa	34260
gcagttctct	tgctcagct	tactgagtag	ctgggattac	aggcgtgcac	caccacgccc	34320
agctaatttt	agtattttta	gtagagatgg	tgttttacca	tgttggccag	gctgggtctcg	34380
aactcctgac	ctcaggtgat	acgcctgect	cggcctttca	aagttctggg	attacacgca	34440
tgagctacca	tgcccagcca	tcacatcttt	taaaattgtt	gtttttatac	ccctgtctaa	34500
tcttctactc	actcagtgct	tgttagccaa	caattgaatc	aggattccat	tttgcctgct	34560

13/14
FIG. 3K

agaaaatcag	tggctgtcta	gttatgaaac	aattgataac	tcagatatca	agccatttta	34620
aaacaagtat	catgggaatt	aaaatttaaa	attaggcatg	tgtggtaaga	aggggtgaggc	34680
cacattcatt	tttaaaatat	caggaggtct	tagtcatttc	ctttcctcta	tggttttctg	34740
aaccatgtaa	actgaaatta	gattgttcaa	tcatttttaa	tatctaaaag	atatagagag	34800
ggttcctttg	ttttaacaaa	aaaataccaa	aggagaaaa	acactcataa	cgtgaattaa	34860
aatatagttt	ttattttctt	ctttaatggt	tattaatggt	tccccgtaaa	gtagaacttt	34920
ccttttctgt	tctgttttct	gtgttctcta	cacgtatgtg	aaccacaaga	ctgaagaaat	34980
ctagcctctg	aaaaacccat	agttggagtt	tatttttctt	aaaacaattt	agttattttt	35040
gtttgttagg	ttcaaggatt	taagagacct	tttatattat	cttagtctta	aaccaatttg	35100
ttcccagttt	gcgtgtggat	gacagctcat	caaaactggg	caactaggac	tgaggctaag	35160
attcaggaag	gtaatttaga	ctggaaatgg	taattcaagg	gttgaagaac	tcagagctgg	35220
cagagatcac	aacagagtcc	aagagtttgt	agtattcaaa	gagaagccag	aaagccagga	35280
ccaaagccaa	ggacagtagc	acttagctta	aagtctgcaa	agcagagaat	catgatgggg	35340
agaatcatga	cgttggggag	atgttagaat	aatttacaaa	tattggcatt	tacaaagctc	35400
ttagttatct	catgattata	tcaactcttt	aaagtgggta	ctgttatctg	ctttattcaa	35460
agacattaag	agacttgggt	caagcaatca	cagtaagtag	ccgagctgag	actgaaatct	35520
tataatttaa	ttcttcagac	tgaaaatctc	atcttctgag	atagtagtgt	ttttcagact	35580
gctctgttga	ttctgaggat	tctgcaaagg	taaccaaggt	gagggcttgg	ggatggggag	35640
cctcatccct	tctaggccac	actccatccc	agcttcattc	catcagagtt	gctcagtttt	35700
aaatattatt	ataggccagg	caccatgggt	caaccctgtg	gccccactac	tcaggaggct	35760
gaggttggag	gattgcttga	gcccaggggg	ttgagtttac	agtaagttgt	gtttgtgcca	35820
ctgcacttaa	gcctgggcaa	cagagggaga	ccctatctca	aaaaaagggt	gggggttatac	35880
acacgattcc	tttgaattgt	tttgttgtgt	aaaaaatcag	ttggattagg	agcagcagaa	35940
ttctaatttc	agtattgtca	attagtgact	gtaggcaagc	ttggtcctat	gaaatgggaa	36000
agttagtctt	agataacttt	tagatttatt	tttgccatag	cccagtcctat	ttaaaaagtt	36060
ttaaaaatta	tttttagaga	tgaggtcttg	ctatgttgtc	caggctgggt	ctttatcatg	36120
tgaaaatagt	tcatttaaca	ttccatgcca	gttcagtgaa	gtctgtgttt	atatccttta	36180
ggcagaatga	gaatgttttg	gtgtgtgtat	gttttattct	agtagctgaa	gttaaggcag	36240
ggtgaaacac	agtcatacag	ccaaacacta	gccagcttc	ctacccctcc	cagggctccc	36300
tttcccttct	atctctgacc	aaaaaataag	ccctcgaaag	gtttttaaaa	aataatcttt	36360
ttcctctata	ttttaatatt	ttaggaacaa	gttccagttc	cagtctacca	cccaacacct	36420
agccagactc	ggctagcaac	tcagctgact	gaagaggaac	aaattaggat	agctcaaaga	36480
ataggcttta	tacaacatct	gcctaaagga	gtttatgacc	ctggaagaga	tggctcagaa	36540
aaaaagatcc	gggagtaagt	tttaattaat	ttgtacattt	caaagtttta	ttttcagatt	36600
gcttttgaaa	aatttgccct	ttctcctgca	ctttagaaag	tcagacattt	aatatattga	36660
aacacttcgc	ttaatgcaag	agaatgttta	attttttttc	atagctctat	tactggctac	36720
tagcaagaga	atgttatgta	gtaattaaga	attttccacag	gccgagcaca	gtggcttatg	36780
ctgttaatcc	cagcactttg	ggaggctgag	gtcgggggat	cacttgaggc	caggagtctg	36840
agaccaacct	ggccaacatg	gtgaaacctc	atctctactg	aaaatacgaa	aattagccag	36900
gcatgggtgg	acgcgcctgt	aatcccaacc	acttggggag	ctgaggtggg	agaatcactt	36960
gaaactctgt	ctcaaaaagt	aaaataaagt	aaaataagag	aaagttagtg	ttaatgaaga	37020
gagctttaac	ttacagcaac	ccagtaagta	ggctgaagtt	agtgtttctg	tttttacagt	37080
tattaaaaatg	aaaattatct	tactctagga	ttactctaaa	tagcacaagg	aaacaaagtt	37140
gcccgaagtt	agtgtttctg	ttttacagtt	actaaaatga	aaattgtctt	agtcacagat	37200
tacactaaat	agtgcagaaa	aacaaaagttg	acttaactga	tgctttttcta	cctaaaaata	37260
tcccattctc	cttcagggtat	ctgctataat	atgtagctgt	ttacaagcac	agcagtagat	37320
ttgatgcata	tgtaatccat	ttctcttttg	tctgttgatt	gctcctaagt	cctgcaaat	37380
ctcaggggat	tgaaataaga	gactgtggac	agatcaacat	taggaaaaaa	ttcagtttgc	37440
atgctttggc	aataagatga	caggcaaaagc	attctgatgt	gttactcaga	ttaacactgt	37500
ctttaattggg	atttaaaagag	ttttctgaat	aggacacttc	tgaaaatgcc	ttctgatttc	37560
tctccattgc	tctcaacagg	tgtgtgactc	gtatgatgga	ctttgtttat	ggggaccocaa	37620
ttcgattttct	gocgtgcatg	cacatctatc	acctggactg	tatagatgac	tggttgatga	37680
gatccttcac	gtgcccctcc	tgcattggagc	cagttgatgc	agcactgctt	tcatectatg	37740
agactaattg	agccaggggtc	tcttatctga	cttcaagtga	accaccattt	tggttggtttt	37800
gatcttttgt	cactgagccc	aaagagccag	ggattaggaa	ttaagatcgt	gcacaaaagt	37860
ttccttaaaa	ttcctggatg	gctgcagatg	ttgggggaaa	aagtacgtga	tattttagaa	37920
acttagtggg	aaaagtagga	tggatatttt	atgtaaagcc	ttgaccacat	gtttaaaaat	37980

14/14
FIG. 3L

```

ataattgtat ttagatcttg ttattgctcc agtacatagg aattgtgtaa agtggttaaca 38040
gcagctgtat ttgttttaaat tgtgtgtatt gaagattagg aaaaagatag tagttatttt 38100
tcctaaatga aataactttc ttctcttccc cttccccacc cgaattcttt tctgaagttg 38160
ctggcatttg ggtcaagggt ttattaaaag ctacatttta taacactggc acacacaaaa 38220
aagtagtttt aagcttggtt gcacagttct ttttttccat tggaaatgga attcattgcc 38280
ttaggtcttt ttaaataagt tattattatc gttggggctg gctctatgct tgaaccag 38340
tttattttata acctgttata agtgctatat tctgtttgca gttaggaaat gcagaattca 38400
aagtgatctc ctagcttgta agcaaaactga gatgcactat cccttttcta taaaaaataa 38460
gttaatgtgt caagaaacca actctattaa ggtgggggtt aatattaccc tttcctatgt 38520
gtttttatcta attatttttg ttgttaatat ggtgataatg gaaagtcaag ttaaatttta 38580
aatattaaga attctgattt attgagattg aattatgcca ccacgtttat gtaaaaatga 38640
aggtggcacc gtggtgagac ctaatgagaa atagttactc agttgtaaaa attttgattt 38700
attctctttc ttctgacctc cttgcctctt gtcttgaacc atagcaaaag gatactgcat 38760
ctctcattac tgtagtgtg aggttattga agttatacaa aacacatctc agtctctgtt 38820
tcttggaag gtatctatta catcctgcta gctgactgac aaaactaagc agggagaata 38880
aagataattg tatttttatgt tttgcacaca aacgcagaat ttgtataacc atatgacttc 38940
atagttgtga tctcaaaaaa gaaggaattt ctcctttgtt tcttgcaagt aatgtaagaa 39000
tacttttaaat ctctaagctt ctgaagtgtt agaggtagag atggtctagt aaagatgtag 39060
tagtaatgtt ttatccattt agcatgtgtt tattttttca tatgtactca aaggtgactt 39120
attggttcac ctcagtgata ttacagctaa aaaaatcatt cattagcaaa aggaaaagtg 39180
gtctcaacct aacatcagaa gtgtttctta ttattatttt atattgagtt gaattattgaa 39240
ctctaacagt tttctacata caaaacacag tgtcatgaag gttattcata attgcattat 39300
agaggaatgt agtatgtcat aagtactttg taaagatttg acattcaact gtagtatcca 39360
tatgttgctt aaatttctct atgagcccca tgatggaaag acttaaagat gaatttgaga 39420
aaaattgaaa gaaattagat tatcagggtc tgttaaattg ttacatgtat cttgcttaaa 39480
tttctgttta ttaatttata tccaccaag tacataaagc aaatttgagg gaaacaactg 39540
aagttgtgca atattttctg ataattgctt tttttattct tgtgttttct acttaaacat 39600
aatgtctgtg tcatcaagta ttatagtcag acttttcttt ttttctagat tgttaaaatt 39660
ggcaaatgaa ctttttttaa aatcatcttc catgttgca ttagtctttc ttttcattac 39720
aagtctttca cagaagtttg gtggtaatat tgaaagaact agcattgggc agaattgtgc 39780
ttttt SEQ ID No. 1 39785

```

RNF-11 Coding region

```

Met Gly Asn Cys Leu Lys Ser Pro Thr Ser Asp Asp Ile Ser Leu Leu
 1          5          10          15

His Glu Ser Gln Ser Asp Arg Ala Ser Phe Gly Glu Gly Thr Glu Pro
 20          25          30
Asp Gln Glu Pro Pro Pro Tyr Gln Glu Gln Val Pro Val Pro Val
 35          40          45
Tyr His Pro Thr Pro Ser Gln Thr Arg Leu Ala Thr Gln Leu Thr Glu
 50          55          60
Glu Glu Gln Ile Arg Ile Ala Gln Arg Ile Gly Leu Ile Gln His Leu
 65          70          75          80
Pro Lys Gly Val Tyr Asp Pro Gly Arg Asp Gly Ser Glu Lys Lys Ile
 85          90          95
Arg Glu Cys Val Ile Cys Met Met Asp Phe Val Tyr Gly Asp Pro Ile
100          105          110
Arg Phe Leu Pro Cys Met His Ile Tyr His Leu Asp Cys Ile Asp Asp
115          120          125
Trp Leu Met Arg Ser Phe Thr Cys Pro Ser Cys Met Glu Pro Val Asp
130          135          140
Ala Ala Leu Leu Ser Ser Tyr Glu Thr Asn SEQ ID NO. 2

```

1/12

SEQUENCE LISTING

<110> deCODE genetics efh.
Hicks, Andrew A.

<120> A Susceptibility Gene for Late-Onset
Idiopathic Parkinson's Disease

<130> 2345.2025002

<150> 60/363,220

<151> 2002-03-08

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 39785

<212> DNA

<213> Homo sapiens

<220>

<221> exon

<222> (3059)... (3308)

<221> exon

<222> (36385)... (36554)

<221> exon

<222> (37580)... (39685)

<400> 1

```

cccagctatt caggaggctg aggcaggaga attgcttgaa ccgggggaagt agagggttgcg 60
gtaagccaag atcgacccat tgcactctag cctggggcaac acaagcaaaa ctctgtctca 120
aaaaataaaa attaaaaaaa attaaaacta actaaataaa tctatgtctg gccaggcata 180
cagtggctca cacctgtaat tccagcactt tgggaggctg aggcgggagg atcgcttgcg 240
cccaggagt ttagaccagc ctgggcaaca tggcaagact tgcctctac caaaaacaaa 300
aacaatgca aggcagtggt gtgtgcatct gtagttctag ttactggaga ggccctgaagc 360
aggaggatca cctgagccca ggagggtgaa gctgcagtga gcctcgatca agccagcctg 420
ggtgacagag tgagaccctg tctccaaaac aaacaaacaa tgtctacaaa ttctagcact 480
gtgtaaataat tatgtcaaat aattgtataa attattatta ataaaaattt ctttaggttt 540
gacaataatt tgtggggtaa attttctcac tttgtaaaaa ttccagggtta cctctgattt 600
ctggtaaatt tagccaatca taaattaaat gagttcttgg aagctcaaca attccaaaac 660
caaaattgtg agtcagtttg ttctttcttt ccttcttttc tttctttttc tttttctttc 720
tttctttctt tctttctttt ctttctttct tctttttctt tctcttttct ctttctcttt 780
ctctcccttc cttctttctt tcttctctgc ctcccttctc tctctctctc tttctccttc 840
cttttttttt tgagactgag tcttactcac tccctcgccc acgctagagt gcagtggcac 900
aatctgggct cactgcgctg caacttccac ctcccagggt caagcgggtt tcctgcctca 960
ccctcccag tagctgggac tacaggcgtg caccagcaca cctggctagt ttttgtattt 1020
ttagtagaga tggggtttca ccatggtggc caggctactc tcgaatccct gacctcaagt 1080
gatccaccog ccttgacctc ccaaattgct gggattacag acgtaagcca ccacgcctgg 1140
cccaaaatta tgagtctttt caaaaatttt atatcaaaaa ggtgatattt aatgtggaat 1200
ttgagtgcac ttaaataaga tagtgacttc gtagaataagg gactgcagag taagagtgtt 1260
cagacccatt cgagtttaat atagccctac ctctaagaat cttttctggt cctcactcaa 1320
atgaactaat tgctgtcttt cagttcctct aaaaaccttg gggtcogtgg cagggtgtgg 1380
gcttaggact cacctgatta cttgtcttcc cagggtgtct ctgggctcta tcaggaaaca 1440
gccaggatg atcatccttt tcccagtc ttagcgtggg gtctgggtata cacacgcaca 1500
cacaacttca gtaaattgtg aatgaaacga aaggcagtc agatccacct gttgaatgaa 1560
cgtctatcag gagcactgtc atccttcttg cttccttctt ttgcatatgt tgtttgagct 1620
gctcattcaa ccaaggagag agcatactct accttgggca gtgtgccagc cttgcacaga 1680

```



```

gggacagatg attcagcttg atcaggctgt gacagagaaa agctcagggt ctgagagcac 1740
acaggatgcg actaaccag actggagggt caggagagtc tccccagggt aaatgaagtt 1800
gcatccagaa ggattcctga gaataatgat tagcctgatg agaagcagaa aggttgggag 1860
tggagggag tgggtttctg tgagagaaac aatatggaca aaggccccag gcagaggcaa 1920
tagtattcca gataacgaaa agcatttttag agagtctagt ttagaatttg tgaaggaggt 1980
gacaatgctg ctaatgagat tgaaagggag tcagatttgt aaaccattta aggattgtct 2040
taaggacagc cttgaggaga cactgaaggt tttaacagga gaatgacatg atccgattta 2100
aattttaaaa agataactct gtcaactgtg ccaacagtga attggatgtg ggcaatgatg 2160
aactcaggaa cagctgagag tctattgcag aagccaaggt gagagatgat ggtggcttgg 2220
actttggtgc tgggactgga aagaaatgaa caatctgata tacaactgga agaataatct 2280
ctctggctgt gatgtggaag gataaggacg tgattggaca ggcagggtatg gttcagtaac 2340
gagctaggac tttattgtga agggataaag gggaagcttt taacatttta atcatgggac 2400
tgatccattc cgatatgggt ttatataaat agaccgcttg gcggagggtg gtgagaagac 2460
tgtcaggcag tgcacaggta agaactgagc cctagacggg gcaggagcaa tgaatgtggg 2520
gagcgcgagg agacgggaga ttggtttcgg agccaggtae ggagccaagc agtcagagag 2580
aagcaaaaat tgacgcagca ccgagaacag ctgctagtgg agagggggat gggcgccgcc 2640
ggagccgccc tcgcctcctg gcgcgggggg cgggaccaga gcacgcacgg cgcgatgacg 2700
cagtgcgccg gccggcctcg ttctggctgc cgccgtctcg ctgaggcgga gtaggatgag 2760
gcccgcggcc gtggctccgg cgtcggcggg ggcagcagca gctgaggcag cagctgaggc 2820
agccgcgagc gccgcgcccc ccccgcgtga cctggattag gccacgagc tccgtggccc 2880
ccgcgccccc gcgggggggg ggggtgggga agtgcttcgt ctccccgcc ccccccccc 2940
atcgctgcct cgcaggaggg gaacgcgcgc accccagcgg agcccgcgcc ccagccttga 3000
tcccccaacc ccgggggctg gcatgagcgg cccctcggcg gcaccgtggg gcggtggagt 3060
cgccctcgcc tgatccccgg cctgtcgccc gacccacct cgccaaccga ggcggaccgc 3120
ggagtgtgcg aacgacccca ccgctgcttt ctctccccc agatcacgca cccagctcc 3180
ggaagatggg gaactgcctc aaatccccc cctcgatga catctccctg ctacacagat 3240
ctcagtcgga ccgggctagc ttggcgagg ggcaggagcc ggatcaggag ccgcgcgcg 3300
catatcaggt aggggagggg gtgtgttggg gggagcgagt agaggcagct ctggcgagga 3360
ttgagggggc ttcggggccc tctctgcccc tggcttcggc aaggcctggc ctgggcggca 3420
ttgacccctt agggctggat ctgagggcac ttgctctctg atctcagagt aagggtgatt 3480
cttcgcctgc cctcgggcac cgtgtgggga tgataccctc tgcccttgag ttctgggatc 3540
agagtattgt atcacatccc cttggccagt gtctggtggt tcgcttgggg agtttgggag 3600
tgacatttcc cgtctcttat gtctgaatcg tatgatttcc tcatcgaccc gccaaactgga 3660
ttatgggttc tggatagggt gtgtccaagc accaccccc cgccccattt atgttttcat 3720
gtgtggctcg cctcttacc accctccctg tctttttgtt aattggatct ggcaggtttt 3780
ccctctgctt gggagacgga tctccaagt gtgattttta ccctagcgac atcgagttac 3840
ttgtgtgtgt gtgtatatat atatatatgt gtatatatat atatatatat atgtatataa 3900
atttlaatcc ctctcttttt tgcctcaccc atatgacaca ctttttaaac gtgtgactt 3960
aagaaaactt gattagcttg aactttggaa accctttaaac ctggcttggg aaattccttc 4020
ggttactcgt gttctccctt tgtatcaaag actctcctaa atacgttgta ctgctttttg 4080
tacaataatc agtagtccca gatgtgttgc agaattcgag tgaagacctc ttaaactcaa 4140
aataggtatg tggatgttat aatccacaat agatgtgtga aaacctttcc tgtacttttt 4200
ccattttaga tgatattgaa tacacccttt tccagagggc ttcaatagta gtagtgctta 4260
atttcttccc gaaagtttta gttttctgac ttggtaggct cctttgttgt ttcatgtgat 4320
gacatcatta tctagtgttt tctttttcca tgcctgtgta aaccaatgtc tcatcacacc 4380
agaaaaacct gatcatatat atgctcgttt tctgaataaa attcttctgg gggcatttca 4440
tatataccag taaggctccag tcttgattgt ggtattacag aagcctccat gacttctccc 4500
tcttacgttc tatattccag gcctacccaa ccccttcgc ccgggtcagc tggtcacagc tttgttttgc 4560
tccagttcct ctctgcttgg agcccttcgc ccagcattcc cttccttccc agccgaatc 4620
tttgagaact cagctttcat gtctgaagtc ccagcattcc cttccttccc agccgaatc 4680
ccttgtgtcc ccactgaaac ctctacactt ccataagcaa tatctataac actttagtgt 4740
tgtatctttg ttagatgtgt gtctcatcct tghtaatgcc tccttcagtg caagctgcgt 4800
gaaggtagag aatctgtgtt tccgggttgc tgttgtatcc ctgcgatctg cctcagtagg 4860
gactcagtaa ctgggagata aattacgagt aaaagccctt gagaacagggt actctcccct 4920
cgctcagttt ctggcacata agcacctaaa tgcgtgaatta attaatgaag ttgaatttag 4980
tattttctgt atattacaaa atatttttcc caaagtaagt tgtcacaggg tagtctotta 5040
aaaatcaaag ctgaatctgg gtgtctttac aagtaacctt gagtgaagca agcaagctat 5100
gtttatcctt cactgtcttt cctctctatg tttactatac aacaaaagtg cttattttaac 5160
tttttttttt taatgagatg gagtctcgct ctgtcacccc ggctggagtg cagtggcaca 5220
atctcactgc ttactgcaac ctccacctcc cgggttctag cgattctcct gcctcagcct 5280
cctgagtagc tgggattaca ggcgcgtgoc accacaccta gctaattttt gtatttttag 5340
taaagacggg gtttcacat gttggctcagg ctggtcttga actcctgacc tcaagcagtc 5400

```

3/12

cacccacctc	agtctcccaa	agtgctagga	ttacagggcat	gagccaccgc	atctggcatg	5460
aagttttttat	tttaaaatct	cttatgctcc	ctaccctcac	ccccttctat	ttttaaaaaa	5520
atagagacag	ggactccctat	gttgccctagg	ctgggtcttga	actcctggcc	tcaagcaaat	5580
tctcctgcct	cctatccctc	ttcttaattg	aatatctttg	acttgttctc	tttctcctat	5640
ccttatgata	attgtactat	taaaggtact	agaatttatg	gaaactgtgt	ttgccttttc	5700
cagaagaact	aggtgatgat	gagggatgag	gggttttttg	tgtcatgaag	gaactttttt	5760
tggaaatggt	atattttttga	cagtgggagt	tttttatggg	tgcagtttcc	tgaagtgaat	5820
gacgcagact	aatatacaaa	ttcagtatca	atcagaagaa	aattacttta	aaacatggga	5880
gcataaaaaag	aaactttttg	agaaaaagta	ttgtcccca	cccccaga	aataagatct	5940
gtccttaggaa	tgggtatttt	agatgatctg	agaaacagca	atccaagggt	atttattcat	6000
ttatttgagt	tgagaatctc	cctctgtcat	ccaggttaga	ctggattgct	cacttggcag	6060
cctcaaaactc	ctggcttcag	gtgatccctc	tccctcagcc	tcccaaagac	tgggattaca	6120
ggcggttagct	acctcacaca	gcagatttat	agtattctca	gttgataaaa	gtaacttttt	6180
caacaaatta	tatgtaatta	acagtgaata	gctgattgta	aaggaacatg	ttctcttgag	6240
gtgagtagtt	aaaagatgtc	attgtttgct	gctttatatg	tacaatgtac	atataatgac	6300
aagagccagt	tacagtttat	tcctattaac	atctgacaaa	tttgttttta	tttatttttg	6360
ccttaaagta	aatcccttga	ccattatgat	ccaagtttgt	aggaagtgtg	tatttctttc	6420
catggttttct	tttgtagcct	cctaacagtt	atccctgctt	tcacccttgt	cctcgctaag	6480
gcctgtcctc	aatacaacag	ccacagttat	tttggtaaaa	ctgagcatga	cagtctcccc	6540
aaccctctgt	gtggatccct	gtttcattca	aagtaaaaaat	cagattcctt	atagtgtcgc	6600
ataaaccccta	cataatctgt	accccttgtt	tccacgcag	tcccttgaca	cctacagcta	6660
acccctttgt	tggcttccct	ccagcttccc	tgtctcatt	gctattctag	gacctttgtc	6720
ctccttattc	tggaaactc	ttccccagat	ttcatggctg	actgactccc	ttacctcctt	6780
caagtctttt	ctcactgccc	ccttaaacct	tctctgacca	ccctgtttga	aagtgaacc	6840
tgccctaata	acctggaagt	ccctctcacc	ctggtgtttt	ccccccaat	accatttatt	6900
acattccaac	atgtgttaga	aagttgcgtt	gtctattacc	tgtcttctcc	cactaggtag	6960
aaaggaggaa	aggggatttt	tttttttaat	tgggtgtttcc	taagtactta	taacagtgcc	7020
tggcacatgt	taggcattca	gtaatttggt	tgaacgaatg	aatagatttc	ttttaaatga	7080
actaatgtat	ttgaggcagg	tatagttgca	ctgcttacia	gaactctgca	tattcctagt	7140
gccatttttg	cttctatatt	gtagatcagg	tttttttttg	tttgtttttt	tgttttgtga	7200
ctgggcctcc	ctgtgtttacc	caggctgggtc	tctctctgta	tatatatgtt	tgggtttttt	7260
tgttttctct	tttttgagac	caagtctcac	cttggtgccc	agctagagtg	cagtgggtgtc	7320
atcttggtct	tgcctcttgg	gttcaagcga	ttctcctgcc	tcagcctctg	gagttagttg	7380
tactacagcc	atggccacc	aaggccaaat	gattttttgta	cttttggtag	agatggagtt	7440
ttgccatgtt	gaccaggctg	gtctcaaaat	cctgacttca	gggtgatctgc	ccaccttggc	7500
cttccagagt	gctgggatta	caggcgtaag	cccctgagcc	tgccctttat	attttttaaa	7560
tttaaaaaat	agagacaggg	tctcattatg	ttgctagctc	caaactcctg	ggctcaaggg	7620
atactcctgc	ctcagcctct	tgagtagcta	gggttacagg	tgcacttcta	ctctgcctgg	7680
ctcaggtttt	aaaaaaaaat	tatttctttt	agagatgagg	tcttgctgtg	ttgcccaggc	7740
tggagggcag	caggtattca	cagggtgcaat	tatagtgcat	tgcagcctcc	acttctgggt	7800
ctcaaaggat	cttgtggctt	cagcctcctg	agtagctggg	actacagggg	tacaccaccg	7860
tgtctagctg	ttgtagatca	gttttaagga	atcctaaaaa	gtcaaattcc	agtaatatata	7920
aatacagcaa	ttgggtttaca	ctaagtgtta	agtgatttag	gggtttttac	cgtgtatata	7980
tatcacccga	agatatttat	gtaatgggaa	agtacttggg	ggagaaaaag	aaagtacttg	8040
aatccctatt	cttgaagtat	tggatgcaaa	gagattttagg	gtgtttgtca	aattagaaaag	8100
tagaaacaaa	tttgtcgcac	cctctaccca	actcccttat	tcctaaatgt	ttaaaaataa	8160
tacagaggaa	atctgcccag	cgaaggcaat	cttgggaagg	cagtgagtgg	gaggataagc	8220
caggaaaggc	tgaagaaggg	aggtccatga	gagggggagg	ccaggtaggc	agcccagccc	8280
tgaaggcat	atgtaaaaca	gcttgaggta	cccctgtgtc	actgtcaaga	gctttgttat	8340
gtgctaaatt	gagggaggca	ctttgttaaa	agaggtgaat	attcattgaa	caacaaacca	8400
tgttacattt	tctaacttga	atatataaaa	ataaggatag	gtgtctctca	attttgcagt	8460
agttatatag	ttttagattc	gccagttctc	ttccccgacc	tatacttttt	gattgatata	8520
tttgaaattt	taaaatcctg	agaaaataag	tttgtatagc	attgaatgca	agtatagctc	8580
tgtttttaga	gtcagattgt	cctgtgttca	aattctggct	ctgccgctta	catgtaaaat	8640
atgaaaaagg	aaagaattta	tcagattgtt	ttggggagct	tttttgacaa	ataagaaaaat	8700
gtaacatttt	ggataattca	aattgtgtct	gcataaagct	ttcttcaaga	tacctttttt	8760
tttttttttt	tttggctggg	cacagtggtc	cacacctgtc	atcccagcac	ttaggtaggca	8820
gaggcaggag	gatcacttga	ccccaggaat	tcgagaccag	cctgggcaac	aaagtggagc	8880
ccccatctct	attaaaaatac	caaacaaaaa	caaaaaacaa	acaaaaccaa	aaaccctctt	8940
ttgttggttaa	aaggattggg	ttatcctgta	gaatgcacta	aaaataaccc	ccttccttat	9000
aaaaaatcta	gaatgtactg	cttattttta	agcatgcaat	gctataatgt	tttgtggggg	9060
atgggcttgt	tttttttaga	gatggagtct	cactttgccc	aggctagttt	cgaactcctg	9120

ggctcaagtg	atcctccac	catgtctccc	agtgttggga	ttacggatgt	gagtcactgt	9180
gccctgcctg	taatgggtata	ttaatgcctc	attttcctga	taacttacga	agttaaattt	9240
agataattaa	aggggttggt	ttttttatta	gcattttggt	taacatttgg	gtggaaaata	9300
tctccaaatt	tatttcacgt	atctaggcct	tattatacaa	ttattcagct	tttaacaatt	9360
tacctttttg	aagttttatc	cctcccccctc	tttatgtctca	agaagttcag	ccttcttatt	9420
gaggggcaga	tcaactaact	ccacctttgt	taataaagcc	ttcactgacc	atttttttcc	9480
tgtctctgct	gattttgtcat	gtacagtttt	tttgtgtttg	taacatttat	ctggaaatca	9540
tatattgcct	tattagcttt	tgttgcttta	acagttgttt	ctccacatca	gtttcctcaa	9600
gaatgagaat	gatacattaa	acttgtaaga	tatcttagtg	gagtagaatg	ttaccttcca	9660
tattgtagac	accagtgaa	tatttgatga	tagactaaat	tagaactgtg	acttcttacc	9720
ttgtaaggtc	accatcataa	ttgtctcat	cagttcttac	agcaacataa	ttgatgtctc	9780
ctcctcattc	attttataacc	atgttgccag	ataaatttca	tcccggatca	gatcacttgc	9840
ctcataatcc	ttaatgattg	ttattattat	tattattatt	ttttgaaaca	gagtcctcac	9900
tctgttgccc	aggctggagt	gcagtggtgc	ccctcagct	cactgcagcc	tccgcctccc	9960
gggtccgagc	aattctcctg	cctcagcctc	ccgagtagct	gggattacag	gcattgcgcca	10020
ccacaccag	ctaatttttg	tatttttaat	agaaatgggg	tttcaccata	ttgctcaggc	10080
tgggtgtgcaa	ctcctaacct	caggtaatcc	actcaccttg	gcctccgtaa	gagctgggat	10140
tacaggcgtg	agccaccacg	cccggccctt	aatgattcct	tattaggact	aaccactgaa	10200
gatatctgac	ttagcattca	aagtcattat	ttggtctctac	atatactttt	tcagctcttc	10260
atagccttgt	gctttctttt	atacaacctg	tacactccag	tcatactgag	cagtttgctg	10320
tattctcatg	atgtcttctg	ctttcctgtc	tttgcccatt	ctgtatccat	tgcccagaat	10380
gttcttctct	aatccttccc	agtctcattt	ctaatatcca	gggcccagtt	caaagtccaa	10440
gaatccacga	attctgattt	ctcctacata	cacttttctt	aatctgaact	cctttattca	10500
tgcaccattc	ttaagacact	ttaccctttt	aatttttaatt	atttgtgaca	gtgtcacatc	10560
tgtcttttta	gaattcaagt	ctgggttcatt	ttcacattgc	tagaactaca	attttcacaa	10620
agcacgcact	tatactttag	tgaatgtaat	gatcagcatt	ttgctgtaag	agtgtgcaat	10680
tgtatgggtg	ttagtgtcta	ttaagcatcc	ccagaatcct	gtgcttttagt	gtttggccta	10740
tcacttctaa	tttataaagt	acgttgagct	ttgggaaagt	taatttcatt	atataatttt	10800
tgaatttggt	tttttttttg	tttggttggt	tgagacgaag	tctcgctgtg	tcaccagggc	10860
tggagtgcag	tggcgcgatc	tcagctcact	gcaagctccg	cctcccgggt	tcacgccatt	10920
ctcctgcctc	agcctgtccc	gagtagctgg	gactacaggt	gcccgcacc	acacctggct	10980
aatttttttg	atttttagta	gggacggggt	ttcacctggg	tcttgatctc	ctgaccttgt	11040
gatcctcctg	cctcgccctc	ccaaagtgct	gggattacaa	gcgtgagcca	ccgcgccag	11100
cctgaatttg	gttttggtgt	ccatgaagtt	cagcttgctt	aggtgacttt	tataaataag	11160
taaccagtta	tttggtattt	gtgtgacccc	attggtgcag	gatttttctt	tgtttctgcc	11220
tgacctctca	ttctgaatgt	gctttaataa	aggetgattt	tttggcatta	agattgtatg	11280
catcactaag	agtaagatag	tctgttcaga	gttttaattc	agagctaatt	atagggtaac	11340
ttgagagat	ggagatggga	tgggtgattt	cctgggtacat	aagatctgag	cacttgattt	11400
tcttaaaata	tttttttaggt	aatagtagaa	acctttgttg	cagaattttg	atcttttaaaa	11460
gttttaatag	aaatacttat	gtagattggg	attctttttc	tttctttgag	acataatctt	11520
actctgttgc	ctaggctgaa	tgtagtggca	tgggtcacggc	tcactgaagc	ctcaacctca	11580
cgggcccag	ccatcctccc	acctcagcct	cctgagtagc	tgggactata	ggcgtgcacc	11640
actttgcctg	gctaattttt	atttttttga	gagacgggtc	aagcagtcct	cccatctcag	11700
tctcctgaat	agctgggacc	acaggtgcct	accaccacac	ccagctattt	tttgattttt	11760
tagtagagac	ggggtctcac	tatatgtccc	aggctgggtc	caaactcctg	aactcaagca	11820
gtccaccac	ctcgccctcc	caaagtgcct	agattacaag	tgtgagccac	catgcccacc	11880
caacagcctt	tttttttgga	gatggagtct	tactccatcg	cccaggctgg	agtgcagtggt	11940
tgcagtctca	gcccactgca	acttctgcca	cctgggttca	agcgattctc	atgcctcagc	12000
ctcctgagta	gctgggatta	gaggcaagca	ccaccacacc	tggctaattt	tttgattttt	12060
tagtagagat	ggggtttcac	catgttggtc	agactgggtc	taactcctga	cctcgatgatc	12120
caccacacta	ggcctaccaa	agtgtctgaga	ttacaggcgt	gagctactgg	gctggacacc	12180
aacagcctat	ttttaataac	ccatatgagt	acaggacaga	aatacatccc	taactctgta	12240
cctgaagtaa	ggaaggtaat	acataaaaaga	catatttgca	aacgacttga	ggcaagaaaa	12300
gaaatacaac	acatctctaa	ttctgattgt	atctgcaatc	aacctcttat	cacttccctc	12360
ttcatgtgca	gaatttacct	tggctgagac	acagtcagaa	aagaagacag	gtggccaggc	12420
acagtggctc	acacctgtaa	tctcagta	ttggagggtc	gaggtgggag	ggtcacctga	12480
ggttaggagt	ttgagaccag	cctgaccaac	atagagaaac	cccgtctcta	ctaaaaatgc	12540
aaaaatagcc	gggtgtgggtg	gcacatgcct	gtaatcccag	ctacttggga	ggctgaggca	12600
ggagaatctc	ttgaaccag	gaggtggagg	ttgtgttgag	gctaggttgc	gctgttgcac	12660
tctagcctgg	gcaacaagag	tgaaactcca	tctcaacaac	aacaacaaaa	aagaagacga	12720
caggctgtgt	gcactgggtc	atacctgtac	accagcactt	tgggaaggcca	agtggaagg	12780
attgcttgag	cccaggagt	cgaaccagc	ctgggcacaaa	tagcgagatc	tcgtctctac	12840

aaaaaaataa	aaaattagtc	agggtgtgtg	gcacatgcct	gtagtcccag	ctataggctg	12900
aggcagaagg	aatgcttgag	ctcaggagtt	ggaagggtata	atgagctgtg	atggcaccat	12960
tgcactccag	cctgggcaac	agagtgaatg	ggggcatggg	gaaggccagg	tgtggtggct	13020
cacacctgta	atctcagcgc	tttggtaggc	tgaggcggga	ggattgcttg	catccaggag	13080
tttgagacca	gtctaggcaa	cacagtgaga	ctcccatttc	tacaagaaaa	tatttaggct	13140
gtaagtggag	agttattgtt	tagtgggtag	agttttctgt	tttataagat	gaaaagttaa	13200
ggagatggat	agtttaaatg	ctacataact	ttatgtaata	ccactgaact	atacactgaa	13260
aaattggagc	tgggcttgtg	cctgtgggtc	cagttaatca	ggaagctgag	gcaggagggt	13320
tacctgagcc	caggagttcg	aggctgcagt	gagttataat	tgagccactg	cattccagcc	13380
taggcagcag	agtgagacct	tatctcttaa	aaaaaaaaaa	aaaaaggaaa	aaataatagg	13440
ctgtaaacag	ttgattcctt	accagtaact	tttaatatgt	aattaacaaa	tatttatggg	13500
atttttaaca	tgctcagagt	tcaggctttt	ttcagctgtg	atctaaatga	aagtgagagt	13560
gaggtggtga	gagaagtcag	tggaaatgtg	agtgaagat	tgagggaagag	ctggccttaga	13620
tagccacagt	gtgtagttat	tttttttttt	agagacgggg	tttcaccttg	ttgcctaggc	13680
tggagtgcag	tggctattca	caggtatgat	catagcacac	tacagccgca	aactccttag	13740
ctcaagccaa	cctcctgggt	cagcctocca	agtagctggg	accacaggct	catgccacca	13800
catccagtca	aagtgtctgg	gttttttggg	tttcaattag	gttcctcagg	ttaaatggaa	13860
gtatgtgggt	ttttgttttt	ttgttttttt	tttttgtaaa	gacagtgtct	cattatgttg	13920
gccaggctgg	tcttgaactc	ctggccocaa	gccatcctcc	tgccctaccc	tcctaaagtg	13980
aagtgtctgga	ataacaggca	tgagctgcta	ggcctggcca	aagttgaaaa	gtaaagtgat	14040
aagggaag	taaatgtatt	ttatcctctt	ggagaatttg	cctgacctat	tgatttttat	14100
attcaaattg	gccttttgaa	ctcttagatg	agttccttat	tttgacaatg	aatgctgtgt	14160
tccctatctt	ttaatataat	tgccagccta	gagtgactc	ccaggggcca	aatgagtaat	14220
tatcttgtaa	cttaatctag	aaagcatact	gtaaggtaac	taaaggatct	gaaagtgtgg	14280
gaatgaagaa	agcaaccctc	caaatatatt	tgcttctaaa	actcttaaaa	ttttctgaac	14340
actcataaag	ttgaatgggt	ttaagaagag	tgagacttta	taattgacct	agttagttaa	14400
agttacatgt	aatttttgtat	aacagtttaa	accttatttt	tgtggaagaa	aaagaagcag	14460
tttaccataa	ttgagtgcg	aggccttaag	ggtaagaaat	accatgcttg	atacctagtt	14520
tcttcttttt	tttttttttt	tttttttgag	atggagcttc	gctcttggtg	ctcaggttgg	14580
agtgacgtgt	cacgagaaaa	tacattttaca	gtgctatact	gtattttctt	tttctttttt	14640
tttttttttg	ccttgagatg	gagtccttgc	ctgtcaccc	ggctggagtg	cagtggcacg	14700
atcttggtc	attgcaacct	ctgcctcctg	ggttgaagcg	attctcctgc	ctcagcctcc	14760
cgggtagctg	ggatttatag	cggcgccacc	atgcctggct	aattttgtat	tttttagtaga	14820
ggcagggttt	ctccatgtca	ggctgggtgc	gaactcccga	cctcagggtga	tccgctcgcc	14880
tcggcctcac	aaagtgtctg	gattactggc	gtcagccacg	gcgcccggcc	tctagtttct	14940
tctatcagtt	agcaagtatg	ttttaagctc	aacggggaaa	ggagaaatga	tgagtctctt	15000
acccttagga	gcctacagtt	aagggtataag	acatgaagca	attatgaggt	cagcatgaaa	15060
tagtacataa	tcaattatta	aatgggtttg	tatatagttt	tgaagttgtg	tgatcagttt	15120
gtgataggcg	agtgatcac	aaatgtactt	tttagcttct	gtatcctttg	gataatctta	15180
cttggaactt	gagtataaaa	aatgaataaa	aacaacagag	ctgccctgat	taaattgagt	15240
ggtggagctt	ggagtcaaaa	agatagcctt	ctgtattcac	aggttccaca	tcctctgatc	15300
catccaatca	cagaaaatat	ttgggaaaga	aaacaataaa	aaataataca	agagctaata	15360
caaattaaaa	aaatatatag	tgtaactatt	acataacatt	gtattaggtg	ttataagtaa	15420
tctagcgatg	atttaaagta	tatgggaggg	tgtacaggtt	atgtgcaaat	atgccatttt	15480
atataaggga	ccttgggcac	tgaggatttt	gggtgttcaag	gattttggag	tcagtcgggt	15540
cggactaatt	gttagatggg	ggacatgaat	ttagaggtca	ttgagttgtg	taattttgta	15600
cagtaaaagt	atgtgtgtgt	aaattttaat	taaaatgtat	tatacagaaa	ctagtgtatc	15660
tttaacagaa	tatcttgagt	ttcttttgat	tgactgattg	attggtcgat	tgattgagat	15720
agggtctctg	ctgtgttacc	caggatagca	ttgggtcaa	gtgatcttcc	tgccctcagc	15780
tcccaaagct	ctgggattac	agggtgtgagc	cactgcaccc	agcaggtttc	tttaattacgt	15840
aggctagctg	acttgcaaaa	tatagccaca	actataatat	agtctgtttc	caagccccc	15900
aaaggctccc	tcctgcccc	tccaacagtt	agtacctttt	ttccaaagg	aactgttggt	15960
ccttatgacc	tcctatcacc	catatttggt	ttgtgtgggt	atgaatttca	aactgaataa	16020
cattctagca	ttctttgtga	aatttgtgtt	cttacgtaat	ggcagtagtt	cacatttctt	16080
ttcattgcta	tgcagtattc	aaaattgtgt	aaatatacca	cattttactt	attcattcca	16140
ttatgtgtat	ttgggtagta	tcaatttttg	gctgtataaa	taaagatgct	gtgaacatta	16200
tacctgagca	cctattttga	gtatatatcc	agggatagag	ttactggata	atggagccac	16260
atgtatatat	agtttttctt	gcagcatttt	actacagaaa	ttttcaaaaa	taaacaagag	16320
ttgacagaat	tgttttgaata	cccatattca	ttcctaccac	ctagattctg	cagtaaacgt	16380
tttgctgtat	ttgctttcac	acatacctat	tcgtcgttct	tctgtcaatc	tatcctgttg	16440
atgtgtttca	aaaataagtt	gccaaatagt	tttccaagtg	gttgacttaa	ttttctgctt	16500
gtactgacaa	tatgagagtt	tcatttgtgc	cacgtcttca	ccagtatctg	gtattgtcaa	16560

tctttatttt	tgaaactttt	tttagctttg	aagtataatt	gatataatta	tatataactta	16620
tgatgtacac	catggtgttt	taatatatgt	atacatcatg	aatgattac	cacagacaag	16680
ctaatttaca	gacctttcac	ctcacagtta	tgatttgcta	ttgtgagaat	atttaagatg	16740
tattttcata	gcagttttca	agtatacaca	atacattatg	ctaagctgta	gtcactatgt	16800
tatacaacag	atctctggaa	ttgtagatct	gttttatttt	agacatttta	ataggtgtgt	16860
agaagtatag	aaatgcagtt	gacctttgaa	caacatagag	ttgaatagcg	tgggtccact	16920
tacagtgcta	atttgtttac	acaagtatgt	tgggaattttt	gtttgagatt	tgtgacaatt	16980
tttttttttt	acgcttaatt	cgcttttattt	tccttgtcta	aaaaccctat	gttgtagcca	17040
cagctggagc	ctgggtccgc	tgcacggaga	ctctggcggtg	ggccttgatg	aggtggtcag	17100
tgaattcctg	atcgggagac	ttggtaaata	cagtctcctt	ccagaggtcg	ggggtcaggt	17160
agctgtaggt	cttagaaatg	gcatcaaagg	tggccttggc	gaagttgccc	aggggtggcag	17220
tgcagcccca	ggctgagggtg	cagcagtcac	cgataccagc	catcatgagc	agcttcttgg	17280
gcacaggtgc	ggagacaatg	ccagtgtccc	tgggtacagg	gatgagggtg	accagtgcag	17340
agccgcagcg	gcctgtcacc	ttgcaagggg	cggtgtgggg	cttgccaatc	ttgttcccc	17400
agtagcctct	gcgcacgggg	acaatggaga	gcttggccag	gatgatggcc	ccatggatgg	17460
cgggtggccac	ctccttggag	cacttaacac	ccagaccgac	gtggccattg	tagtccccga	17520
tagcaacaaa	cgccttgaac	ctgggtgcgt	ggccagcacg	ggtctgcgtc	tgcactggca	17580
taatcttcaa	aacctcatcc	ttgagagagg	ccccaggaa	aaagtcaatg	atctctgatt	17640
ccttaatggg	cagggagaag	agatagatct	cctccaggga	cttgatcttc	atgtccttca	17700
ccaagcagcc	cagcttgggtg	acgggcatcc	actccttattc	ctcggccttg	cctccgcgag	17760
ctccgcggcc	tgggccccgg	ccccgtctac	ggctgcgacc	ccggccccgg	atgccactgc	17820
cgaaacctcc	ctccttggag	cgcgagttcc	ccatcccagg	gcctccgggg	cccccccg	17880
tgcactgggtg	tcacccacca	tttgggtgtt	tctcggagaa	gaaaggattt	gtgacaattt	17940
gaataaactt	aggtgattct	cattttttga	aatatcaaaa	aattaaggta	tgtcatgatg	18000
gatgcataaa	atatgtaaat	actagtccat	tttatcattt	actaccgtaa	agcattcaca	18060
tctattataa	aaaattaaaa	tttgggctgg	gcatggtggc	taataacctgt	catcccacac	18120
ctttggggagg	ccgaggcagg	aggatcactt	gaactcagga	ttttgagaca	gcctgggcag	18180
gagagcaaga	ctccatcttt	acaaaaaatc	aaaagaatta	gctggagccg	ggcgagggtg	18240
ctcacgcctg	taatctcagc	actttgggag	gccaagggtg	gtggatcact	tgaggtcagg	18300
agtttgcgac	gagcctggcc	aacatggtga	aaccctgttt	ctactaaaaa	tataaaaaatt	18360
agctgggtgt	ggtagtgcac	gcctgtaatc	tcagctactc	aggaggctga	ggcaagagaa	18420
ttgcttgaat	ccgggagaca	ggtcgcagtg	agccaagatc	atgccactgc	actccagcca	18480
gggtgacaga	gcaagatacc	atctcaaatg	aaaaaaaata	aaaaaacagaa	agaaacagaa	18540
aaagaaaaata	cagtataaca	ctgtaaatgt	atcttctctt	ccttatgatt	ttcctaatat	18600
tcttttctct	ggcttatttt	gtaagaatgc	aatatgttat	acatgtaaca	tacaaaatat	18660
gggttaataca	agtttgtgtt	atccataagg	tttcttttgt	caacagtagc	ttattagtag	18720
ttaagttttt	gggaagtcaa	agtttagggc	atgcatgggg	catatacccg	taatcctagg	18780
tatatgtcct	gggaagccaa	gacagaagcc	aagacagcag	atcatttgag	ctcaggaatt	18840
cgagaccagc	ctgggcaaca	cagcaaaact	ctgtttctat	aaaaaataca	aaatttagct	18900
ggatgtgggtg	gcgggcacct	atagtcaccag	ctacctgaga	ggctgaagca	ggaaaattgc	18960
ttgagcctgg	gaggcggagg	ttgcagtatg	ccaagattgc	gtcattgcac	tccagcctgg	19020
gtaacgggag	tgaaacctcg	tctcaaaaaa	aagaaaaatt	atatgaagggt	ttgcgactgc	19080
actgggggtt	gagaccccta	acccccatgt	tcaagggtca	actgtatttc	attgtggttt	19140
taattttgcat	tttcccagtg	agtagtagag	ttaacctttt	caagtgcctt	ttggcctttc	19200
gggtattgtc	ttttgtgaag	tcttttgtcc	agttttgtgtg	tgtgtgtgtg	tgtgtgtgtg	19260
tgtgtttggg	ggggacagag	agtcttgctc	tgttgcccag	gctggagtgc	agtggcgcga	19320
tcttggtctca	ctgcaacctc	cacctcccag	gttcaagcga	ttctcctgcc	tcagcctccc	19380
aagtagctgg	gattataggg	gcccaccacg	cgcggtcaat	ttttttgtag	tttttagtaga	19440
gatgggggtt	caccatgtca	gccaggcttg	tctcaaaact	cctgacctcg	tgatccgccc	19500
gcctctgcct	cccaactgtc	tgggtttaca	gatgcgatcc	accacgcccc	acgttgtcca	19560
gttttttaatt	tctgttgtctg	actgttatgg	actgttatgg	taggagttaa	aagtataatt	19620
tactaataaaa	aaagaatggg	aattgttctc	tgcataatat	ttagaaaaata	aggccgggca	19680
caggggttca	agcctgtgat	ttcagtgtct	tgggatgcca	aggtgagagg	atcccttaag	19740
ggaaggagggt	tgagaccagc	ctgggagaga	tactgacacc	ccatctctac	aaataatata	19800
aaaaagttag	gtgtgggtgg	atgcaacctg	agtcccagct	acttgggaaga	ttgaggcagg	19860
aggatcactt	gagcccagga	gctcgaggta	acagttagat	atgatcacac	cactacactc	19920
cagcctgggc	aaocctgaaga	tccgtgtctc	taaaaaaaa	aaaaaaaagg	aggtggggga	19980
aacgaaataa	agaatagaag	gaaagtagag	atttgtgttag	atcctagaat	gtgaagataa	20040
gtaaaatgat	ctccatgttc	tctgtacccg	cgttctagag	agggatgtag	gtaaatggat	20100
ataaaatata	ctgccataaa	ttttatgaag	aagaatgttt	aggggtgctat	aatttgcctca	20160
acacttcatt	atttttgctt	tcttgatatt	ttaaataata	ctatgaatgt	ttaatcgata	20220
aaacacttct	tgttttagaa	tatttttattt	gtataaaattt	ttttagggaat	tgctggatct	20280

tgccaggcac	aatgactcat	gcctgtaatc	ctagcacttt	gggatgtgga	ggcgggagga	20340
ttgcttgagc	ctagaaattg	gagactagcc	tggacaacat	agtgaggtcc	catctctaaa	20400
aaaaaaaaag	ggaaggaatt	gctaaatcaa	aggatgtgag	gatttttaaag	ctctacacga	20460
tcaatcggat	catcctaaat	aattttatcga	aacagtgga	aaatatgttc	cacaataaag	20520
catacctctt	tgggtgaccaa	aatgtggcat	tgatgaatat	tgggggggttc	cccctaaaac	20580
tttaaccccc	tttgtgttg	cacattcatg	agataattct	gttgattagg	ttatagtttt	20640
tttttttaaat	caaagaataa	aacatggtct	ccttgattag	agttagatat	tccttgcttc	20700
cttgaatgaa	ttcctttttc	tttttctgtt	tttgagatgg	agtcttgctg	tgttgcccag	20760
gcctgtagta	cattggcacg	atctccactt	actgcaacct	ctgcctccca	ggttcaagca	20820
gttgtgcctc	agcctcccga	gtagctggga	ctacaggtgt	atgccaccat	gcttgggctaa	20880
ttttttttgta	tttttaattt	ttttttgaga	tggagtctcg	ctctgtcacc	caggttggag	20940
tgcagtggca	ggatctcggc	tcaactgcaag	ctccatcccc	tgggttcaaa	cgattctcct	21000
gtctcagccg	cctcccaagt	agctaggatt	acaggcgtgt	gccaccactc	cctgctaatt	21060
tttgtatttt	tagtagagag	gggatttcac	tatgttggcc	aggcaggtct	cgaactccca	21120
gactcaagtg	atctgcccac	ctcgtcctcc	caaaatgctg	ggattacagg	tataagccac	21180
tgcacccggc	cttttttttg	tattttttgta	aaggcagagt	ttcgccacat	tggccaggct	21240
ggtctggact	tcaggttgcc	ctggcccttt	aaagtgtctg	gattacaggc	atgagcacc	21300
agcctagtct	ctttttcaaa	tgaatagcac	ataagtatat	gctggctctt	actaacttta	21360
ctctgggaga	aaaaaacata	gctccaattt	tcttttcatt	ataggctctt	tcttgaatag	21420
aatacttgca	tagaaaagca	atagcttata	cattgggtgag	gggagtgttt	acattgcccc	21480
caacatactg	tttaatgcac	aacatacatt	attttatttta	attatcacat	agtatctgta	21540
aagaggaact	atattatttt	taatactatt	ataatgtctat	ataatatgta	tatatatgtt	21600
tctactactt	atatatcatg	caatgtgtac	attatagctg	acatagagac	tcagcagttt	21660
gtactctgga	taagtttggt	acattttaatt	ttttattttt	cttttttagtg	acaggggtctc	21720
acactgtttg	ccatgcttga	gtgcagtggc	acaatcatag	ctcattgcag	cctcaaactc	21780
tgggctcaag	cgatccacct	gcctcagcct	cctgagtagc	tgggactaga	ggtgcatgcc	21840
accacacctg	gctaattttt	gtcttttttg	cagagacaag	gtctcactct	ttttcccagg	21900
ctggccttga	attcctgggc	ttaagcaatt	ctaccttggc	ttcccaaagt	gttgggatta	21960
caggcgtggg	cgactgcacc	cagctgtgtt	tcactttctt	gctgggtgtt	ttggaagcac	22020
aaaagtgatt	aatcctgata	aaaaccagtt	tgtctatttt	tttctttggg	gagcttttgg	22080
tatgttcaag	gaggggggtca	aacttgattc	ttctgcatgt	gactagcctg	atgttccagc	22140
accatttggt	gaaaatagtt	ttctttttctc	attgaattat	cttgggtattc	ttgccaaaga	22200
tcagttgtct	ataaatatga	gagtacatct	ctggactctt	ctgttccatt	ggtctatatg	22260
tctgtcctta	ggctagtact	gtactgtage	tttataagta	agggtttgaaa	tcagaaagtg	22320
tgagtctttt	ttgttgttgt	tgttctccct	tttcaggatt	gttatggcta	ttcttagtcc	22380
cttgtatttc	catgtgaatt	ttaggatcaa	ctgtcaattt	ctgcaaataga	gccagctaga	22440
attttgatag	agctacattt	aatttttttt	aatgaacca	cattgaaata	ttcaacgatt	22500
gccaaaacat	tatcacccca	aaccactgt	ttatcttaga	gttcattctt	ggtgttgtac	22560
atggattttg	catgtataat	gacatgcac	caccattata	gtatcatacg	tgtagtttta	22620
ctgctctaaa	aattttccgt	gttccatctg	ttcatccctc	ccccaaacac	ctgacaacca	22680
ctgatgggtc	tattgtctcc	atagttttgc	cattttgcaga	atgtttgcata	tttggaaatca	22740
tacagtatgt	agccttttca	gattggcttc	tttcatgtag	taatatgtat	ttaaagttcc	22800
tccatgtttt	tcattggctg	atagctcatt	tatttttttag	tgctgaataa	cattccattt	22860
gcattgatat	actgtagttt	atctatttac	ctatcgaagg	acaccatagt	tacttccaca	22920
tttcgatagt	catgaataaa	gctcctgtaa	acatttgttt	ctgggttttg	ggttgatgta	22980
tttttcaact	cctttgggta	aataccaaaag	ggtgcaattg	ctggatcaaa	tggtaataat	23040
atgttttagtt	gtgtgagaat	tatcaaactg	tcaccctaag	cataccattt	ttgttgttgt	23100
tggtgttgtt	attgtttttt	gagatggagt	ctcgtgttca	cccaggtctg	agtacagtat	23160
ggcgtgatct	cagctcacca	caacctccac	ctccctggct	caagcgattc	togtgccctta	23220
gcctcccag	tagcttggat	tacaggcacg	tgccaccatg	cccagcta	ttttgcattt	23280
ttagtagaga	cggggtttca	ccatgttggc	caggtgtgtt	tcaaactcct	gacctcagg	23340
gatcctcccg	ccttggcttt	ccaaagtgtc	gggattactg	gcgtgagcca	ccgtgcctgg	23400
tcgcaaagca	taccattttg	cattcccacc	agcagtaaat	gagagtttct	gttaccacac	23460
atccttgcca	ggacttaatg	tcagtgtttt	ggattttcac	cattctgata	ggtgtgtgtg	23520
gtattttttg	tttttaattt	cagttctcag	tgcttctcag	tacctcccac	ccaccttatc	23580
tgggacagga	tggctggagg	ggctggagtt	gggtagttct	ctttccccag	gtagggttaa	23640
ctctggtaaa	agttttctcc	agaactttat	attaaattaa	aagttttcgca	tgaggataag	23700
acttattagg	agcagaatgc	tctggcatat	ttaaaatggt	ttatttttct	ctccgcctcc	23760
tgggaagcact	cacgtgagga	cctggtagag	gttttggagg	taaaattcac	aaaagtgtgg	23820
tggccccaat	tgggtccact	tggagttttt	attttaattt	tctttatttt	ttatttacat	23880
tttttgtttg	tttttttgtt	ttggagatag	tcttgctctg	cggaccagaa	tggaaatacaa	23940
tggcacaatc	tcagctcact	gcaacctctg	ccccctccga	ttcaagctat	tcttgtgcct	24000

cagcctctct	cgagcagctg	ggattacaga	tgtacaccac	catgcccgc	taatttttgt	24060
atTTTTtga	gagatgggg	ttcgccacat	tgcccaggct	ggctctcaaga	tcctagcctc	24120
aagtgatccg	cctgcctcag	cctcccaaag	tgctgggatt	acaggcgtga	gctactgtgc	24180
ccagccttga	ctttttaata	atagccattc	tgactgatga	gatggatatct	cattgtgggt	24240
tttgatttgc	atttctcttc	ttatttcttt	tcttttcttt	tctttttttt	tttttttttt	24300
gagacaaagt	ctgttgctga	tgctcaggct	ggagtacagt	gggtgcaatct	tggctcactg	24360
aaacctccgc	ctcccagggt	caagcagttc	tcctgcctca	gcctcccgcg	tagctgggat	24420
tataggcacc	caccaccatg	cccaactaat	ttttgcattt	gtagtagaga	tggagtttca	24480
ccatgttgcc	caggctggcc	tcgaactcct	gacctcagggt	gatccgcctg	ccttggcctc	24540
ctaaagtgc	gggttaccg	gtgtgagcca	ctgcaccag	ccaatttgca	tttctctagt	24600
gatcagtgat	aatcggaatg	gcacgcaatt	tacaacatta	gttggttatt	tctggaattt	24660
tccatatagt	attttcagac	catggttgac	cacagttaac	tgaaaccttg	caataagtgg	24720
ggactgctgg	agatcctctt	cattttaaag	atgcagaaat	agggtgggca	gtagagcagg	24780
gcaactagga	gaaatgcatt	taaacaaatg	ggataactgc	acagtgaggc	agaaaatggt	24840
atataatata	ctagatttgg	ctcaaaggca	gtcacaggag	cctctaggag	ttcattttcca	24900
gtagagtcca	ggagaggaat	gagatactgg	aattaagtag	gttatacagt	gatacttgaa	24960
gtaatgagac	ttctttaaaa	tgaaatgggt	cttctaaaaa	tgtttcataa	atcctaaagg	25020
taggcacaac	atatggcaca	taaattatca	gaaataccca	tatgtataac	atctcttttt	25080
tcattttgaa	gtaaacagcc	ctgcctcagc	aaattttctg	agttaataaa	atgtttttag	25140
tgtccccgtg	tcttttttct	tattctcagt	tgttgatttc	ctttcttttg	ccaatctccc	25200
tgtatggcaa	tctgtgctct	ctgtctaacg	tttctctctt	gaattttatg	tgtagtattt	25260
actaaggcac	caatttcctat	caattaaggc	tcatttcagt	gtaatgtgga	tgtgttttat	25320
ttagtattat	gtccactggg	cctttgtata	tttagcggtt	gcaccactcc	ccaccccat	25380
ttcatgtgac	aactggaggc	cttggttcaaa	aaactaccag	aaaaaggaca	tgtatcccat	25440
ccttttatgg	tttcttgtaa	caccagaaac	tatccagcct	tgttttgtcc	tgtttactgt	25500
aagatccata	gccagtgggt	ctcaaccagg	atgaatttgc	tctccaggaa	acgttttagca	25560
aagtctagag	acattttttg	gttgctcaca	tgtggcaggg	aagaggggtg	cactggcatc	25620
tagtggtatg	agagaactgc	caaacaccct	gtgatgtaca	ggacagcccc	tacaacaaag	25680
aattgtctta	ctaaaatgtc	agtattgccc	agggtgagaa	gcccttcact	aagcaagccc	25740
cttttcctct	ctaacctcag	ttaggtcctt	aattaagttt	gtttcttcaa	ctgaaaagtg	25800
gaggttattg	caactttttc	aaatgggtgc	aaagataaat	gaatttaagg	cgtggaaata	25860
tttagcacag	tatctgacac	acagtggcac	tctgctgaaa	gaataaatta	gggtttttta	25920
aaaatgttgt	ataatgcagc	ttctcatcca	tcctgatttt	cctgcaaaaa	ttctcatgtt	25980
aaatgttttg	atccattatc	actgtaaatc	tcttacatgt	tatagaaatt	cctgtattta	26040
agcttctaaa	atttcctaga	ctacctctta	aatatgtttt	gattttttgg	catgaaagca	26100
atgattatac	caccactgga	acaaatcttt	ttaagtaaca	gaaacctttt	cctgttcttt	26160
tctaaagcac	ttcagtgaat	taaagatttg	tgaggagtgt	aggctcaaag	ttagcttact	26220
cagtaattga	atattttctg	ttgtcaaaag	gttcaaaact	tcattgatca	atagcgtatg	26280
taggagaaga	cgtagaaaag	atttcagaaa	cactaaaact	atcgcatctc	ctttgtgctt	26340
ttaattttat	gtagcaattc	aaggccatca	atagttgtag	tcttaaaagc	ccctaaaagc	26400
agaaatgata	ttactttgtg	gattgttttag	atttttatga	tgtacccctg	tttgcaagg	26460
gggtgttaggt	cctatgaatt	aggagtgtgt	aagtttagtt	aattggctga	ggcccatgtt	26520
tgatctgtta	atttttttgt	gaatttagtt	ttaacatacg	gatcctgcac	aagataaatt	26580
tataaccttta	aacatttctg	tttttttggt	tcgtaaatgg	tgttcaaaact	ttttattttg	26640
gcttccagtt	cattgctggg	atttacaaat	acaattaatt	tatgtgtgtt	cttttaacct	26700
gcaaccttgc	tgaattcatt	ttaggagggt	ttgggttagag	tccttgggat	tttctaaata	26760
ggctcatgtc	tgtttgtctc	tcttttaatta	aaattttttt	gggtgtgttt	ttgtaaagcg	26820
ttaatatcca	gttttgggtg	ttttcattct	cagactgatt	ctcaacctgg	ccctctttca	26880
aactttcaca	ccttctccct	tttcaacttc	actcccttcc	ccagaaatca	ctgaaatgac	26940
ttctgagcac	attgtcattt	tatcttactg	attcaaaatt	attattagat	acgttattat	27000
acctggagg	taacagaata	gtgcatccag	agtctttaat	tatgtaggac	aattgtgtta	27060
gtgggtgaaa	gctgttaggc	ttttggattc	ttgcacctac	tttttattga	tttttttttc	27120
ctcattgtca	gttcttcctc	tgctgttagt	gtgtctgccc	ttaaactacc	tcttcctact	27180
tctaataatt	tggcatgttg	gaaaaccaga	tactcaagct	catcacagta	ttttctagca	27240
actcccaata	gagagatccc	agaggcagtg	gcagttaaag	tgcattttca	cctgtgaata	27300
aactattctg	gggttttagat	acataggtag	tttatatttt	tttaagttaa	aaatttttta	27360
aagtttgga	caaatttgct	taataaagtc	agtttttagcg	ggaaattcac	atgcacatga	27420
gaatcgaaag	aaagaacctt	taatgttgat	gtaagcttat	cattcctttt	tcacatatac	27480
ctcaccacct	cctctgtgtt	taattatctg	gacttttttc	tcattccctag	attttgtttc	27540
tcaaaaatgt	ttctccctta	aaacatgttt	taatgaactc	tgtaagatct	aagttcttaa	27600
tctcaaagta	atcttttagat	tgaggagtac	taaaattgag	atccacagac	cctttaagg	27660
cagggataga	actgctttca	gtgtgattga	tttcttagt	aatcttatgt	gttttattca	27720

aaaacggttat	ctgaaatagc	tttcattgga	ctgcataagg	tttccatggc	aaaaaaaaaa	27780
agtgttaaga	atccgtgaga	ggcaatccca	gagtgaagctc	ctgtcattgc	tgccagaaac	27840
cacaaagcct	tttgagagtt	ctgaactctg	agtcacagag	ttctgatagg	tatgtgggtat	27900
tgttaattcag	ttgaattttg	ctgttggaat	athtaggtaa	attgtcagac	gtaattaaga	27960
tttgagcagc	gaaatgggcc	caaatatata	tggagtcttg	ctctgttgcc	caggatggag	28020
tgcagtggca	cgatctcagc	tcactgcaac	ctccacctcc	caggttcaag	tgattctcct	28080
gcctcagcct	cccaccacgc	cctgtctgtg	ataagatttt	tttttttttt	tcttgagacg	28140
gagtccttgct	ctggttgccca	ggctggagtg	cagtggcacg	atctcagctt	actgcaagct	28200
cgctcctccc	gggttcacacc	attctcctgc	ctcagcctcc	ggagtagctg	ggactacagg	28260
cacctggccac	cacgctcagc	ctgtgataag	atttttaaat	aaaaatttca	cggctcgttg	28320
ctatgggtca	tgcgtgtaat	cccagcagtc	tcggctcact	gcaacctccg	tctctccggt	28380
tcaagcgatt	ctcctgcctc	agactcccga	gcagctggga	ttacaggcac	ataccaccac	28440
ccccagctaa	ttttttctgt	tttagtagag	atggagtttc	actatgttgg	ccaggctggg	28500
ctcgaactcc	tgggtctcagg	tgatccaccc	gccttggcct	ccctagtagc	ctgaggctac	28560
aggcatgtac	caccactcct	ggctaatttt	tgtagggatg	gggtttcgcc	atgttgccca	28620
ggctgggatt	gcggggtgtg	gccactgcac	ttggccccaa	aacaattttt	aacggatgat	28680
gctgggacac	ctacatatata	ccacatagtt	aagtgaagtt	gggccccttt	cttactatat	28740
gcaaaaatta	actcagaatg	gttcatacac	ctaaatgtaa	gagctaaaaa	tttataaaac	28800
tcttagaaga	tataggagca	aatgctcatg	accttgggtt	tgacaaactt	cttaggatac	28860
tgaagataaa	agtaaccaaa	gttgaaatttc	attaaaaatt	aaaatttggt	cttcaataaa	28920
cgtaaaagaaa	gtgaaaagat	aacccatagg	atgcaagaaa	atatttgggc	ttttttttgt	28980
ttgtttgttt	gtttgagaca	gagttcctct	ctgtcatcta	gactggagtg	cagcagcaca	29040
atcttggctt	attgcaatgc	cacctccacg	gttcaagcag	ttcttgtgcg	tcagctcccc	29100
aagtagtttg	gattacaggt	gtgcactacc	accgcctgct	aatctttttt	tttttttttt	29160
ttttttttgt	attttttagta	gagacaaggt	ttgaccatgt	tggccaggct	ggctctgaac	29220
tcctgacctc	agggtgatctg	cctgcctcag	cctctcgaag	aaaatacttg	taaatacattg	29280
gtctgctaag	ggacttgtgt	ccaggagata	acaaaaagat	aatttgctat	cagagagggc	29340
aaatcaaaaat	cacaatgaga	tatcacatct	tatccacttg	aatgggtata	ataaaaagat	29400
taagtttaag	caatgctgtg	gagaaaactg	aacattctat	ttcccttttt	aaaatgcaca	29460
cttcattgat	ttccagtgtg	ttcagagtta	cacaaccatc	acttaccaat	acagctctcg	29520
atgggattgt	aagatgggtg	agggtgctttg	gaaaagtttg	gcagttctac	aaaagggttt	29580
gcagagttcc	attcattggg	ttatataccc	aataaaatga	aaacatgtac	aaaaacttat	29640
acatgtattt	tcataaacact	gttattcaca	gtagctaaca	agtagaaaca	acccatgtcc	29700
atcagtgact	aaacaaaatg	gtgggtggact	attcagtgtg	aaaaaggaat	gcaattctga	29760
taaatgctgc	atcatgggtg	aactttgaaa	acatgttaag	tgaaagtcca	gccacaaaag	29820
accacatatt	agtatgattc	catacacagg	cataccttgt	tttattgcac	ttcacagggt	29880
tgtgtgtgtg	tgtgtgttta	cacaacttga	aggtttggtg	cagctctgca	tgaaacaatt	29940
cttttggcac	cattttccca	gcagctcatt	tcatttctct	gctacatttg	gtaattctcg	30000
tgctttcaga	ctctttcatt	atatctttta	cagtgtatctg	tgatcagttt	tattaggggtg	30060
ctctggaacg	aaacccacac	atctgaataa	tgcttatcta	tgaaatgccc	agaattaggca	30120
aatctataga	gacaaaaagc	aaattagtta	gtagtagcct	agggccgggg	agtttggggg	30180
agtgaactgt	aatgagtaca	ctttcttttg	ggggtaattga	aaatgttcta	aaattgataa	30240
gtgatgggtg	catagctctg	aacacactgg	aaaccattga	agtgtgtatt	ttaaataggg	30300
aaatagaatg	tgaattatat	ctctaagggtg	ttacagttaa	tggaagcctt	tcaccttatc	30360
gtgataactgt	atttctctcag	tgctgagatg	tgctttttta	ggctaggctt	ggctgtcac	30420
tcctgggatac	ccagcacttt	ggaaggccaa	ggcaggagga	ttgcttgagc	ccaggaattc	30480
tagaccagcc	tgggcaacat	agtgaaaacc	tgtctctaca	aaatgtatat	ttttaattag	30540
cggggcatag	tagcatgggc	ctgtagtccc	agctactcag	gagactgaag	tgggaggatc	30600
acttgagccc	gggggggtcgt	caaggctgca	gtgagccaaag	attgtgccac	tgactcttag	30660
cctaggtaac	agaatgagac	cctatctcaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaat	30720
atatatatat	atatatacac	acacacacac	acacacacac	acacacacac	ttatcaggaa	30780
gatagatgtg	atgctagctt	ttacatctct	ctgtgttaatt	gttcaggaaac	tgcatcagtg	30840
ctaactctggg	gggtttttgtt	ttgggtcaaga	tttcatggaa	catcagaagt	agaacataca	30900
ttgagaccaa	ctattctaaa	tcctccattt	tatgggtctta	aatgtcagtc	tggcaaaatt	30960
cagagaaaaa	atttccaggt	aggagactgc	agctgggaag	aagggtggtg	cagcagcagc	31020
ttgtaaggat	ataaagagaa	ggatcagaag	agctggctct	tatttctctac	tggaggaaaa	31080
gataccgctt	ttggtgacaa	gctgcagtgc	ttagcagtga	ctttattttt	ccttcaccac	31140
aaaccagact	tgtgttattt	ccagcctcag	cacattattt	aggcacttcc	ccactgcatt	31200
gttttcgttt	ctgaaattgt	atcacattcc	ctaaattgaa	tccaactttt	aatgtagtgc	31260
ccttcagaca	gacacgtttt	acattcacct	gttttgtgtc	tttcttggct	taaaccacct	31320
aagattaggg	cccgatatac	tcttgacaac	atccatcatt	ttatagggtg	ttcatttata	31380
tattaacaaa	caaccggaat	gcttcagaga	tttttcgcat	cagatcagac	cttgctgttt	31440

10/12

ttgatgtttg	accctatctt	ctggccgggt	gcagtggctc	acacctgtat	cacacctgta	31500
atcccaacac	tttgggaggg	caaggcaggt	ggatcacttg	aggccaggat	tcgagaccag	31560
cctggccaac	atgggtgaac	cctgtctcta	ctaaaaataa	aaaaattagc	tgggcgtggg	31620
ggcgcgtgcc	tgtactccca	gctactcgag	gttgagggtg	gagaattgct	tgaacctggg	31680
aggtggaggt	tgtagtgagc	caagatcgcg	ccactgcatt	ccagcctggg	tgacagagtg	31740
agaccctgtc	tccaaaaaaa	aaaaaaaaaa	gactgtatct	tctgtcctgc	ttcagcatat	31800
tttataaacc	tgtcttccat	ttctattcta	cccccttcca	tgctgctgca	tttttccaca	31860
atgcatattt	taatttttaa	ttattccttt	tctccttttc	ttaaaggcag	atgatttcct	31920
ttggattctc	gctctttctc	tcttttgcct	gcagacatat	ggagaactaa	agaaagtatt	31980
aaggaaaaaga	ttgtttaaat	ttatttgaaa	tttgcttctc	tgtgaattcc	atcttgaaat	32040
ttaaactcac	agggcaagcc	catgtgtctc	ctaatacaaca	acgaggaaat	ggtagttagg	32100
taagactgta	taagacatct	aagtagatga	tagtggaataa	gggaagagag	gaagtccagag	32160
gaatcaggaa	ggatgagatg	tctatctcca	gtgactagtg	gtgtcattag	agaagagccc	32220
atatattaag	taagccctta	tcttggttaag	tgctttactt	atctgcttat	tccttacaat	32280
actttttttt	tttttttttt	aacagagtct	agctctgtgg	gccaggctgg	agtgcagtg	32340
cgtgatctca	gctcactgca	acctccgcct	cccaggttca	agcaattctc	atgtcgcagc	32400
ctccagagta	gctgggataa	cagagctaaa	tgactgcctc	tggcctcaa	ccctttatta	32460
agatagggtat	tttgtctggt	atgctgatga	ggaaccttaa	tgctcagaga	tattaagaag	32520
cttgcgtaag	gccacataca	taattaaata	ccagagcaga	aattccaggg	aatgcctgta	32580
ctctttccat	tatgtatatt	tgttcattaa	cctaggtagg	gggcatagaa	attctgagtt	32640
tgagaggcat	gtggaaggaa	gtatatattg	tttggttttg	gaacctattg	agttcctgtg	32700
ggatgggtag	gtggagtttt	gaaagagaca	acaaccaggg	tattttcact	tgggagaatg	32760
ttgggtgtaa	tttatatcaa	gttttccttt	ttggttttat	tgttatttaa	tccaaatcat	32820
tagcagtttt	tctttttttt	ttctttttga	gacagcagtt	tttctttttc	ttattgttat	32880
ttaatccaaa	tcattagcag	tttttctttt	ttctttttct	ttcactttgt	caccagtcct	32940
ggagtgtagt	ggtgtgatct	cgtctcactg	tagctcaacc	tctgggctc	aagcgatcct	33000
gctgcctcag	tccccgaggt	agctgggact	acagggttac	atcaccactt	ctggctaatt	33060
tttgatctct	ttatagagac	ggggtttcac	catggtgccc	aggctgggtc	caaactcctg	33120
agctcaagct	atccgcctgt	cttggccttc	caaactgcaa	ggattacagg	cgtgagccac	33180
tgtgccaggc	gcattagcaa	tttttcatag	catatctaca	aagttctaata	atgtatataa	33240
tgtatattac	agaacataa	gtgctttgat	ttagggttatt	cagttatata	attatgttga	33300
gtcccaactg	tgtgccagat	accgtgctga	gtaggtagta	aacattggta	agcaaaacag	33360
acatagcccc	tgcccttatc	agactaccca	catagcccgg	acacagtggc	tctcacctgt	33420
aatctcagca	ctttgggagg	ccaaggctag	aggatcgctt	gaggccagga	gttttggtcag	33480
cctggtcagc	gagacactgt	ttctacaaaa	acaaaaaaat	tgctgggcat	gggtgtgtgt	33540
acctgtaatc	ccagctactg	gggaggctgc	agtgggagga	ttacttgagc	ctagaagttg	33600
gaggttgcat	tgagatgtgt	ttgtatacct	tttgtcatta	ggtccatatt	taggccctga	33660
aataggctaa	tcaaaatatt	tatttttttt	tcattttgtt	tcagctgggg	acgaaaacaca	33720
gtagctttgc	aaatataaag	tgggagcaca	acctagcact	ggcgttggag	gtcctcaaaa	33780
cagtccccag	gtttggtgat	tcaataggag	ggctcttagg	acttagtata	taatcttact	33840
cacatctatg	atttggttaca	gcaaagaatc	aaagcaaaat	cagctaaggg	gaaagggtgt	33900
ttggtctaaa	gggaactaag	cacaagcttc	caagagttat	ctcctagtgg	agtcacacag	33960
gacatgctta	attccttcaa	catatatgaa	aggttttctg	ccagagaagc	tcattttggag	34020
actcagtggc	ccaggtactg	attaggcacc	cactgcctag	catatgacaa	aattcctgat	34080
tctcagaggg	gaagcaggtg	ttgaacataa	accatatagt	gttcgcagat	agggaatggg	34140
gggaaccacc	cccaaatcca	tatctttttt	tggtgttaag	atggagtctc	tctctgttgc	34200
ccaggctaga	gtacagtggc	aagatcttgg	ctcactgcaa	cctctgcctc	ccgggttaaa	34260
gcagttctct	tgccctcagct	tactgagtag	ctgggattac	aggcgtgcac	caccacgccc	34320
agctaatttt	agtattttta	gtagagatgg	tggtttacca	tggtggccag	gctgggtctcg	34380
aactcctgac	ctcagggtgat	acgcctgcct	cgccctttca	aagttctggg	attacacgca	34440
tgagctacca	tgcccagcca	tcacatcttt	taaaattggt	gtttttatac	ccctgtctaa	34500
tcttctactc	actcagtgtc	tgtagcccaa	caattgaatc	aggattccat	tttgctgcct	34560
agaaaatcag	tggctgtcta	gttatgaaac	aattgataac	tcagatatca	agccatttta	34620
aaacaagtat	catgggaatt	aaaattttaa	attaggcatg	tgtggtaaga	agggtgaggg	34680
cacattcatc	tttaaaatat	caggaggtct	tagtcatctt	ctttcctcta	tggttttctg	34740
aacctgttaa	actgttaata	gattgttcaa	tcattttaaa	tatctaaaag	atataagag	34800
ggttcctttg	ttttaacaaa	aaaataccaa	aggagaaaat	acactcataa	cgtgaattaa	34860
aatatagttt	ttattttctt	ctttaatgtt	tattaatgtt	tccccgtaaa	gtagaacttt	34920
ccttttctgt	tctgctttct	gtgttctcta	cacgtatgtg	aaccacaaga	ctgaagaaat	34980
ctagcctctg	aaaaacccat	agttggagtt	tattttctct	aaaacaattt	agttattttt	35040
gtttggttagg	ttcaaggatt	taagagaccc	tttatattat	cttagtctta	aaccaatttg	35100
ttcccagttt	gcgtgtggat	gacagctcat	caaaactggg	caactaggac	tgaggctaag	35160

11/12

attcaggaag	gtaattttaga	ctggaaatgg	taattcaagg	ggtgaagaac	tcagagctgg	35220
cagagatcac	aacagagtc	aagagtttgt	agtattcaaa	gagaagccag	aaagccagga	35280
ccaaagccaa	ggacagtagc	acttagctta	aagtctgcaa	agcagagaat	catgatgggg	35340
agaatcatga	cgttggggag	atgttagaat	aatttacaaa	tattggcatt	tacaaagctc	35400
ttagttatct	catgattata	tcaactcttt	aaagtgggta	ctgttatctg	ctttattcaa	35460
agacatttaag	agacttggtc	caagcaatca	cagtaagtag	ccgagctgag	actgaaatct	35520
tataatttaa	ttcttcagac	tgaaaatctc	atcttctgag	atagtagtgt	ttttcagact	35580
gctctgttga	ttctgaggat	tctgcaaagg	taaccaaggt	gagggcttgg	ggatggggag	35640
cctcatccct	tctaggccac	actccatccc	agcttcattc	catcagagtt	gctcagtttt	35700
aaatattatt	ataggccagg	caccatggct	caaccctgtg	gccccactac	tcaggaggct	35760
gaggttggag	gattgcttga	gcccaggggg	ttgagtttac	agtaagttgt	gtttgtgcca	35820
ctgcacttaa	gcctgggcaa	cagagggaga	ccctatctca	aaaaaagggtg	ggggttatac	35880
acacgattcc	tttgaattgt	tttgttgtgt	aaaaaatcag	ttggattagg	agcagcagaa	35940
ttctaatttc	agtattgtca	attagtgact	gtaggcaagc	ttggctcctat	gaaatgggaa	36000
agttagtctt	agataacttt	tagattttatt	tttgccatag	tccagtcctat	ttaaaaagtt	36060
ttaaaaatta	tttttagaga	tgaggctctt	ctatgttgtc	caggctgggtc	tcttatcatg	36120
tggaaatagt	tcattttaaca	ttccatgcca	gttcagttaa	gtctgtgttt	atatacctta	36180
ggcagaatga	gaatgttttg	gtgtgtgtat	gtttttattct	agtagctgaa	gttaaggcag	36240
ggtgaaacac	agtcatacag	ccaaacacta	gcccagcttc	ctacccctcc	cagggctccc	36300
tttcccttct	atctctgacc	aaaaaataag	ccctcgaaa	gtttttaaaa	aataatcttt	36360
ttcctctata	ttttaatatt	ttaggaacaa	gttccagttc	cagtctacca	cccaacacct	36420
agccagactc	ggctagcaac	tcagctgact	gaagaggaac	aaattaggat	agctcaaaga	36480
ataggctcta	tacaacatct	gcctaaagga	gtttatgacc	ctggaagaga	tggatcagaa	36540
aaaaagatcc	gggagtaagt	tttaattaat	ttgtacattt	caaagtttta	ttttcagatt	36600
gcttttgaaa	aatttgcctt	ttctcctgca	ctttagaaa	tcagacattt	aatatattga	36660
aacacttcgc	ttaatgcaag	agaatgttta	attttttttc	atagctctat	tactggctac	36720
tagcaagaga	atgttatgta	gtaattaaga	atttttcacag	gccgagcaca	gtggcttatg	36780
cctgtaatcc	cagcactttg	ggaggctgag	gtcgggggat	cacttgaggc	caggagttcg	36840
agaccaacct	ggccaacatg	gtgaaacctc	atctctactg	aaaatacgaa	aattagccag	36900
gcatggtggc	acgcgcctgt	aatcccaacc	acttggggagg	ctgaggtggg	agaatcactt	36960
gaaactctgt	ctcaaaaagt	aaaataaagt	aaaataagag	aaagttagtg	ttaatgaaga	37020
gagctttaac	ttacagcaac	ccagtaagta	ggctgaagtt	agtgtttctg	tttttacagt	37080
tattaaaatg	aaaattatct	tactctagga	ttactctaaa	tagcacaagg	aaacaaagtt	37140
gcccgaagtt	agtgtttctg	ttttacagtt	actaaaaatga	aaattgtctt	agtcaggatt	37200
tacactaaat	agtgcagaag	aacaaagtgt	atctaactga	tgcttttcta	cctaaaaata	37260
tcccattctc	cttcagggtat	ctgctataat	atgtagctgt	ttacaagcac	agcagtagat	37320
ttgatgcata	tgtaatccat	ttctctttgc	tctgttgatt	gtcctaagt	cctgcaaatt	37380
ctcaggggat	tgaaataaga	gactgtggac	agatcaacat	taggaaaaaa	ttcagtttgc	37440
atgctttggc	aataagatga	caggcaaaagc	attctgatgt	gttactcaga	ttaacactgt	37500
ctttaatggg	atttaaagag	ttttctgaat	aggacacttc	tgaaaaatgcc	ttctgatttc	37560
tctccattgc	tctcaacagg	tgtgtgatct	gtatgatgga	ctttgtttat	ggggacccaa	37620
ttcgatttct	gccgtgcatg	cacatctatc	acctggactg	tatagatgac	tggttgatga	37680
gatccttcac	gtgccccctc	tgcatggagc	cagttgatgc	agcactgctt	tcatacctatg	37740
agactaattg	agccagggtc	tcttatctga	cttcaagtga	accaccattt	tggtggtttt	37800
gatcttttgt	cactgagccc	aaagagccag	ggattaggaa	ttaagatcgt	gcacaaaagt	37860
ttccttaaaa	ttcctggatg	gctgcagatg	ttgggggaaa	aagtacgtga	tatttttagaa	37920
acttagtggg	aaaagttaga	tggtattttt	atgtaaagcc	ttgacccaat	gtttaaaaat	37980
ataattgtat	ttagatcttg	ttattgctcc	agtacatagg	aattgtgtaa	agtgttaaca	38040
gcagctgtat	ttgtttaaat	tgtgtgtatt	gaagattagg	aaaaagatag	tagttatttt	38100
tcctaaatga	aataactttc	ttctcttccc	cttccccacc	cgaattcttt	tctgaagttg	38160
ctggcatttg	ggtcaagggt	ttattaaaag	ctacattttta	taacactggc	acacacaaaa	38220
aagtagtttt	aagcttgttt	gcacagttct	ttttttccat	tggaaaatgga	attcattggc	38280
ttaggtcttt	ttaaatagtg	tattattatc	gttggggctg	gctctatgct	tgaaaaccag	38340
tttatttata	acctgttata	agtgtctat	tctgtttgca	gttaggaaat	gcagaattca	38400
aagtgatctc	ctagcttgta	agcaaaactga	gatgcactat	cccttttcta	taaaaaataa	38460
gttaatgtgt	caagaaacca	actctattaa	ggtgggggtt	aatattaccc	tttcctatgt	38520
gttttatcta	attatttttg	ttgttaatat	ggtgataatg	gaaagtcaag	ttaaatttta	38580
aatattaaaga	attctgattt	attgagattg	atttattgcca	ccacgtttat	gtaaaaatga	38640
aggtggcacc	gtggtgagac	ctaatgagaa	atagttactc	agttgtaaaa	attttgattt	38700
attctctttc	ttctgacctc	cttgccctct	gtcttgaacc	atagcaaaag	gatactgcat	38760
ctctcattac	tgtagtgtg	aggttattga	agttatacaa	aacacatctc	agtcctgtgt	38820
tcttggaag	gtatctatta	catcctgcta	gctgactgac	aaaactaagc	agggagaata	38880

12/12

```

aagataattg tattttatgt tttgcacaca aacgcagaat ttgtataacc atatgacttc 38940
atagttgtga tctcaaaaaa gaaggaattt ctcctttgtt tcttgcaagt aatgtaagaa 39000
tactttaaat ctctaagctt ctgaagtgtt agaggtagag atgggtctagt aaagatgtag 39060
tagtaatggt ttatccattt agcatgtgtt tattttttca tatgtactca aagggtgactt 39120
attggttcac ctcagtgata ttacagctaa aaaaatcatt cattagcaaa aggaaaagtg 39180
gtctcaacct aacatcagaa gtgtttctta ttattatttt atattgagtt gaatattgaa 39240
ctctaacagt tttctacata caaaacacag tgtcatgaag gttattcata attgcattat 39300
agaggaatgt agtatgtcat aagtactttg taaagatttg acattcaact gtagtatcca 39360
tatgttgctt aaatttcctt atgagcccca tgatggaaag acttaaagat gaatttgaga 39420
aaaattgaaa gaaattagat tatcagggtt tgtaaattg ttacatgtat cttgcttaaa 39480
tttctgttta ttaattttata tccaccacaag tacataaagc aaatttggag gaaacaactg 39540
aagttgtgca atattttctg ataattgctt tttttattct tgtgttttct acttaaacad 39600
aatgtctgtg tcatcaagta ttatagtcag acttttcttt ttttctagat tgttaaaatt 39660
ggcaaagtga ctttttttaa aatcatcttc catgtgtcag ttagtctttc ttttcattac 39720
aagtcctttc cagaagtttg gtggtaatat tgaaagaact agcattgggc agaattgtgc 39780
ttttt                                     39785

```

```

<210> 2
<211> 154
<212> PRT
<213> Homo sapiens

```

```

<400> 2
Met Gly Asn Cys Leu Lys Ser Pro Thr Ser Asp Asp Ile Ser Leu Leu
 1           5           10           15
His Glu Ser Gln Ser Asp Arg Ala Ser Phe Gly Glu Gly Thr Glu Pro
      20           25           30
Asp Gln Glu Pro Pro Pro Pro Tyr Gln Glu Gln Val Pro Val Pro Val
      35           40           45
Tyr His Pro Thr Pro Ser Gln Thr Arg Leu Ala Thr Gln Leu Thr Glu
      50           55           60
Glu Glu Gln Ile Arg Ile Ala Gln Arg Ile Gly Leu Ile Gln His Leu
      65           70           75           80
Pro Lys Gly Val Tyr Asp Pro Gly Arg Asp Gly Ser Glu Lys Lys Ile
      85           90           95
Arg Glu Cys Val Ile Cys Met Met Asp Phe Val Tyr Gly Asp Pro Ile
      100          105          110
Arg Phe Leu Pro Cys Met His Ile Tyr His Leu Asp Cys Ile Asp Asp
      115          120          125
Trp Leu Met Arg Ser Phe Thr Cys Pro Ser Cys Met Glu Pro Val Asp
      130          135          140
Ala Ala Leu Leu Ser Ser Tyr Glu Thr Asn
145                      150

```